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9Common abbreviations
α-KG  α-ketoglutarate
BBB  blood brain barrier
CE  contrast enhancement
Cho  choline
CNS  central nervous system
D-2HG  D-2-hydroxyglutarate
ECM  extracellular matrix
EGFR  epidermal growth factor receptor
EMA  European Medicines Association
FDA  Food and Drug Adminstration (USA)
FFPE  formalin-fixed paraffin embedded
Gd-DTPA gadolinium diethylenetriaminepenta-acetic acid
GBM  glioblastoma
GLUT1  glucose transporter 1
HGF  hepatocyte growth factor
IDH  isocitrate dehydrogenase
IHC  immunohistochemistry
MRI  magnetic resonance imaging
MRSI  magnetic resonance spectroscopic imaging
MVP  microvascular proliferation
NAA  N-acetyl-aspartate
NSC  neural stem cell
OS  overall survival
PDGF-B  platelet-derived growth factor B
PDGFR-β platelet-derived growth factor receptor-β
PET  positron emission tomography
PTP  protein tyrosine phosphatase
RT  radiotherapy
RTK  receptor tyrosine kinase
TCGA  The Cancer Genome Atlas
TK  tyrosine kinase
TKR  tyrosine kinase receptor
TKI  tyrosine kinase inhibitor
TMZ  temozolomide
VEGF-A  vascular endothelial growth factor-A
VEGFR2  vascular endothelial growth factor receptor 2
WHO  World Health Organization
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1
General Introduction
Glioma: classification and histopathology
 Malignant transformation of glial (precursor) cells in the central nervous system 
(CNS) can result in the development of a glioma, a primary brain tumor. The most frequent 
glioma subtypes involve astrocytic, oligodendrocytic and mixed oligoastrocytic tumors [1]. 
The majority of these tumors are characterized by a highly invasive growth pattern in the 
brain parenchyma, which prohibits curative treatment by surgery or radiotherapy. Together 
with an intrinsic resistance towards chemotherapeutic compounds this places these tumors 
amongst the most incurable human malignancies [2]. 
	 Glial	tumors	are	classified	according	to	the	World	Health	Organization	(WHO)	into	
four malignancy grades, based on histopathological characteristics (Figure 1) [1]. The grade 
I tumors (e.g. pilocytic astrocytoma) are relatively circumscribed. Depending on anatomical 
location,	 these	 tumors	can	be	surgically	 removed,	distinguishing	 this	group	 from	WHO	II,	
III and IV diffuse gliomas. Grade II gliomas have a low percentage of mitotic cells, which 
increases in grade III and IV tumors. Grade IV gliomas (glioblastomas or GBMs, previously 
termed ‘glioblastoma multiforme’) are the most aggressive of these cancers. The high growth 
rate of tumor cells in a GBM cannot always be accommodated by the local pre-existent blood 
supply, resulting in foci of hypoxia and necrosis. This induces the expression of angiogene-
sis-related genes such as Vascular Endothelial Growth Factor-A (VEGF-A), which character-
istically results in microvascular proliferations (MVPs). GBMs can develop de novo (primary 
GBM) or evolve from lower grade tumors (secondary GBM). Primary and secondary GBMs 
differ markedly in both genetic alterations and outcome [3-5]. 
 Patients diagnosed with diffuse glioma still face a poor prognosis. This situation 
substantially contributes to the fact that the average number of years of life lost for patients 
with CNS tumors is highest amongst all patients with cancer [6]. GBM is the most common 
diffuse glioma (mean age 59-62), with 3.55 new cases per 100,000 persons annually (Figure 
1) [5, 7]. Lower grade diffuse gliomas (mean age 33-45) are less frequent, but as a group 
account for around 15% of all brain tumors in adults [8]. 
Treatment
	 The	current	standard	of	care	for	primary	GBM	patients	is	first	surgery	to	the	maxi-
mum feasible extent. Next, radiotherapy (RT) and concomitant chemotherapy with temozolo-
mide (TMZ) are given, followed by 6 additional cycles of TMZ [9]. Since the addition of TMZ 
for standard GBM treatment in 2005, median overall survival (OS) increased from 12 to 14.6 
months. Although this increase is modest, the 5-year median survival was improved from 
1.9% in the RT arm to 9.8% when TMZ was added to the RT, showing that a subset of tumors 
is	more	sensitive	 to	TMZ	therapy	[10].	For	WHO	grade	 II-III	diffuse	gliomas,	 the	standard	
of care is more variable. In some centers, a “wait and scan/see” policy is advocated, while 
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others choose to perform surgical resection or stereotactic biopsy, sometimes followed by 
radiation and/or adjuvant chemotherapy. It is now becoming evident that based on genetic 
background (e.g. chromosome arms 1p and 19 q co-deletion) certain subgroups of diffuse 
gliomas	respond	better	to	a	specific	combination	of	chemotherapies	and	RT	[11,	12].	Pa-
tients with grade II-III gliomas need to be monitored at regular intervals, as eventually tumors 
will progress to higher-grade malignancies.
Imaging of glioma
 Non-invasive neuroimaging is indispensable for diagnosis of (glial) brain tumors, 
planning of therapy (surgery, irradiation) and evaluation of tumor progression, the most fre-
quently applied method being magnetic resonance imaging (MRI). 
MRI
 Low-grade diffuse gliomas typically present as hypo- to iso-intense lesions in 
T1-weighted MRI [13]. Routinely, these tumors do not show contrast enhancement (CE) with 
the commonly used paramagnetic contrast agent gadolinium diethylenetriaminepenta-acetic 
Figure 1. World Health Organization 2007 classification of malignant gliomas. 
Classification	of	malignant	gliomas,	as	described	in	the	WHO	2007	classification	[1].	Histological	sub-
typing in grade II-IV is based on phenotypic resemblance with non-neoplastic glia cells – astrocytic 
(green), oligodendrocytic (gray) or mixed oligoastrocytic (purple) – in combination with a number of 
pathological features, as described under ‘Pathobiology’. Incidence rates per 100.000 individuals per 
year are given for each subtype as reported by Ohgaki & Kleihues [7]. For low-grade astrocytic tumors, 
the number (0.22) represents diffuse astrocytoma. Exact incidence rates for GBM-Os are unknown, 
partly	due	to	an	imprecise	definition	for	this	group,	hence	the	question	mark.	Abbreviations:	AO,	ana-
plastisch oligodendroglioma; AOA, anaplastic oligoastrocytoma; GBM-O, glioblastoma with an oligo-
dendroglial	component;	MVPs,	microvascular	proliferations;	WHO,	World	Health	Organization.	Drawings 
from the different subtypes are reprinted with permission from Claes et al. [2], © Springer.
Grade
GBM-O 
(AOA with necrosis)
Phenotype
astrocytic
mixed/
oligo-astrocytic oligodendrocytic
Pathobiology
IV  
inﬁltrative growth
anaplasia
proliferation
necrosis
ﬂorid MVPs
angiogenesis
II
inﬁltrative growth
slow proliferation
III
inﬁltrative growth
anaplasia
 proliferation
necrosis (AO)
ﬂorid MVPs (AO & AOA)
angiogenesis (AO & AOA)
0.22 0.1
“anaplastic”
0.27
0.070.060.25
3.55
?
“low-grade”
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acid (Gd-DTPA), as extravasation and accumulation of the agent is absent due to an intact 
blood brain barrier (BBB). T2-weighted MRI usually is able to visualize gliomas as hyperin-
tense lesions, but cannot distinguish between tumor and edema. 
 Also in high-grade gliomas MRI is used to evaluate tumor extent (Figure 2) [14]. 
These lesions typically present as masses with heterogeneous signal intensity and poorly 
defined	margins.	The	BBB	in	parts	of	the	tumor	is	leaky,	resulting	in	extravasation	and	accu-
mulation of Gd-DTPA in the tumor interstitium. Often, enhancement is ring-shaped surround-
ing a central, necrotic tumor area. It is however well known that CE-T1-MRI underestimates 
tumor burden in glioma. Also in T2-weighted MRI tumor burden is underestimated as tumor 
cells can be detected in brain areas that appear normal in T2-weighted images [15]. Thus, 
there is a need for more reliable imaging modalities.
 Other MR methods that are being explored for diagnostic imaging of glial brain 
tumors include assessment of perfusion by arterial spin labeling, blood oxygenation by T2* 
imaging, and diffusion weighted imaging. Another interesting MR modality is MR spectros-
copy, which allows monitoring of tumor based on metabolic characteristics [16, 17].
MR spectroscopic imaging
 MR spectroscopic imaging (MRSI) is the technique that obtains metabolic spectra 
from three-dimensional voxels, which can be superimposed on anatomical MR images, thus 
providing metabolic maps. There are several nuclei that can be measured in MRSI (e.g. 31P, 
13C, 19F), but protons (1H)	are	still	most	widely	used	due	to	their	high	natural	abundance	in	
organic structures and their high magnetic sensitivity compared to other nuclei. The major 
brain metabolites detected by 1H	MRSI	include	N-acetyl-aspartate	(NAA),	choline,	creatine,	
myoinositol, lipids, lactate, glutamine and glutamate [18]. These metabolites can be used to 
distinguish normal brain from tumor. NAA is a marker of neuronal integrity [19]. In gliomas 
T1 + CE T2 MRSI: cho/NAA
A B C
Figure 2. Magnetic resonance imaging and spectroscopic imaging of a glioblastoma patient.
A:	T1	image	of	a	glioblastoma	patient	showing	CE	using	Gd-DTPA,	with	the	arrow	depicting	a	contrast	
enhancing	region.	B:	T2	image	of	the	same	patient.	C:	MRSI	shows	relative	cho/NAA	intensities	accord-
ing	to	the	color	bar	(scale:	0=	blue,	to	red=	0.83).	Underlying	is	the	T1	+	CE	image	from	(A).	Note	the	ev-
ident spread over the corpus callosum envisioned by cho/NAA measurement, while CE is partly lacking. 
Imaging	was	done	at	3	tesla.	Abbreviations:	CE,	contrast	enhancement;	cho,	choline;	MRSI,	magnetic	
resonance spectroscopic imaging; NAA, N-acetyl-aspertate. Courtesy of Drs. A.J. Idema.
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and other brain tumors, neurons will be replaced by tumor cells, leading to a decrease in 
NAA levels. Choline compounds are involved in membrane synthesis and are present at high 
levels in areas with proliferating cells. A high choline/NAA ratio is therefore indicative of the 
presence of tumor (Figure 2).  
	 To	achieve	a	sufficiently	high	signal-to-noise	ratio	in	MRSI,	spectra	need	to	be	ac-
quired from relatively large voxels at the expense of spatial resolution. Furthermore, the lower 
signal to noise requires more sophisticated software than for CE-T1-MRI, mainly to deal with 
relatively stronger potential artifacts, and therefore needs knowledgeable staff. Methods to 
overcome these limitations are being developed and MRSI may possibly be used in the di-
agnosis and clinical management of patients with glial brain tumors. 
Other imaging modalities
  Positron Emission Tomography (PET) can be used for molecular imaging by mea-
suring accumulation in the tumor of systemically administered tracers, thereby providing 
information	about	 tumor	metabolism	and	proliferation	 rate.	Whereas	 [18F]-fluoro-2-deoxy-
D-glucose (FDG)-PET is often used to detect tumors elsewhere in the body, it is less suited 
for brain tumor imaging, given the high glucose consumption of normal brain. Especially 
[18F]-fluorothymidine	(FLT)-	and	amino	acid	PET	tracers	might	be	promising	for	brain	tumor	
imaging, because there is high uptake in tumor tissue but not in normal brain [20, 21]. 
Glioma-microenvironment interactions
 The brain is one of the most richly vascularized tissues in the human body. Glioma 
cells can use this abundant blood supply as a source of oxygen and nutrients. Furthermore, 
blood vessels and white matter tracts provide scaffolds for glioma migration [22]. Low-grade 
diffuse gliomas can thrive on the pre-existent blood supply and do not depend on angio-
genesis. This situation is different in high-grade gliomas, where local increases in tumor cell 
mass cannot be accommodated by the pre-existent vasculature and tumors experience an 
angiogenic switch. 
Blood brain barrier 
	 The	BBB	serves	as	a	protective	barrier	against	for	example	toxins	and	fluctuations	
in ionic substances in the blood. Endothelial cells (ECs) comprising the BBB are intercon-
nected with pericytes, astrocyte feet and basement membrane components, with astrocytic 
end feet and pericytes being responsible for the induction of BBB properties of ECs (Figure 
3)	[23,	24].	Molecules	like	glucose	use	transport	proteins	(esp.	glucose	transporter-1	(GLUT-
1)) to pass both the luminal and abluminal EC membrane [25]. Receptor-mediated transcy-
tosis occurs via for example the transferrin receptor, which is responsible for iron uptake in 
the brain [26]. Clearly, only a limited number of substances have access to the brain paren-
chyma via these mechanisms, leaving most molecules, including many therapeutic agents, 
incapable of passing the BBB.
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BBB permeability is altered in many pathological conditions, including high-grade gliomas 
[28]. As a result of hypoxia VEGF is expressed, which reduces the expression of endothelial 
junction proteins [29-31]. Loosening of the barrier leads to extravasation of plasma proteins 
and cerebral edema, contributing to increased intracranial pressure and clinical symptoms. 
Corticosteroids (e.g. Dexamethasone) reduce vascular permeability and are often used in 
daily clinical practice to reduce edema in/around CNS tumors [32, 33]. 
 
Angiogenesis
 Judah Folkman hypothesized already in 1971 that solid tumors will not grow beyond 
a size of 2-3 mm3 unless they acquire the ability to undergo angiogenesis [34]. This certainly 
applies to tumors growing in relatively avascular tissues, but it is now clear that co-option 
of	pre-existent	vasculature	may	allow	significant	 tumor	progression	 in	 the	absence	of	an-
giogenesis [35]. As discussed, lower grade gliomas may progress via co-option only while 
high-grade gliomas characteristically contain areas of angiogenesis.  
 VEGF is the master regulator of angiogenesis [36]. It activates VEGFR-2 on en-
dothelial cells, which, together with neuropilins as co-receptors, induces numerous down-
stream effects. VEGF signaling stimulates migration and proliferation of ECs, induces hy-
perpermeability, stimulates the outgrowth of new blood vessels from pre-existent ones and 
promotes	the	formation	of	the	blood	vessel	lumen	[36,	37].	Under	normal	physiological	con-
ditions there is a delicate balance between the activities of VEGF, the angiopoietin family of 
proteins, Notch signaling molecules, and anti-angiogenic factors like endostatin, angiostatin, 
and the thrombospondins [38], ultimately resulting in a functional and mature vasculature 
[39]. In maturing brain capillaries ECs are covered by pericytes and basement membrane, 
thereby stabilizing EC channels. Several growth factor receptor families contribute to this 
process [40]. To induce vessel maturation, ECs from the angiogenic sprout excrete factors 
like	PDGF-B,	which	acts	as	a	chemo-attractant	for	PDGFR-β-positive	pericytes	[41].	Pericyte	
deficiency	as	a	result	of	platelet-derived	growth	factor	B	(PDGF-B)	ablation	leads	to	vessel	
leakage, microaneurysms and hemorrhages. 
Figure 3. Blood brain barrier structure. 
Simplified	 overview	 of	 the	 cells	 involved	
in forming the BBB. In the brain, ECs cov-
ering the walls of capillaries are closely 
connected via tight junctions. Pericytes 
partly surround the ECs and share a basal 
lamina with them. Astrocytic end feet and 
pericytes are important for inducing and 
maintaining BBB-properties. Abbrevia-
tions:	BBB,	blood	brain	barrier;	EC,	endo-
thelial cell. Reprinted with permission from 
Abbott [27] © Springer. 
tight junction
endothelium
basal 
lamina
end foot
astrocyte
neuron
microglia
pericyte
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In tumors, the balance between anti- and pro-angiogenic factors is often changed in favor of 
angiogenic factors, leading to a so-called angiogenic switch [42]. VEGF and other pro-an-
giogenic factors are induced by several factors, including hypoxia, oncogene signaling, and 
via	proteolytic	release	of	inactive	VEGF	variants	in	the	extracellular	matrix	(ECM)	[43].	Un-
controlled VEGF production is involved in sustaining angiogenesis in tumors [44]. 
	 Based	on	the	presence	of	areas	with	a	remarkable	angiogenic	response	(florid	or	
even glomeruloïd microvascular proliferations) in GBMs, angiogenesis inhibition has long 
been considered promising for the treatment of these tumors [2, 45]. Initial phase II clinical 
studies indeed showed clear radiological responses and improvement of quality of life [46-
49]. Preclinical studies in orthotopic glioma xenografts suggested however that anti-angio-
genic therapy increased invasiveness, without improving survival [50]. BBB restoration was 
also	reported	to	reduce	efficacy	of	TMZ	[51].	It	is	now	evident	that	anti-angiogenic	therapy	
induces vessel normalization, which in high-grade glioma implies (partial) restoration of the 
BBB and explaining reduced CE in the initial clinical trials [52]. Although it is still matter of de-
bate [53], several studies, both preclinical and clinical, have suggested that anti-angiogenic 
therapy promotes invasive growth in brain parenchyma [51, 52, 54-56]. 
Mechanisms of diffuse infiltrative growth
 A major factor contributing to the poor outcome of gliomas is the invasive manner 
in	 which	 these	 tumors	 grow.	Understanding	 the	 underlying	mechanisms	 that	 lead	 to	 the	
invasive nature of gliomas is imperative for the development of effective invasion-inhibiting 
therapies that might greatly improve the survival of patients [2].
 The extracellular matrix (ECM) in the brain is distinct from that in other organs in that 
it lacks laminin and collagen I, principal ECM proteins in other sites in the body. In contrast, 
brain	ECM	mainly	consists	of	 the	glycosaminoglycan	hyaluronic	acid	 (HA,	also	known	as	
hyaluronan and hyaluronate) and proteoglycans of the lectican family. These are connected 
directly or via small hyaluronan and proteoglycan-binding linking proteins and tenascins to 
the cell surfaces [57]. Collagen is only present around blood vessels and at the pial surface 
(glia limitans) where a basal lamina is formed [58-60]. 
 The spreading pattern for diffuse gliomas preferentially involves white matter tracts 
(e.g. corpus callosum) and blood vessels, although glial cells can also accumulate around 
neuronal perikarya (perineuronal sattelitosis) and grow along the pia mater [61]. Cell ad-
hesion and migration is regulated by a number of cell adhesion protein families, including 
cadherins and integrins. Several proteases are excreted by glial cells, glioma-associated mi-
croglia/macrophages or ECs, and promote degradation of ECM or basal lamina components 
[62]. Lecticans in the ECM are for example cleaved by metalloproteases of the ADAMTS and 
MMP	families,	which	can	be	induced	by	glioma	cell-derived	TGFβ	[57,	63,	64].	This	enables	
glioma cell invasion through the brain parenchyma or along blood vessels. Furthermore, 
proteases may regulate chemotactic or growth factors (e.g. VEGF as described before), or 
their receptors, produced in the brain parenchyma or the tumor. 
18
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Molecular and Metabolic Characteristics of Diffuse Gliomas
 Important progress has been made in recent years to unravel the molecular land-
scape of gliomas [65-69]. In 2008, the Cancer Genome Atlas (TCGA) project mapped the 
genomic aberrations of a large series of GBM specimens [66]. This provided understanding 
of the major pathways that are genetically altered in GBMs, namely receptor tyrosine kinase 
(RTK)/Ras/PI3K,	p53	and	Rb	signaling	pathways.	Furthermore,	these	studies	have	identified	
previously unrecognized driver mutations for subsets of gliomas. Together, unraveling the 
molecular alterations important for glioma development has provided hints for future thera-
pies to more effectively treat glioma patients.
 
Epidermal growth factor receptor (EGFR)
 EGFR	(also	referred	to	as	ERBB1	or	HER1)	is	a	frequently	altered	in	cancer,	with	
modifications	 found	 in	57%	of	all	GBMs	 [65].	EGFR	can	be	activated	by	several	 ligands,	
including epidermal growth factor and transforming growth factor a [70]. EGFR alterations in 
GBM	involve	mutations,	amplifications	and/or	partial	deletions	[65].	The	deletion	variant	EG-
FRvIII (also named ΔEGFR or de2-7EGFR), lacking exons 2-7, leads to a constitutively active 
protein	and	is	found	in	about	half	of	the	GBMs	that	contain	amplified	EGFR [71]. Interestingly, 
the in-frame deletion introduces an alternative amino acid at the exon 1-8 junction. Since this 
abnormal extracellular part of the protein is unique to the tumor, EGFRvIII is an attractive 
target for (immune-based) therapy [72]. As the receptor is frequently overexpressed in GBM, 
this creates a therapeutic window that can be used to preferentially target tumor cells without 
affecting normal tissue, making EGFR an attractive target in GBM therapy. 
MET
 A receptor-ligand pair that recently received attention as a therapeutic target is 
the RTK MET (also named scatter factor receptor and hepatocyte growth factor receptor), 
together	with	its	ligand	hepatocyte	growth	factor	(HGF).	MET	dimerizes	as	a	result	of	HGF	
binding, leading to phosphorylation of the TK domain. Phosphorylated C-terminal tyrosine 
residues serve as docking sites for molecules involved in a number of pathways, including 
PI3K/AKT and RAS/MAPK/ERK (Figure 4). Eventually, this leads to protection from apoptosis, 
stimulation of proliferation, branching morphogenesis, scattering, motility and invasion [73]. 
 Missense mutations in MET are infrequent in glioma, in comparison with for exam-
ple EGFR	[65].	Amplification	of	MET however, is seen in 47% and 44% of the primary and 
secondary	GBMs,	respectively	[74].	In	WHO	grade	II	diffuse	astrocytomas	MET	amplification	
is also a frequent event (occurring in 38% of cases), and is associated with poor survival, 
making it a prognostic factor for these patients. MET gain is less frequent in oligodendroglio-
mas (16%). Especially its role in invasion makes MET an interesting candidate for therapy in 
glioma.  
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	 A	number	of	MET	pathway	 inhibitors	 targeting	either	HGF	or	MET	have	 recently	
entered	clinical	trials.	Whether	MET	targeting	would	be	beneficial	for	glioma	patients,	maybe	
in combination with anti-angiogenic therapy, and whether it would especially inhibit the inva-
sive tumor cells remains to be shown.
Protein tyrosine phosphatases
 Signal transduction via phosphorylation cascades initiated by RTKs is evidently im-
portant in gliomagenesis. The dependence on kinase activity urges for a closer look on the 
role that is played by a second class of critical enzymes in signal transduction, the protein 
tyrosine phosphatases (PTPs) (Figure 5). There are 109 genes in the human genome that 
belong to the PTP superfamily of enzymes and, based on the sequence homology of their 
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Figure 4. MET structure and signaling. The tyrosine kinase receptor MET consists of an extracellular 
α-chain	linked	via	a	disulfide	bridge	to	a	β-chain.	The	β-chain	consists	of	a	partial	extracellular	domain,	a	
transmembrane	region	and	an	intracellular	part	that	includes	a	kinase	domain.	Upon	HGF	binding,	MET	
receptors dimerize and the intracellular kinase domain is autophosphorylated leading to phosphorylation 
of C-terminal sites that function as interaction surfaces for a number of proteins. Downstream signaling 
as a result of MET activation leads to transcriptional changes in processes that are also involved in on-
cogenesis. Figure based on Gherardi et al. [75], reprinted with permission © Nature Publishing Group.
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catalytic domains, these have been categorized into four different classes [76, 77]. PTPs 
may not simply oppose tyrosine kinase (TK) actions but, as some kinases are (auto)inhibited 
by phosphorylation, could also act in synergy. Thus, next to some tumor suppressors, the 
PTP superfamily also harbors proto-oncogenes [78].
 PTEN represents the PTP that is most well known as a tumor suppressor, i.e. the 
gene is frequently deleted or mutated in tumor specimens [80]. Several other PTP genes 
are deleted or mutated in cancer tissues as well, but the frequency is usually quite low and 
causal relationships often have not been assessed. A screen encompassing 87 of the human 
PTP genes revealed mutations for six of them, all encoding classical PTPs (PTPRF, PTPRG, 
PTPRT, PTPN3, PTPN13 and PTPN14) in 26% of the colon cancer samples analyzed [81]. 
Alterations	in	these	genes	were	also	identified	in	lung,	breast	and	gastric	cancer	samples,	
but at a lower frequency. 
 
 Several years ago, we reviewed literature on the evidence for PTP involvement in 
glioma biology [79]. At that time, 15 PTPs were linked to glioma (Figure 6). Since then, ad-
ditional candidate PTPs with potential involvement in gliomagenesis or glioma progression, 
have	been	 identified	(e.g.	PTPN4,	DUSP4	and	DUSP6	[82-84].	Careful	assessment	of	 the	
exact functional relevance of PTPs in glioma biology is needed. 
Figure 5. Receptor tyrosine kinase and phosphatase 
functioning. The opposing actions of RTK and PTP en-
zymes provide the cell with a functional diad that regu-
lates the activity of the mutual substrates through phos-
phorylation of Y residues in a reversible manner. Some 
PTPs	 have	 a	 so-called	 dual	 specificity;	 in	 addition	 to	
their activity towards phospho-Y they can also dephos-
phorylate S and/or T residues in protein substrates that 
have been phosphorylated by S/T-Ks. A subset of these 
dual-specific	PTPs,	most	notably	the	tumor	suppressor	
PTEN, even demonstrate the potential to dephosphor-
ylate	phospholipid	substrates.	Abbreviations:	PTP,	pro-
tein tyrosine kinase; RTK, receptor tyrosine kinase; S, 
serine; S/T-K, serine/threonine kinases; T, threonine; 
Y, tyrosine. Reprinted with permission from Navis et al. 
[79] © Springer.
Next page:
Figure 6. Interplay of PTP signaling and the major pathways affected in GBMs. Proteins in orange 
are frequently hyperactive in gliomas, while proteins in blue are often hypoactive or even inactive. The 
green asterisks represent the receptor-type and non-transmembrane PTPs described in literature to be 
involved in glioma biology. PTEN, being a predominant glioma tumor suppressor protein, is depicted in 
blue.	Abbreviation:		PTP,	protein	tyrosine	phosphatase.	Reprinted with permission from Navis et al. [79] 
© Springer.
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IDH1
	 A	major	discovery	in	the	field	of	glioma	was	the	identification	of	IDH1 mutations in 
2008,	using	next	generation	sequencing	[85].	This	alteration	was	first	 identified	 in	a	small	
number	of	secondary	GBMs,	and	then	confirmed	in	the	majority	of	grade	II	and	III	astrocyto-
mas (74 and 62% respectively) and oligodendrogliomas (71 and 67% respectively) [86]. 
 IDH1 encodes the enzyme isocitrate dehydrogenase 1 which is responsible for the 
conversion	of	isocitrate	to	α-ketoglutarate	(α-KG)	in	the	cytosol.	During	this	reaction	NADP+	
is	used	as	an	electron	acceptor	and	is	converted	to	NADPH	(Figure	7).	IDH2	and	3	are	re-
sponsible	for	this	reaction	in	the	mitochondria,	with	the	only	difference	that	IDH3	is	NAD+,	
rather	than	NADP+,	dependent.	IDH mutations in glioma always involve the NADP-depen-
dent enzymes, and involve IDH1 in ~95% of all cases [87]. These mutations involve a spe-
cific	arginine	residue	on	position	132	in	IDH1 and the analogous residues R172 or R140 in 
IDH2 [87, 88].
	 The	specific	IDH1/2 mutations induce a gain of function, resulting in conversion of 
α-KG	to	 the	presumed	oncometabolite	D-2-hydroxyglutarate	 (D-2HG)	 (Figure	7)	 [90].	The	
underlying	mechanism	of	D-2HG-induced	tumorigenesis	has	been	a	focus	of	extensive	re-
search	in	recent	years	[89,	91].	It	is	essential	to	investigate	the	effects	that	D-2HG	has	on	the	
cellular metabolism, since this might provide hints for future therapy strategies in IDH mutant 
tumors.
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Animal models in glioma research
 Experimental models that are commonly used in glioma research include cell lines, 
either	cultured	as	adherent	cell	 layers	or	as	floating	neurospheres,	xenografts	and	genet-
ically	modified	animal	models.	Although	 these	models	all	 have	a	significant	 value	 for	our	
scientific	knowledge	of	glioma	biology	and	 therapeutic	opportunities,	 there	are	a	number	
of	limitations	as	well.	Using	appropriate	models	is	of	eminent	importance	in	the	research	for	
potential novel therapies to target gliomas.
 
Tissue culture
 Adherent cell lines originating from GBM material are widely available and give rise 
to rapidly expanding xenografts in vivo. One of the most evident problems when exploiting 
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Figure 7. Effects of the oncometabolite D-2HG.	IDH1	mutant	enzyme	has	acquired	a	novel	function	of	
reducing	αKG	to	D-2HG.	D-2HG	binds	competitively	to	enzymes	that	normally	use	αKG	as	a	cofactor,	
thereby reducing activity of these enzymes. Inhibition of TET hydroxymethylases leads to hypermethyl-
ation	of	CpG	islands	in	the	genome.	Inhibition	of	JHMDs	leads	to	hypermethylation	of	lysines	in	histone	
H3.	This	hypermethylated	genotype	results	in	altered	gene	expression	and	a	dedifferentiated	phenotype	
of	the	cell.	Note	that	both	D-2HG-mediated	stimulation	and	inhibition	of	PHDs	has	been	suggested	in	
literature.	As	PHDs	regulate	degradation	of	HIF1α,	this	translates	into	either	upregulation	or	downreg-
ulation of hypoxia-inducible genes. The histopathology of IDH1 mutated (low-grade) tumors, which in 
general	lack	signs	of	hypoxia	and	expression	of	hypoxia	related	genes,	suggests	that	D-2HG	stimulates,	
rather	than	inhibits,	PHDs.	Abbreviations:	αKG,	α-ketoglutarate;	D-2HG;	D-2-hydroxyglutarate;	HIF1α,	
hypoxia	 inducible	 factor-1;	 IDH1,	 isocitrate	 dehydrogenase	 1;	 JHMDs;	 Jumonji-C-domain-containing	
histone	demthylases;	PHDs,	prolyl	hydroxylases.	Adjusted from Van Lith et al., [89], reprinted with per-
mission © Elsevier
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cell	lines	like	U87	or	U251,	however,	is	the	phenotype	of	the	resulting	tumors	when	grown	in	
the	brains	of	immune-deficient	animals	[92].	These	tumors	generally	form	compact,	sharply	
circumscribed	masses	that	do	not	resemble	their	originating	diffuse	infiltrative	tumor.	When	
cultured under classical conditions (e.g. serum addition, trypsin for detachment), tumor cells 
lose heterogeneity and drift away genetically from the original tumor due to selective pres-
sure of tissue culturing. Also primary cell lines already show a genetic drift in early passages, 
when compared to the original tumor [93]. It is now widely accepted that traditional cell cul-
ture conditions alter the phenotype and genotype of cell lines, inducing clonal selection of 
certain subsets of cells, making them less relevant as models for the evaluation of therapies 
for glioma. 
 In recent years novel cell culture methods have been developed. Neural stem cells 
(NSCs) can be grown in vitro	using	specific	culture	media	supplemented	with	certain	growth	
factors (e.g. EGF and bFGF) and without calf serum, since this induces irreversible differenti-
ation	[94-96].	NSCs	form	neurospheres,	which	are	cell	clumps	that	float	in	culture	medium.	In	
contrast to traditional cell lines, neurospheres remain heterogeneous, having both stem-like 
and more differentiated cells. Interestingly, while serum-cultured cells change in both gen-
otype and phenotype and generally grow as compact tumors upon implantation in mouse 
brains, cells grown in neurosphere cultures generally retain heterogeneity. Xenografts de-
rived from such neurosphere cultures are reported to resemble the original tumor genetically 
better than tumors derived from cell cultures [97, 98]. Importantly, as xenografts derived 
from neurospheres retain invasive growth characteristics, the availability of such cell lines 
provides handles to further study glioma biology, for example by manipulating the genome, 
allowing functional studies towards genes that may be involved in gliomagenesis or glioma 
progression. 
In vivo models
 To avoid the introduction of phenotype-changing alterations, glial cells derived from 
patient	biopsies	have	also	been	inoculated	directly	in	the	brains	of	immune	deficient	animals	
[92, 99, 100]. Although sometimes a switch in phenotype has been observed over time (e.g. 
from an invasive to more angiogenic) [99], xenografts mainly remain invasive upon serial 
passaging (Figure 8). 
	 While	most	GBMs	can	be	 successfully	 xenografted,	 no	 stable	 animal	models	 of	
low-grade glioma have been established. Also models of high-grade astro- and oligoden-
drogliomas with IDH1-mutations	have	been	extremely	difficult	to	generate	and	until	recently	
no representative IDH-mutated xenograft models were available. In our own experience and 
that of others it is (almost) impossible to establish stable in vitro cultures of IDH1-mutant cells 
[101]. Only few xenograft lines have become available in the last years that maintain this 
mutation in vivo (described amongst others in this thesis). The lack of such models hampers 
research	towards	therapeutic	targeting	of	these	specific	subtypes.
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Genetically engineered models (GEMs)
 Complex strategies have been used to introduce gain or loss of multiple genes in 
genetically	modified	animals,	which	together	lead	to	the	development	of	glial	tumors.	These	
GEMs frequently represent the histopathology of a human glioma. Pathways that have been 
manipulated include PDGF, p53, EGFR, Rb, Ras and AKT [102]. A major advantage of GEMs 
involves the interactions between tumor cells and stroma from the same species. Further-
more, in contrast to the situation in xenograft models, in which immune-compromised an-
imals are used, interactions with the immune system are recapitulated in GEMs, as these 
animals are immune-competent.
Figure 8. Biopsy-based glioma xenografting. Biopsies direct-
ly obtained from glioma surgery material can be inoculated in 
the	brains	of	immune	deficient	animals	to	give	rise	to	tumors	that	
can stil (partially) grow invasively in the brain parenchyma. An 
H&E	overview	staining	(left)	and	a	magnified	image	are	shown	
from the E98 GBM model. Note the tumor cells that invade along 
white matter tracts.
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Outline of this thesis
 The major aim of this thesis is to evaluate different approaches to target diffuse 
gliomas in relevant models. Diffuse gliomas form a heterogeneous group of tumors that are 
all characterized by extensive invasion of tumor cells into the brain parenchyma, with in high-
grade gliomas areas of hypoxia and angiogenesis. 
 In recent years, many clinical trials for GBM patients focussed on angiogenesis 
inhibition,	especially	based	on	phase	II	clinical	trials	that	revealed	significant	radiological	re-
sponses and effects on progression-free survival. In previous work we found that radiological 
responses of VEGFR2 inhibition resulted from vascular normalization rather than anti-tumor 
effects. In Chapter 2 we extend this work by combining VEGFR inhibition with PDGFR inhi-
bition in two different diffuse glioma xenograft models and test whether combined inhibition 
of PDGFR-associated vessel maturation and of the VEGF pathway would result in better 
anti-tumor effect.
 The poor visibility of glioma in radiological images, especially after anti-angiogenic 
therapy, calls for alternative and better diagnostic tests. In Chapter 3 we compare MRSI 
and	CE-MRI	for	the	ability	to	delineate	tumor	extent,	also	after	anti-angiogenic	therapy.	We	
describe that MRSI is a powerful method to detect glioma, based on altered metabolism and 
independent of the status of the BBB. 
	 	Diffuse	infiltrative	growth	in	the	brain	is	the	main	factor	that	makes	gliomas	incur-
able. One of the potential targets for invasive glioma cells is MET. Studies with invasive pre-
clinical glioma xenograft models treated with MET inhibitors are lacking however. Interesting-
ly, one of our GBM models (E98) is characterized by strong MET expression and activation. 
In Chapter 4	we	therefore	analyze	the	effects	of	dual	 inhibition	of	MET	(infiltrative	growth)	
and VEGFR2 (angiogenesis). As MET activation in E98 is ligand-independent, we further in-
vestigate the underlying mechanism of MET signaling in these cells in Chapter 5. The novel 
findings	obtained	are	also	correlated	to	a	larger	series	of	gliomas	and	a	subset	of	other	tumor	
types.
 RTKs like MET and EGFR are clearly linked to glioma biology. Kinase activity in 
these	receptors	is	under	influence	of	PTPs.	Several	PTPs	have	also	already	been	associated	
with glioma biology. PTPRZ-B has been demonstrated to be strongly upregulated in glial 
tumors	and	implicated	in	proliferation	and	migration	in	glioma	cell	lines.	Up	till	now,	studies	
of the role of PTPs in relevant in vivo glioma models are largely lacking. In Chapter 6 we 
evaluate the importance of the phosphatase PTPRZ-B on glioma growth and migration both 
in vitro and in vivo, using the E98 GBM and E434 anaplastic oligodendroglioma models. 
 Although targeting growth factor signaling is an attractive therapeutic approach, re-
cent years have learned that a subset of diffuse gliomas may also have another Achilles heel; 
their metabolic demand. Mutations in IDH1,	which	encodes	the	cytosolic	IDH1	enzyme	that	
converts	isocitrate	to	α-KG,	are	prominent	in	the	majority	of	grade	II	and	III	diffuse	gliomas	
and secondary GBMs. To successfully study therapies in IDH1-mutant gliomas, obviously 
models that carry this mutation and faithfully recapitulate the resulting (metabolic) chang-
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es are required. In Chapter 7 we describe the characterization of a unique IDH1 mutant 
oligodendroglioma xenograft model. Subsequently, we discuss the implications that these 
alterations must have on cellular metabolism in Chapter 8 and propose potential novel ther-
apeutic strategies to tackle these devastating tumors.  
 In brief, in the studies presented in this thesis we analyze several therapeutic ap-
proaches that involve the inhibition of both angiogenesis and invasion, investigate the po-
tential of novel imaging techniques for adequate assessment of diffuse gliomas, and provide 
clues for future, more promising treatment strategies for glioma patients. 
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Abstract
 Currently available compounds that interfere with VEGF-A signaling effectively in-
hibit angiogenesis in gliomas, but influence diffuse infiltrative growth to a much lesser extent. 
Development of a functional tumor vascular bed not only involves VEGF-A but also requires 
platelet derived growth factor receptor-β (PDGFRβ), which induces maturation of tumor blood 
vessels. Therefore, we tested whether combined inhibition of VEGFR and PDGFRβ increases 
therapeutic benefit in the orthotopic glioma xenograft models E98 and E473, both displaying 
the diffuse infiltrative growth that is characteristically observed in most human gliomas. We 
used bevacizumab and vandetanib as VEGF(R)-inhibitors, and sunitinib to additionally target 
PDGFRβ. We show that combination therapy of sunitinib and vandetanib does not improve 
therapeutic efficacy compared to treatment with sunitinib, vandetanib or bevacizumab alone. 
Furthermore, all compounds induced reduction of vessel leakage in compact E98 tumor 
areas, resulting in decreased detectability of these mostly infiltrative xenografts in Gd-DTPA 
enhanced MRI-scans. 
 These data show that inhibition of VEGF signaling cannot be optimized by addition-
al PDGFR inhibition and supports the concept that diffuse infiltrative areas in gliomas are 
resistant to anti-angiogenic therapy. 
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Introduction
 Glioblastoma (GBM) is a primary brain tumor which is characterized by angiogenic 
tumor areas, but also extensive diffuse infiltrative dispersion in the brain [45]. Treatment 
consists of surgery when possible, followed by radiotherapy and chemotherapy. Curative 
treatment is rare since complete removal of tumor cells is very difficult to achieve [10, 52, 
103]. The majority of patients therefore die within 15 months after initial diagnosis. In the an-
giogenic areas of GBM the vasculature is leaky, allowing contrast enhanced magnetic reso-
nance imaging (CE-MRI)-based detection. In contrast, in the diffuse infiltrative tumor regions 
pre-existing blood vessels with an intact blood-brain barrier (BBB) are involved, preventing 
extravasation of contrast agents and thereby hampering radiological delineation of tumor 
areas in T1-weighted Gd-DTPA MRI [50, 52]. 
 Many compounds have been developed that effectively inhibit the angiogenic fac-
tor Vascular Endothelial Growth Factor-A (VEGF-A). The anti-VEGF-A antibody bevacizumab 
and tyrosine kinase inhibitors (TKIs) of angiogenic receptors are now used for the clinical 
management of a number of tumor types [104-107].  The presence of angiogenic areas in 
GBM suggests that also these tumors may be candidate for anti-angiogenic therapies. Bev-
acizumab treatment of patients with recurrent GBM indeed results in radiological respons-
es and improved progression free survival (PFS) [108]. Yet, the efficacy of anti-angiogenic 
treatment on glioma outgrowth is still an issue of active debate, culminating in FDA approval 
of bevacizumab for treatment of patients with recurrent glioma in the United States, while the 
European Medicines Agency (EMA) declined bevacizumab for this condition.
 We previously showed that vandetanib, a potent TKI directed against VEGFR2 and 
Epidermal Growth Factor Receptor (EGFR) [109] affected angiogenesis-dependent tumor 
growth in brain models of metastatic melanoma and different orthotopic glioma xenograft 
models, but at the same time did not improve survival of the tumor-bearing animals [35, 50, 
51, 110]. This could be attributed to a lack of inhibition of diffuse infiltrative or perivascular 
growth. Vandetanib caused a significant reduction of vessel leakage, resulting in difficulties 
with CE-MRI-based detection [50, 51, 110]. The diminished extravasation of contrast agent 
due to reduced vessel leakage may indeed result in an overestimation of drug efficacy in 
clinical studies (‘pseudoresponse’), not only with respect to glioma but also to metastatic 
tumors in brain [108, 111]. 
 In the Rip-Tag mouse model of pancreatic carcinoma, the efficacy of anti-angiogen-
ic therapy is greatly improved by simultaneous targeting of VEGF and platelet derived growth 
factor (PDGF) receptors [112]. This can be explained by the presence of tumor vessels in 
early stages of development, which are susceptible to VEGFR inhibition only, and vessels 
in later stages of maturation, which are solely responsive to PDGFR inhibition. The promi-
nent vessel heterogeneity in gliomas suggests that similar mechanisms may be operative 
in these tumors as well. Blood vessels with a mature phenotype may not be susceptible to 
anti-VEGF treatment, but additional targeting of these vessels via inhibition of PDGFR may be 
of benefit. A recent phase II clinical study supports this proposition as cediranib (RECENTIN, 
AZD2171), an inhibitor of VEGFR, c-KIT and PDGFR, improves PFS in patients with recurrent 
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GBM [113]. These results warrant further investigations in relevant preclinical glioma models.
 Here we performed in depth analysis of the effects of bevacizumab and sunitinib 
(a TKI with high affinity for VEGFR and PDGFRβ [114]), either alone or in combination with 
vandetanib, in two orthotopic xenograft models of glioma, E98 and E473 [18]. One of the 
morphological key features of both xenograft models is the presence of large areas with dif-
fusely infiltrating tumor cells, whereas the E98 model also presents more compact angiogen-
esis-dependent areas. The diffuse infiltrative phenotype closely mimics the growth pattern in 
large areas of human gliomas, distinguishing these xenografts from many other orthotopic 
glioma models. Since this phenotype may be an important determinant for the susceptibility 
to anti-angiogenic compounds, it is of paramount importance to investigate the effects of 
these therapies in such relevant models. We show that in E98 xenografts (partial) restoration 
of the BBB is a result of anti-angiogenic treatment and that additional targeting of the PDGFR 
pathway does not exert a beneficial effect on the infiltrative part of the tumor and therefore 
does not improve outcome for both xenograft models.
233
Materials and Methods
Animal tumor models 
 All experiments were approved by the Animal Experimental Committee of the Rad-
boud University Nijmegen Medical Centre and were carried out in accordance with national 
and international guidelines. Balb/c nude mice (6- to 8-weeks-old, weighing 18–25 g) were 
kept under specific pathogen free conditions and received food and water ad libitum. Or-
thotopic E98 and E473 gliomas were xenografted as described previously [92]. Both lines 
consistently produced intracerebral tumors displaying diffuse infiltrative and, in case of the 
E98 line, additional angiogenesis-dependent growth in the brain parenchyma. 
Anti-angiogenic treatment 
 Mice carrying orthotopic E98 xenografts were randomly divided into groups of five, 
except for the control group (P), which consisted of seven animals. Three different anti-an-
giogenic agents were used in four treatment groups: bevacizumab (B), sunitinib (S), vande-
tanib (V) and vandetanib plus sunitinib (VS). Treatments started on day 8 after intracerebral 
injection of tumor cells. On that day, two mice from the control group were sacrificed to check 
tumor burden. Bevacizumab (Avastin, Genentech, San Francisco, US) was administered 
four times (day 8, 10, 12 and 14 after intracerebral injection) by intraperitoneal injection in a 
volume of 100 ml (5 mg/kg in phosphate buffered saline). Mice received vandetanib (ZAC-
TIMA™, AstraZeneca, Macclesfield, UK) (50 mg/kg as a suspension in 1% polysorbate-80) 
or sunitinib (Sutent, Pfizer, New York, US) (30 mg/kg as a suspension in 12.5% cremaphor/ 
12.5% ethanol in water) once daily by oral gavage in a volume of 100 µl. At these concen-
trations, the therapeutic agents have shown in vivo efficacy in preclinical models [51].  Mice 
were treated from day 8 until day 21 after tumor injection. A fourth group (VS) was treated 
with a combination of vandetanib and sunitinib using the dosage scheme as described for 
the individual compounds. The control group (n=5) received 1% polysorbate-80 vehicle only. 
To limit the number of animals in this study, we relied on historical controls, which showed 
that IP injection of PBS did not affect mouse welfare or tumor behavior.
 A similar protocol was applied to mice carrying orthotopic E473 xenografts. Mice 
were left untreated (n=6), treated twice weekly with bevacizumab (n=5), or daily with the 
combination vandetanib and sunitinib (n=6) as described above. Treatment in these groups 
started at day 29, when signs of tumor development were observed in MRI (data not shown).
CE-MRI 
 Throughout the experiments, mice were monitored closely by visual inspection. Af-
ter 16 to 20 days, when tumor-related symptoms became apparent for the E98 model (weight 
loss and neurological defects), imaging was performed on a 7T preclinical MR setup (MR 
Research Systems, Guildford, UK) as described previously [50] using a 12-mm diameter 
transmit/receive head coil. In short, 16 T1-weighted coronal images (TE= 8 ms; TR = 100 ms; 
flip angle = 90°; number of averages = 1; field of view = 25 × 25 mm2; matrix size = 256 × 
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256; slice thickness = 1 mm) were acquired. A bolus of 0.2 ml of Gd-DTPA (20 mMol/l, Mag-
nevist®, Schering, Germany) was injected intravenously and additional sets of T1-weighted 
images were acquired immediately following injection and at 2 and 10 min after administra-
tion. CE-MRI was carried out on at least two mice per treatment group (P: n=2; B: n=2; S: 
n=4; V: n=3 and VS: n=3). For mice receiving daily doses of sunitinib and/or vandetanib, 
CE-MRI was performed on the same day as the last dose. Mice in the bevacizumab group 
received the last dose on day 14 and CE-MRI was performed five to seven days later. With a 
half-life of approximately 20 days [115] significant levels of bevacizumab are still expected 
in the circulation at the time of imaging. 
Immunohistochemistry 
 Mice were sacrificed when effects of tumor development were apparent, and their 
brains removed, formalin-fixed and cut in coronal slices of approximately 2 mm before em-
bedding in paraffin blocks. Sections of 4 µm were subjected to H&E or immunohistochemical 
stainings using antibodies against Ki-67 (Clone SP6, Lab Vision Corporation, Fremont, CA, 
USA) for proliferating cells, CD34 (MEC14.7, Hycult Biotechnology, Uden, The Netherlands) 
to detect mouse brain capillary endothelial cells, mouse IgG (DakoCytomation, Glostrup, 
Denmark) to detect vessel leakage, and GLUT1 (DakoCytomation) to highlight brain vascula-
ture with an intact BBB. GLUT1 was simultaneously used as a marker to detect hypoxic tumor 
cells [116] . The fraction of hypoxic cells in E98 tumors was quantified as described [50] and 
expressed as percentage hypoxic tumor area (GLUT1 staining area) / total tumor area x100. 
Proliferation indices were measured in 4 random, non-overlapping microscopic fields (mag-
nification x200) in both compact and diffuse infiltrative growth areas. A proliferation index of 
50% or more was considered high, 20% or less was considered low. Measurements were 
performed in tumors of all placebo-treated and anti-angiogenesis-treated E98 and E473 
mice. Hypoxia data (percentages) were subjected to a one-way ANOVA with treatment as 
factor. A post-hoc T-test (two-sided) was performed where appropriate and a p-value <0.05 
was considered significant.
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Results 
Anti-angiogenic treatment 
 Mice bearing E98 tumors were treated with bevacizumab, sunitinib, vandetanib or 
a combination of sunitinib and vandetanib. All treatments were well tolerated. Mice were 
sacrificed when obvious signs of tumor growth (evident weight loss, neurological defects) 
were present (P: day 22 +/- 9; B: day 22 +/- 3; S: day 18 +/- 2; V: day 19 +/- 3; VS: day 19 
+/- 3, p=n.s.). Although none of the therapies delayed development of tumor-related symp-
toms, treatments did cause anti-tumor effects in the expansive compact growing tumor areas 
which, in E98 xenografts, are reproducibly found in the lateral ventricles and leptomeningal 
spaces [92]. Mice from groups V and VS showed a significantly higher percentage of hy-
poxia in the compact tumor areas compared with the vehicle-treated mice (Figure 1, one-
way ANOVA: treatment effect: p<0.05; 13.4% in P vs 32.7% in V and 29.9% in VS groups, 
p<0.01). In mice treated with bevacizumab or sunitinib alone, there was a similar trend al-
though significance was not reached (Figure 1, 13.4% in placebo vs 22.4% in B (p=0.1) and 
22.9% in S groups (p=0.2)). A prominent effect of all therapies was the near absence of florid 
microvascular proliferations [45], which were found in 80% of the vehicle-treated animals 
(Figure 2C, D).
 Importantly, although inhibition of VEGF signaling resulted in an increase of hypox-
ia in the compact tumors, tumor growth was still possible here to some extent (Figure 3A, 
asterisk), presumably due to diffusion of nutrients from the surroundings. This hypothesis is 
supported by a high proliferation index in the tumor rim whereas the proliferation was strong-
ly decreased in hypoxic areas (50-60% in non-hypoxic tumor parts vs 10% in hypoxic areas, 
Ki67 stainings in Figure 3B). In sharp contrast, none of the anti-angiogenic treatments nota-
bly affected diffuse infiltrative tumor areas (Figure 2B and H&E stainings in Figure 4), similar 
to previous observations with vandetanib treatment alone [51]. No hypoxia was detected 
in the diffuse infiltrative tumor areas (Figure 3A, arrow head) and the proliferation index re-
mained high in these areas (± 70%, Figure 3B, arrowhead). 
Figure 1. Percentage of hypoxia in E98 
xenografts in the different treatment 
groups. All anti-angiogenic treatments 
cause an increase in hypoxia in the com-
pact tumor compartments. Hypoxia in 
compact tumor areas in mice treated with 
vandetanib (V) or combination vandetan-
ib-sunitinib (VS) was significantly higher 
than in compact tumors in placebo-treated 
mice (P) (*: p<0.01). A similar increase, 
although not significant, was present in 
compact tumor areas of mice treated 
with bevacizumab (B) and sunitinib (S). 
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Figure 2. Effect of anti-angiogenic treatment on mice carrying intracerebral E98 tumors.  Shown 
are representative H&E stainings of vehicle-treated mice (A,C) and vandetanib + sunitinib-treated 
mice (B).  Panels C and D show an example of  a glomeruloid microvascular proliferation in a ve-
hicle-treated mouse in H&E and CD34-immunohistochemical staining respectively. Whereas this 
phenotype was observed in 80% of vehicle-treated mice, this phenotype was only occasionally ob-
served in the sunitinib group and was absent  in all other treatment groups (panel G). Panels E and 
F show immunostainings for mouse IgG in vehicle-treated and vandetanib treated mice respectively. 
Note the extravascular deposition in the control tumor whereas IgG is confined to the blood vessels 
in the treated mouse. The diffuse infiltrative areas in e.g. the corpus callosum (A,B, arrow heads) 
were not notably affected by the treatment. Original magnifications: A,B: x12; C,D: x400; E,F: x200. 
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To rule out tumor-specific features that cause resistance to anti-angiogenic compounds, we 
performed similar experiments in orthotopic E473 xenografts, characterized by only diffuse 
infiltrative growth (Figure 5A). E473 bearing mice were left untreated (P) or where treated with 
bevacizumab (B) or the combination vandetanib and sunitinib (VS). Again, treatment did not 
notably prolong time until tumor-related symptoms became evident (P: day 42 ± 8; B: day 
44 ± 9; VS: day 35 ± 2, p=n.s.). Mice in the VS group had to be sacrificed earlier than the 
other groups, due to extensive weight loss. Reason for the early deterioration is unknown. 
Examination of liver and kidney showed no obvious signs of toxicity. Histological analysis of 
E473 mouse brains revealed no treatment-induced alterations in the infiltrative growth pat-
tern (Figure 5A). Proliferation indices were not significantly influenced by treatment  (Figure 
5A, control group: 34%, treatment groups 37%, p=0.13). Thus, targeting VEGF or its recep-
tors, either or not in combination with inhibition of PDGFRß, does not interfere with invasive 
growth of E473 glioma cells.
Effect of anti-angiogenic treatment on the blood-brain barrier   
 The angiogenic areas in E98 tumors allow CE-MRI based detection. In diffuse 
infiltrative areas leakage is lower than in the compact tumor parts, consistent with a pre-
dominantly intact BBB in these regions [51]. Bevacizumab, sunitinib and the combination of 
sunitinib and vandetanib all resulted in (partial) restoration of the BBB and, consequently, 
decreased visibility in CE-MRI, despite the presence of large tumors. Characteristic exam-
ples of MR images and corresponding histology of tumor bearing brains are presented in 
Figure 4. CE-MRI results were in agreement with the lack of IgG extravasation in treated mice 
(compare Fig 2F to 2E).
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Figure 3. Effect of anti-angiogenic 
treatment on hypoxia and prolifera-
tion index in the tumor. Representa-
tive GLUT1 (A) and Ki-67 (B) immuno-
histochemical stainings of intracerebral 
E98 lesions of a bevacizumab-treated 
mouse (shown are serial sections). The 
compact tumor areas show a striking 
increase in hypoxia (A, asterisk). The 
proliferation index of tumor cells re-
mains high in both diffuse infiltrative 
(A,B, arrow heads) and compact (A,B, 
arrows) tumor areas despite anti-angio-
genic treatment. Only in hypoxic tumor 
regions in the compact tumor areas (A, 
asterisk, GLUT1), there is a strong de-
crease in proliferation index (B, aster-
isk, Ki-67). There is no hypoxia detect-
able in the diffuse infiltrative areas (A,B, 
arrow heads). Graph (C) illustrates that 
there is no difference in proliferation in-
dices when comparing placebo-treat-
ed and anti-angiogenic-treated mice. 
Original magnifications: A,B: x100. 
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Figure 4. Correlation between CE-MRI and histopathology of intracerebral E98 glioma lesions. 
For each treatment group, a representative image is shown of the intracerebral lesion before (pre) 
and after (post) injection of Gd-DTPA contrast agent. Maps of the relative signal enhancement upon 
contrast agent injection (Spost-Spre)/Spost are displayed in the third column. All post images are tak-
en immediately after the contrast agent injection. H&E stainings of corresponding slices are shown 
to the right. Tumors in vehicle-treated mice (P) were readily detectable using Gd-enhanced MRI. No 
tumor was detected in MRI of mice treated with the anti-angiogenic compounds bevacizumab (B), suni-
tinib (S), vandetanib (V) or with the combination vandetanib-sunitinib (VS). H&E staining of the corre-
sponding brain slice, however, shows extensive tumors. Original magnification of H&E stainings: 12x.
239
  The unresponsiveness of E473 tumors to anti-angiogenic compounds strongly sug-
gests that for growth, these tumors do not need angiogenesis. Indeed, these tumors have 
incorporated pre-existent vessels with an intact blood brain barrier, as illustrated by GLUT1 
expression (Fig 5B) and lack of extravasation of plasma IgG proteins (Fig 5C). The intact 
BBB in E473 tumors hampers detection in Gd-DTPA contrast-enhanced (CE) MRI scans and, 
as expected, this does not change upon treatment with bevacizumab or sunitinib/vandetanib 
(data not shown). 
A
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H&E Ki67
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B
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B
Figure 5. Anti-angiogenic treatment of highly diffuse infiltrative E473 glioblastoma xenografts. Rep-
resentative H&E and Ki-67 images (A) of E473 brain slices of mice left untreated (P), treated with bevacizum-
ab (B), or the combination vandetanib and sunitinib (VS) are shown. The mainly diffuse infiltrative phenotype 
nor the proliferation index are notably effected by anti-angiogenic therapy. Regions of which Ki67 images 
are shown are indicated in the H&E stainings. Presence of vasculature with an intact BBB is illustrated by 
GLUT1 positive vessels intumor regions of an untreated E473 mouse (B) and the absence of IgG vessel 
leakage in these regions (C). Original magnifications: A: H&E 20x, Ki67 400x B: 400x, and C: 20x/400x.
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Discussion
 
 GBM is a highly malignant brain tumor characterized by the presence of areas with 
highly cellular and more compact, angiogenesis-dependent growth as well as large diffuse 
infiltrative areas which up till now leave these tumors essentially incurable [103]. Characteris-
tically, in the more compact tumor components prominent angiogenesis occurs, suggesting 
that gliomas may be good candidates for anti-angiogenic therapies [117]. However, the 
effectiveness of anti-angiogenesis for glioma is still matter of debate since the angiogene-
sis-dependency of gliomas is not as clear-cut as in many other tumor types. This is mainly 
due to the extensive diffuse infiltrative growth of glioma cells in the pre-existent brain paren-
chyma and to the very high density of pre-existent blood vessels in the brain, which can be 
co-opted by infiltrating glioma cells [118, 119]. Still, the improved PFS seen with anti-angio-
genic therapies in other tumor types, together with a disturbing lack of effective treatment 
options for glioma patients, has resulted in implementation of anti-angiogenic compounds, in 
combination with chemotherapy, in the clinical management of these patients. 
 We here show that anti-angiogenic treatment (bevacizumab, sunitinib and/or van-
detanib) results in at least a partial restoration of the disrupted BBB and reduced vessel 
permeability in orthotopic glioma xenografts. This phenomenon may lead to overestimation 
of response to treatment on Gd-DTPA-enhanced MR images [50]. It is important to take this 
knowledge into account when evaluating treatment response based on standard CE-MRI. 
There is now increasing awareness of this pitfall, which has recently also led to a proposition 
of updated criteria for the assessment of therapeutic response in high-grade glioma patients 
[120]. 
 In previous work we showed that normalization of brain tumor vasculature and con-
comitant closure of the BBB may have an antagonizing effect on the distribution of chemo-
therapy to tumor cells [51]. The current data show that antagonism of chemotherapies could 
also be anticipated when other VEGFR/ PDGFR-targeting compounds are used that result in 
BBB restoration. Yet, it has to be realized that (partial) BBB closure and the resulting reduc-
tion of edema and intracranial pressure has a clear clinical benefit [113, 121]. Clinically, this 
may be misinterpreted as tumor regression and this effect may also account for improved 
PFS. 
 Anti-angiogenic therapies in gliomas do not result in tumor regression but rather 
induce a shift from angiogenic to infiltrative, but progressive growth [35]. This is in agree-
ment with recent studies showing that anti-angiogenic TKIs can increase invasiveness of 
tumor cells in pancreatic carcinoma, breast carcinoma, melanoma and GBM and even may 
accelerate metastatic tumor growth [122, 123]. We here show that anti-angiogenic therapies 
do not affect progression of the diffuse tumor areas, whereas angiogenesis in the compact 
growing components in gliomas is potently inhibited, resulting in increased hypoxia. A con-
version to an exclusively co-opting phenotype may provide gliomas with a mechanism of 
escape from anti-angiogenic therapy [124]. 
 It was recently published that diminishing edema by anti-angiogenic compounds 
in mice with intracerebral glioma xenografts prolonged survival [46]. Why survival of mice 
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xenografts in our study was not elongated is not clear but may be related to the extensive dif-
fuse infiltration in our models. Mice carrying E473 xenografts receiving the TKI combination 
had to be sacrificed earlier than the other groups due to illness and weight loss. We cannot 
explain this phenomenon. Investigation of the livers of treated mice did not reveal signs of 
hepatotoxicity. We can however not exclude that other toxicities exist.
 Whereas PDGFR inhibition is effective in preventing the maturation process during 
later stages of angiogenesis [112], it does not affect vasculature in diffuse growth areas in 
our tumor models. This provides further evidence that these co-opted vessels are pre-exist-
ing, incorporated vessels and are not newly formed. 
 It must be noted that stromal cell derived mouse VEGF-A is not neutralized by bev-
acizumab [125]. We consider it unlikely that mouse VEGF-A contributes to angiogenesis in 
E98 xenografts as VEGF-A is expressed solely by hypoxic tumor cells in angiogenic regions 
[92]. 
 The role of the BBB in treatment of glioma is an important issue. In order to neutral-
ize VEGF-A, bevacizumab should be able to freely diffuse through the tumor to reach hypox-
ic cells. In angiogenic areas this diffusion is initially facilitated by leaky vessels, but this will 
be a self-limiting process due to vessel normalization. This may not be an issue with TKIs as 
these directly target endothelial cells.
 Several recent clinical studies using bevacizumab or cediranib (AZD2171, Astra-
Zeneca) revealed reduced contrast-enhancement in half of the GBM patients [108, 113, 121] 
without prolonged overall survival. The difficulties in obtaining post-therapy GBM material 
for histopathological analysis make it difficult to determine whether radiological reduction 
is the result of true tumor regression or whether therapeutic efficacy is overestimated due 
to restoration of the BBB. Recent clinical data are in favour of the second hypothesis [52]. 
In conclusion, our data show that the incorporation of pre-existing brain vasculature in dif-
fuse infiltrative growth parts of GBMs prohibits effective curative therapy using approaches 
targeting VEGF. These results suggest that anti-angiogenic therapies need to be used in 
combination with compounds that can target the diffuse infiltrative parts of these devastating 
tumors.
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Multivoxel 1H-magnetic resonance spectroscopy is 
superior to contrast-enhanced MR imaging for response 
assessment after anti-angiogenic treatment of orthotopic 
human glioma xenografts and provides handles for 
metabolic targeting.
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Abstract
 Anti-angiogenic treatment of glioblastoma characteristically results in therapy re-
sistance and tumor progression via diffuse infiltration. Monitoring tumor progression in these 
patients is thwarted since therapy results in tumor invisibility in contrast-enhanced mag-
netic resonance imaging (CE-MRI). To address this problem, we examined whether tumor 
progression can be monitored by metabolic mapping using 1H-MR Spectroscopic Imaging 
(MRSI). 
 We treated groups of BALB/c nu/nu mice carrying different orthotopic diffuse-infil-
trative glioblastoma xenografts with bevacizumab (anti-VEGF antibody, n=13), cabozantinib 
(combined VEGFR2/MET tyrosine kinase inhibitor, n=11) or placebo (n=15) and compared 
CE-MRI to MRS-derived metabolic maps before, during and after treatment. Metabolic maps 
and contrast-enhanced MR images were subsequently correlated to histology and immuno-
histochemistry. 
 In vivo imaging of choline/N-acetyl aspartate ratios via multivoxel MRS is better able 
to evaluate response to therapy than CE-MRI. Lactate imaging reveals that diffuse infiltrative 
areas in glioblastoma xenografts do not present with excessive glycolysis. In contrast, gly-
colysis is observed in hypoxic areas in angiogenesis-dependent compact regions of glioma 
only, especially after anti-angiogenic treatment.
 Our data present MRSI as a powerful and feasible approach which is superior to 
CE-MRI and which may provide handles for optimizing treatment of glioma. Furthermore, we 
show that glycolysis is more prominent in hypoxic areas than in areas of diffuse infiltrative 
growth. The Warburg hypothesis of persisting glycolysis in tumors under normoxic condi-
tions may thus not be valid for diffuse glioma.
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Introduction
 Glioblastoma (GBM) is a highly aggressive primary brain tumor with dismal prog-
nosis. Current therapy consists of surgery to the maximum feasible extent, followed by lo-
cal irradiation and chemotherapy with Temozolomide (TMZ). These treatments are however 
palliative rather than curative: almost without exception GBMs eventually recur with fatal 
outcome, and median survival is currently still only 14.6 months [10].
 GBMs characteristically contain areas of necrosis, surrounded by regions of active 
angiogenesis [45]. The lack of curative treatment options results from the presence of addi-
tional tumor zones in which cells infiltrate in a spiderlike pattern over considerable distances 
in the brain, often using white matter tracts or blood vessels as a scaffold and preventing rad-
ical surgery and radiotherapy. Diffuse infiltrative tumor growth does not strictly rely on neo-
vascularization as incorporated pre-existent vasculature in these areas suffices to comply to 
the tumors’ metabolic demands [119]. As the blood brain barrier (BBB) in these incorporated 
vessels is mostly intact, regions of diffuse tumor growth go largely unnoticed on contrast-en-
hanced (CE-)MRI scans, which might result in an underestimation of tumor burden [50, 52, 
54, 126, 127]. Also, the BBB in diffuse infiltrative tumor areas complicates treatment with 
intravenously administered therapies [51].
 In the absence of curative treatment options, the presence of angiogenic areas in 
GBMs has made these tumors candidates for anti-angiogenic therapy [108, 128, 129]. The 
VEGF-A neutralizing antibody bevacizumab induces a radiological response in the majority 
of patients and may considerably improve quality of life [49, 52, 130]. Bevacizumab was FDA 
approved for treatment of recurrent glioma in 2009. 
 In the past years we have generated a number of orthotopic human glioma xeno-
graft models by direct implantation of surgically obtained GBM specimens in nude mice 
[92]. Unlike most cultured glioma cell lines which develop to circumscribed and angiogenic 
tumors upon intracerebral implantation (e.g. U87-MG, see [131]), our xenograft models have 
retained the capacity to grow via diffuse infiltration, sometimes concomitant with local angio-
genesis. It is increasingly recognized that these models that recapitulate the heterogeneous 
phenotypes of clinical glioma, including intact blood-brain barrier in diffuse areas, are of high 
value for preclinical investigations of anti-glioma therapies [132]. We previously reported 
that treatment of diffuse glioma xenograft models with angiogenesis inhibitors (bevacizum-
ab, vandetanib, sunitinib and combinations thereof) affects compactly growing, angiogen-
esis-dependent regions in glioma, but does not have an impact on the diffuse infiltrative 
phenotype [50, 51, 127]. These treatments did not improve overall survival in our models. 
 Whereas the perinecrotic angiogenic areas in clinical GBM can be readily visual-
ized in CE-MRI scans, this visibility drops rapidly when VEGF-targeted therapies are applied 
[52, 113]. In our orthotopic glioma models this effect is also observed and it is well estab-
lished that this does not represent an anti-tumor effect but is rather due to vascular normal-
ization and (partial) restoration of the BBB [50, 51, 127, 133], making it difficult to evaluate 
response to therapy via routine CE-MRI. We argued that non-invasive in vivo measurement 
of tumor metabolic characteristics is a better method to detect diffuse infiltrative glioma, as 
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tumor metabolism does not depend on the status of the BBB. 
 We here investigated whether metabolic mapping via multivoxel in vivo 1H-MR spec-
troscopic imaging (MRSI) is more appropriate to detect glioma progression under anti-angio-
genic therapies and we examined the effects of these therapies on tumor metabolism.
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Materials and Methods
Animals 
 Athymic female BALB/c nu/nu mice (18-25 gram, age 6-8 weeks) were kept under 
specified pathogen free (SPF) conditions and received food and water ad libitum. The local 
Animal Experimental Committee of the Radboud University Nijmegen Medical Center ap-
proved all experiments. E98 or E473 GBM cells were injected orthotopically as described 
previously (approximately 300,000 tumor cells per mouse) [92]. Animals were closely moni-
tored and subjected to MRS and MRI followed by sacrifice when evident signs of tumor bur-
den (e.g. >15% weight loss in two days, severe neurological abnormalities) were observed. 
In some cases, tumor-bearing animals were subjected to longitudinal measurements (T2w 
imaging and MRSI). Brains were harvested, formalin-fixed and paraffin-embedded for further 
analysis.
Therapy 
 Animals carrying E98 tumors were randomly divided into three groups. Treatment 
was started when signs of tumor growth became apparent, evidenced by the presence of 
edema in T2 weighted MR imaging (characteristically at day 13 post implantation, not shown). 
Bevacizumab (Avastin, Genentech, San Francisco, CA) was administered twice a week at 
a dose of 5 mg/kg in 100 µl PBS via intraperitoneal injection (n=13). XL184 (cabozantinib, a 
combined VEGFR2/MET tyrosine kinase inhibitor, Exelixis, San Francisco, CA) was given by 
oral gavage by daily dosing at 100 mg/kg (n=11). Placebo-treated mice (oral administration 
of PBS) were used as control group (n=15). Previous studies already showed that ip injection 
of PBS did not affect tumor growth, allowing us to use this control group for both treatment 
regimens. Treatment of mice carrying E473 human glioma xenografts, which grow in a highly 
diffuse fashion, has been described before [127]. E473-carrying mice, both controls and 
bevacizumab-treated, were also subjected to the MRSI protocol described below (n=4 or 5).
Magnetic Resonance Imaging and Spectroscopy
 Animals (n=4 for each group) were anesthetized using 1-2% isoﬂurane in a 70%:30% 
N2O/O2 mixture and placed in a prone position in an MR cradle. Breathing was monitored 
throughout the MR experiment and the animals’ core temperature was maintained at 37.5°C 
using a continuous ﬂow of warm air (SA Instruments, Inc., Sunny Brook, NY, USA). 
 MR investigations were performed on a 7T animal MR system (ClinScan, Bruker 
BioSpin, Ettlingen, Germany) equipped with a clinical user interface (syngo MR, Siemens, 
Erlangen, Germany). All used MR sequences were adopted from their clinical counterparts 
and received minor modifications to allow for optimal usage of the available gradient and RF 
power without compromising compatibility with the clinical (post processing) platform. After 
acquisition, data were fitted in LC-model software and choline, NAA and lactate (having 1H 
resonances at 3.5 and 3.19 ppm; 2.01, 2.49 and 2.67 ppm; and 1.31 ppm respectively) in 
0.85 mm3 voxels were quantified. Cho/NAA ratios were projected as 2D heat maps, super-
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imposed on T2 weighted MR maps. Similarly, absolute lactate levels were depicted in heat 
maps. Further details on these analyses can be found in the online supplementary data 
(http://neuro-oncology.oxfordjournals.org/content/15/12/1615/suppl/DC1). Cho/NAA ratios in 
sets of 4 independent voxels, chosen in contrast-enhancing or non-enhancing tumor areas 
(as identified on H&E staining of corresponding sections), as well as in normal brain, were 
compared using a Mann-Whitney-U test.  
 Contrast-enhanced MRI was performed as described previously [50]. In short, after 
acquiring MRS data, T1-weighted images were acquired, followed by an intravenous bolus 
injection of 0.2 ml of Gd-DTPA (20 mMol/l, Magnevist, Schering, Germany). Additional sets of 
T1-weighted images were acquired at 2 min after injection.
Immunohistochemistry
 Immunohistochemical stainings were performed as described before [127] with an-
tibodies against GLUT1 (Neomarkers, Fremont, CA; a constitutive marker for normal brain 
capillary endothelial cells and for hypoxic tumor cells), MCT1 (a lactate importer, expressed 
near and in glycolytic cells), MCT4 (both Santa Cruz, CA; a lactate exporter, expressed 
by glycolytic cells), and HIF1α (clone 54, BD Biosciences Pharmingen, Breda, The Neth-
erlands). Anti-CA-IX (M75) antibody was a generous gift from Dr. E. Oosterwijk (RUNMC). 
For HIF1α staining, signal was additionally amplified using catalyzed reporter deposition 
(CARD [134]). In some cases, tumor-bearing animals were injected with pimonidazole prior 
to sacrifice after which the accumulated pimonidazole in hypoxic tumor areas was visualized 
using a specific rabbit antiserum (Hydroxyprobe Omni kit), a generous gift of Ing. H. Peters 
(RUNMC) [135].
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Results
Detectability of glioma by MRSI 
 The poor visibility in CE-MRI of diffuse infiltrative areas in clinical and preclinical 
models of GBM, a phenotype that is characteristically present in untreated tumors and is 
increased upon treatment with angiogenesis inhibitors [50, 51, 110], led us to investigate 
whether the metabolic profile of tumor cells in these areas allows visualization via multivoxel 
MRSI. N-acetyl aspartate (NAA) is a metabolite that is synthesized by neurons in abundant 
amounts whereas choline compounds (Cho) are precursors of cell membrane components 
that increase in cells after malignant transformation [136]. Both NAA and Cho-containing 
compounds (total choline, tCho) can be detected by chemical shift imaging in 1H-MRSI. 
Increased tCho and decreased NAA tissue levels are hallmarks of brain tumor growth, and 
tCho over NAA ratios (Cho/NAA) are increased in gliomas, discrimating tumor from normal 
brain tissue with a specificity of 86% and a sensitivity of 90% [137, 138] [139]. E98 xenografts 
present with the heterogeneous phenotypes that are also present in clinical gliomas and 
respond similarly to anti-angiogenic treatment with respect to loss of MRI visualization [50, 
51, 127]. Compared to normal mouse brain (Figure 1A) E98 xenografts present with highly 
elevated tCho/NAA, both in compactly growing (Figure 1B) and diffuse infiltrative E98 areas 
(Figure 1C). Panels D-F in Figure 1 show spectra corresponding to the respective encircled 
voxels in panels A-C. Voxels with elevated ratios co-localize with tumor, as established by 
gadolinium-DTPA-enhanced T1-weighted MRI (see post-pre subtraction image in Figure 1G) 
and H&E staining of corresponding brain sections (Figure 1I and J). Note that the diffuse 
tumor in panel J is hardly detectable on CE-MRI (panel H) but results in elevated Cho/NAA 
ratios (panels C and F).
MRSI of glioma under anti-angiogenic treatment 
 To investigate whether the tCho/NAA ratios can be utilized for detection of dif-
fuse infiltrative glioma under anti-angiogenic treatment, we treated E98 and E473-bearing 
mice with bevacizumab. Treated animals were sequentially subjected to MRSI and CE-MRI. 
Whereas Gd-DTPA-enhanced imaging showed a greatly diminished signal as compared to 
non-treated E98 mice (Figures 2B, compare to Figure 1G), MRS mapping of the tCho/NAA 
ratio revealed the extensive presence of tumor (Figure 2A,D). Comparison with correspond-
ing H&E-stained brain sections (Figures 2C) showed that, despite the relatively low resolu-
tion, the tumor was far better delineated by 1H-MRS than by CE-MRI. 
 To exclude that these findings are somehow specific to E98 xenografts, we per-
formed similar experiments with the E473 xenograft model. E473 tumors grow in a diffuse 
infiltrative manner without evidence of an angiogenic response [92]. We previously showed 
that the apparent absence of angiogenesis coincides with a lack of response to bevacizum-
ab [127]. Similar to the results obtained with E98 tumors, CE-MRI was not able to delineate 
tumor in E473 xenografts (Figure 2F, see also [127]) whereas MRSI revealed extensive tumor 
involvement (Figure 2E) consistent with histology (Figure 2G). tCho/NAA ratios in the contrast 
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enhanced area in Figure 2B were 2.9 ± 0.84 (mean ± S.D. of 4 voxels in the red boxed area 
in inset) and did not differ from tCho/NAA ratios outside the contrast-enhancing area (2.64 
± 0.83; mean ± S.D. of 4 voxels in green-boxed area, p=0.69). These numbers were signifi-
cantly higher than tCho/NAA ratios in voxels outside the tumor area and in non-neoplastic 
mouse brain (0.45± 0.38 and 0.49±0.12 respectively, p=0.03 for both comparisons, see 
Figure 2H). 
 In our experience tyrosine kinase inhibitors of VEGFR2 can be more effective in 
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Figure 1. MRSI visualizes the diffuse infiltrative E98 tumor component better than CE-MRI. Repre-
sentative in vivo tCho/NAA (scaled 0-1.5) MRSI metabolic maps of one non-tumor bearing control brain 
(A) and two untreated brains infiltrated with E98 xenografts (B, C). E98 tumors characteristically display 
compact, angiogenic growth as wells as diffuse infiltrative growth, the ratio of these being variable. For 
clarity, a tumor with profound compact growth and relatively small areas of infiltrative growth (B,E,G,I) 
and one with the converse ratio (C,F,H,J) are shown. Panels D-F show spectra (TE=24 ms) of the re-
spective white encircled voxels in panels A-C. Choline (Cho), creatine (Cre), N-acetyl aspartate (NAA), 
lipid and lactate peaks are indicated. Panels G and H show contrast enhanced (Gd-DTPA) MRI delta 
map (Spost-Spre)/Spre of corresponding slices of the tumor bearing animals. Note that contrast agent 
entered the brain in panel G and H, indicated by the high signal intensity in the skull and skin. Panels I 
and J show matched endpoint H&E histology. Size bars correspond to 2 mm. T=tumor, N=normal
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normalizing tumor blood vessels in glioma xenografts than bevacizumab [50, 127]. We have 
previously published that cabozantinib, a tyrosine kinase inhibitor with specificity for VEG-
FR2, MET and RET fully reduces blood vessel leakage in E98 xenografts, resulting in tumors 
which are invisible in CE-MRI (Figure 2J and [140]. In agreement with the E98 and E473 
data, MRSI heat maps of tCho/NAA were indicative of extensive tumor presence (Figure 2I, 
compare with H&E staining in Figure 2K). 
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Figure 2. MRSI visualization of bevacizumab treated E98 xenografts. Cho/NAA (scaled 0-1.5) MRSI 
metabolic map of representative mouse brains with E98 tumor (A and I) or E473 tumor (E) after treatment 
with bevacizumab (A,E) and cabozantinib (I). The short echo time (24 ms) spectrum of the white encir-
cled voxel in panel A is depicted in D. Note that the MRSI correlates better with histology (H&E staining 
in C,G,K) than contrast enhanced (Gd-DTPA) MRI (see delta map (Spost-Spre)/Spre in B,F and J). The inset 
in panel B shows a red and a green area (corresponding to enhancing and non-enhancing tumor) in 
which Cho/NAA ratios were quantified. These data, together with Cho/NAA ratios from non-neoplastic 
brain, are presented in H. Size bars in C-K correspond to 2 mm. Note that only the central part of the 
brain is included in the metabolic maps as the boundaries between brain and other tissues severely 
compromise the quality of spectra collected from these regions.
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Glycolysis in E98 xenografts is limited to focal areas of hypoxia 
 Inhibition of angiogenesis has been shown to result in hypoxia and an increase of 
glycolysis in glioma [55]. Based on the observed lack of hypoxia in diffuse areas of glioma, 
also after anti-angiogenic treatment [116, 127], we evaluated the extent of glycolysis during 
development of E98 xenografts by directly measuring tissue lactate levels in treated and 
non-treated E98 xenografts. In addition to MRSI at short echo time (TE; 24 ms), we acquired 
data at TE = 144 ms, allowing quantification of tissue lactate concentrations (representative 
examples shown in Figure 3N). At this long echo time the lactate peak at 1.3 ppm shows a 
characteristic inversion due to the strong J-coupling of the lactate- CH3 and CH proton spins. 
Furthermore, at long echo times the contribution of overlapping lipids (as is present at TE = 
24 ms) is minimized by their short T2 relaxation time. 
 Lactate levels were low in control-treated E98 bearing mice (Figure 3B,E, compare 
with panels A, C and D, F which show elevated Cho/NAA levels in tumor containing voxels, 
note that this is the same mouse as presented in Figure 1). Bevacizumab treatment clearly 
induced glycolysis, as reﬂected by gradually increasing lactate levels at D13, D20 and D26 
(representing day 0, 7 and 13 after start of treatment (Figure 3H,J,L, mean concentration at 
D26: 9.9 +/- 2.2 mM in compact tumor areas, as established by corresponding histology 
[n=76 voxels], vs. 2.6 mM in control mice [n=495 voxels], p<0.0001). In the tumor periphery 
however, large areas of highly elevated Cho/NAA ratios were detected (Figure I,K) with rel-
atively low lactate (Figure 3J,L). The tumor heterogeneity with respect to lactate production 
stresses the importance of performing multivoxel instead of single voxel MRSI. Importantly, 
after cabozantinib treatment, a number of mice showed only diffuse infiltrative growth with no 
detectable hypoxia markers [140]. Whereas tumor was readily detected by tCho/NAA map-
ping (Figure 3N), lactate levels were even lower than after bevacizumab treatment in these 
mice (Figure 3O, compare with 3P).
 The diffuse infiltrative tumor that remains after anti-angiogenic therapy takes ad-
vantage of the high cerebral vascular density for its blood supply. As these areas are well 
perfused (as indicated by the absence of hypoxia) lactate may be rapidly drained from the 
tumor, resulting in underestimation of lactate levels. In this scenario, glycolytic cells should 
express monocarboxylate transporters (MCTs) to facilitate efficient lactate secretion, and 
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Figure 3. Bevacizumab treatment results in a highly localized increase in lactate production in E98 
xenografts. Panels A and D show maps of Cho/NAA metabolite ratios (range 0-1.5, values obtained 
using TE=24 ms), in panels B and E absolute lactate concentrations are depicted (range 0-15 mM, val-
ues obtained using TE=144 ms). C and F represent H&E stained corresponding coronal sections (same 
animals as shown in Figure 1). A-F: untreated; G-M: bevacizumab-treated. Panels G-H, I-J and K-L rep-
resent MRS maps at day 13, 20 and 26 post tumor implantation which corresponds to day 0, 7 and 13 
of bevacizumab treatment. Note in panels J and L that lactate levels gradually increase after treatment 
with bevacizumab, but predominantly in compact tumor areas. Panel N shows a representative short (24 
ms) and long (144 ms) echo time MR spectrum of a selected voxel of the bevacizumab treated animal 
(day 26, white encircled voxel in panel L). Panels O-Q represent mouse brains with E98 xenografts after 
treatment with cabozantinib. Note that only low levels of lactate are observed (P) whereas high Cho/
NAA ratios are detected throughout the tumor (O). All metabolite values were obtained using LCModel 
and plotted regardless of the fits’ Cramér-Rao lower bound value. Voxels in which one of the metabolites 
could not be fitted by LCModel are omitted. Size bars correspond to 2 mm.
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CA-IX to prevent intracellular acidosis [141]. GLUT-1 and MCT4 were absent in diffusely 
growing tumor cells (Figure 4A, arrows point at diffuse infiltrative cells) and this was also 
true for MCT1, HIF-1α and CA-IX (data not shown). Similar results were previously obtained 
with diffuse E473 xenografts [127]. This contrasted to the situation in compact tumor regions 
where significant areas stained positive for GLUT-1 and MCT4 proteins in a pattern that was 
reminiscent of central hypoxia (arrow heads in Figure 4A). Hypoxia was far more pronounced 
in compact areas in response to bevacizumab treatment (lower panels in Figure 4A) and this 
is in agreement with previous data [127]. 
 To further prove that excessive glycolysis in our models is confined to areas of 
hypoxia, we injected mice just before sacrifice with pimonidazole, accumulation of which is 
the gold standard for hypoxia [142] and stained serial sections of treated E98 xenografts for 
GLUT-1, MCT4 and pimonidazole. As shown in Figure 4B, especially MCT-4 had a strong 
colocalization with pimonidazole, and this staining pattern largely colocalized with GLUT-1 
(data not shown). 
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Figure 4. Hypoxia levels in E98 xenografts upon treatment. Representative immunohistochemistry 
of the hypoxia markers GLUT1 and MCT4 (stained in red) in untreated and bevacizumab treated tu-
mor-bearing animals (A). Figure 4B shows that MCT4 expression correlates well with pimonidazole ac-
cumulation (brown) and further demonstrates that hypoxia is limited to foci in central compact tumor 
areas only. Size bars: 1 mm.
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 In conclusion, comparison of the lactate map in Figure 3L with histological analysis 
in Figure 3M and immunohistochemical data from Figure 4 strongly suggests that elevated 
lactate levels concentrate in areas of hypoxia. The absence of glycolysis-related proteins in 
diffuse tumor areas, together with the absence of elevated lactate levels, suggests that in 
these areas tumor cells do not excessively depend on glycolysis for their growth. 
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Discussion
The lack of reliable modalities to visualize the diffuse infiltrative component of GBM, espe-
cially after treatment with anti-angiogenic compounds, is a serious problem in neuro-oncol-
ogy. The necessity for novel imaging modalities is emphasized by the recent finding from 
randomized clinical trials that, despite dramatic radiological responses upon bevacizumab 
treatment, overall survival of GBM patients was not improved [143, 144]. 
 CE-MRI is the common standard in routine examinations of brain tumors, but it is 
not able to delineate the entire tumor volume and detectability is even more decreased upon 
VEGF inhibition, a phenomenon that was confirmed in multiple orthotopic glioma xenograft 
models after treatment with different anti-angiogenic compounds [50, 127]. Recently, new 
guidelines for response assessment of high-grade gliomas were proposed by the RANO 
consortium in which T2-weighted and ﬂuid-attenuated inversion recovery (FLAIR) imaging is 
used to detect invasive non-enhancing tumor areas [145]. T2-FLAIR imaging visualizes tu-
mors to some extent, but has a number of limitations as well. Again, therapy may complicate 
T2-based tumor detection [113] due to vessel normalization and resulting edema reduction. 
We routinely performed T2-weighted imaging of the mice in the current study and indeed 
found that T2 weighted imaging in general was a less reliable measure of tumor volume (not 
shown). 
 Thus, novel diagnostic modalities that properly visualize tumor extent and provide 
patients with realistic information on therapeutic effects and prognosis are urgently needed. 
In recent years specific physiological and metabolic MR methods have been implemented 
to assess response to brain tumor treatment, such as imaging relative cerebral blood volume 
(rCBV), water diffusion in tissue (diffusion weighted imaging, DWI) and MR spectroscopic 
imaging of metabolites [139, 146-150]. The potential of these approaches to reliably detect 
tumor load and spread and thus to circumvent the registration of mainly pseudoresponses 
in anti-angiogenic treatments is currently a topic of intense research. As proper validation 
of this potential may be difficult in patients, studies of orthotopically growing human brain 
tumors in animals is important for validation. 
 We show here in two independent orthotopic glioma xenograft models, both dis-
playing the characteristic diffuse infiltrative growth of glioma, that 1H-MR spectroscopic im-
aging of tCho/NAA ratios identifies the presence of infiltrative tumor tissue better than CE-
MRI. This metabolism-based visualization is not hampered by vessel-normalizing effects (i.e. 
functional restoration of BBB) of anti-angiogenic compounds. With increasing accessibility of 
high field MR equipment and robust spectroscopic imaging acquisition software also in the 
clinic [151, 152], inclusion of 1H MRSI-based visualization of GBM growth becomes feasible 
and an attractive and promising modality. Of importance, this technology may also yield fur-
ther information on the metabolic status of tumors that could aid in tumor classification [153]. 
 Whereas bevacizumab treatment resulted in increased hypoxia in E98 xenografts, 
corroborating a previous report [55], our multivoxel analysis revealed that lactate levels were 
increased in areas of hypoxia only. Cabozantinib treatment resulted in predominantly dif-
fuse infiltrative tumors, often without any sign of hypoxia, and this was corroborated by the 
57
3
absence of significantly elevated levels of lactate. The combined findings suggest that an-
ti-angiogenic treatment induces glycolysis only in compactly growing areas in which a rapid 
shutdown of blood supply may result in local hypoxic conditions. Possibly, the local shut-
down of blood supply and the resulting poor wash-out in glycolytic areas contributes to even 
higher accumulation of lactate. Also in E473 glioma xenografts no glycolysis markers could 
be detected, even after treatment with bevacizumab [127]. Our finding of limited glycolysis 
in glioma is therefore not a one-model artifact. Furthermore, since glycolysis markers cannot 
be found in diffuse infiltrating tumor cells in clinical samples [154] these findings seem to 
have clinical relevance. Recent studies in glioma patients and in mice carrying orthotopic 
patient-derived glioma xenografts revealed that in glioma mitochondrial oxidative phosphor-
ylation predominates over glycolysis [155, 156]. This is in line with our findings and does not 
conform to Warburgs hypothesis that tumor cells depend more on glycolysis than on mito-
chondrial oxidative phosphorylation [157]. It is likely that the potential for extensive vessel 
co-option by glioma cells, a result of the dense vascular bed in the brain, equips the diffusely 
infiltrating glioma cells with sufficient oxygen and nutrients to allow mitochondrial metabo-
lism to proceed. Only in highly proliferative tumor areas that outgrow the local blood supply, 
hypoxia may develop, resulting in a shift of the glycolysis/OXPHOS equilibrium towards gly-
colysis. In a previous report a symbiotic relationship was suggested between hypoxic and 
normoxic tumor areas [158].  In this paper it was suggested that lactate, produced by hypox-
ic cells, is taken up by normoxic cells via the monocarboxylate transporter 1 (MCT1). As we 
did not find increased MCT1 expression on diffuse infiltrative tumor cells in our models, it is 
not clear to what extent this phenomenon applies to our xenografts. 
 Glycolysis is gaining interest as a therapeutic target, e.g. with inhibitors like dichlo-
roacetate [159]. This pyruvate dehydrogenase kinase (PDK) inhibitor has been proposed as 
a potential adjuvant treatment to bevacizumab [55]. Indeed, cells that shifted their metabo-
lism to glycolysis as a result of bevacizumab treatment would be forced to turn to mitochon-
drial oxidative phosphorylation and this would result in cell death in the absence of oxygen 
[160-164]. Our data show that the effects of glycolysis inhibition on E98 tumor growth would 
be limited to hypoxic tumor areas, leaving the larger volume of diffuse infiltrative tumor unaf-
fected. 
 Yet, the highly heterogeneous nature of clinical GBM makes it worthwhile to gener-
ate 1H-MRS-based maps of Cho/NAA and lactate. Patients in whom a significant fraction of 
the tumor is glycolytic (as determined by the total voxel volume with elevated lactate / total 
voxel volume with elevated Cho/NAA) may indeed significantly benefit from DCA therapy. In 
this way MRSI can help in selecting patients that are eligible for anti-glycolytic treatment. 
 Besides pruning of newly formed vessels, bevacizumab treatment has been pro-
posed to normalize tumor blood vessels and improve tumor perfusion and oxygenation, 
thereby increasing susceptibility to radio- and chemotherapy [44]. In our study, treatment 
with bevacizumab increased the hypoxic tumor cell fraction in compact E98 areas, an effect 
that was also seen previously with vandetanib [51]. This is in agreement with a model in 
which bevacizumab rapidly decreases blood ﬂow to compact growing tumor areas, rather 
than improving perfusion. We propose that anti-angiogenic treatment of tumor areas that 
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have undergone the angiogenic switch [42] will result in consolidation of vasculature in these 
areas. Continuing tumor expansion in the absence of novel vascularization (initially via vas-
cular co-option [119]) will result in increased hypoxia. On the other hand, in earlier stage tu-
mors in which the angiogenic switch did not yet occur, treatment would prevent development 
of these areas, resulting in diffuse tumor growth exclusively.
 In conclusion, we have shown that MRSI is superior to contrast enhanced MRI for 
a reliable non-invasive evaluation of therapeutic effects in the anti-angiogenic treatment of 
gliomas and yields additional information about tumor metabolism that may be exploited for 
individualized treatment. We further showed that infiltrating glioma cells in our models do not 
display the glycolytic phenotype that has been suggested to be a hallmark of tumors (i.e. the 
Warburg effect).
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Abstract
 Anti-angiogenic treatment of glioblastoma with Vascular Endothelial Growth Factor 
(VEGF)- or VEGF Receptor 2 (VEGFR2) inhibitors normalizes tumor vessels, resulting in a 
profound radiologic response and improved quality of life. This approach however does not 
halt tumor progression by diffuse infiltration, as this phenotype is less angiogenesis depen-
dent. Combined inhibition of angiogenesis and diffuse infiltrative growth would therefore be 
a more effective treatment approach in these tumors. 
 The HGF/MET axis is important in both angiogenesis and cell migration in several 
tumor types including glioma. We therefore analyzed the effects of the MET- and VEGFR2 
tyrosine kinase inhibitor cabozantinib (XL184, Exelixis) on MET positive orthotopic E98 glio-
blastoma xenografts, which routinely present with angiogenesis-dependent areas of tumor 
growth, as well as diffuse infiltrative growth. In in vitro cultures of E98 cells, cabozantinib 
effectively inhibited MET phosphorylation, concomitant with inhibitory effects on AKT and 
ERK1/2 phosphorylation, and cell proliferation and migration. VEGFR2 activation in endothe-
lial cells was also effectively inhibited in vitro. Treatment of BALB/c nu/nu mice carrying or-
thotopic E98 xenografts resulted in a significant increase in overall survival. Cabozantinib ef-
fectively inhibited angiogenesis, resulting in increased hypoxia in angiogenesis-dependent 
tumor areas, and induced vessel normalization. Yet, tumors ultimately escaped cabozantinib 
therapy by diffuse infiltrative outgrowth via vessel co-option. Of importance, in contrast to 
the results from in vitro experiments, in vivo blockade of MET activation was incomplete, 
possibly due to multiple factors including restoration of the blood-brain barrier resulting from 
cabozantinib-induced VEGFR2 inhibition. In conclusion, cabozantinib is a promising therapy 
for MET positive glioma, but improving delivery of the drug to the tumor and/or the surround-
ing tissue may be needed for full activity.  
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Introduction
 Glioblastoma (GBM) is a highly aggressive primary brain tumor that is character-
ized by extensive areas in which tumor cells diffusely infiltrate the brain parenchyma. A well-
known hallmark of this cancer type is the presence of a necrotic core, surrounded by a rim 
in which hypoxia-induced neovascularization occurs [45]. Angiogenesis in these areas is 
associated with vessel leakiness, which contributes to edema and high intracranial pressure, 
aggravating symptoms that by themselves can be lethal. Local vessel leakage is exploited 
to diagnose GBM, as it results in extravasation of intravenously administered contrast agents 
like Gd-DTPA, which can be readily visualized by MRI. GBMs are generally operated upon 
to the maximum feasible extent, followed by radiotherapy and chemotherapy with Temozolo-
mide (TMZ). Remnants of diffusely growing tumor cells will however inevitably result in tumor 
recurrence and median survival is currently still only 14.6 months [10]. 
 It is well recognized now that inhibition of VEGF-A signaling pathways in neovascu-
lar endothelial cells, either by the neutralizing antibody bevacizumab or selective VEGFR2 
tyrosine kinase inhibitors, induces a radiological response, significantly reduces edema and 
may substantially improve quality of life [49, 52, 128, 130]. Bevacizumab is now approved by 
the FDA for treatment of recurrent glioma. However, it has also become clear from a number 
of preclinical but also clinical studies that the diffuse infiltrative phenotype of GBMs is not 
sensitive to angiogenesis inhibition [52, 92, 127]. We previously showed that different an-
ti-angiogenic treatments of orthotopic E98 xenografts (displaying both angiogenesis and dif-
fuse infiltration [92]) affect only the angiogenic tumor component [51, 110, 127]. Apparently, 
anti-angiogenic therapies drive tumor cells to adapt a resistant, angiogenesis-independent 
phenotype in which tumor cells obtain their blood supply entirely from pre-existent vascula-
ture [35, 55, 119, 126, 132]. These therapies have even been suggested to increase tumor 
cell invasion in glioma and other tumor types [122, 123] and this appears to be associated 
with induction of hypoxia [165]. It is therefore of major importance for effective glioma treat-
ment that approaches become available that tackle diffuse infiltrative tumor growth. 
 The MET tyrosine kinase receptor has been linked to both tumor angiogenesis and 
the invasive phenotype of glial and other tumors [165, 166]. Upon binding of its ligand he-
patocyte growth factor (HGF, scatter factor), MET is phosphorylated on tyrosine residues 
Y1234/1235 (kinase domain) and Y1349 and Y1356, the latter two residues with their sur-
rounding amino acids functioning as docking sites for substrates such as Gab1, Grb2 and 
phosphatidylinositol 3 kinase (PI3K) [167, 168]. Downstream signalling of MET involves im-
portant pathways including RAS/PI3K and ERK/MAPK, which are associated with tumorigen-
esis and cancer progression [169]. 
 Amplification of the MET gene (located on chromosome 7) is seen in GBMs [170] 
and both MET and HGF are frequently overexpressed in glioma specimens and cell lines. 
HGF is a strong stimulator of in vitro glioma cell migration [171-173] and MET expression has 
also been demonstrated in invasive glioma cells [171]. Simultaneous targeting of the VEGF 
and MET pathways may therefore be an interesting therapeutic approach for MET-positive 
GBM because it will reduce vessel leakage (resulting in edema reduction) and simultane-
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ously may reduce tumor cell migration and thus tumor progression. Cabozantinib (XL-184, 
Exelixis, South San Francisco, CA) is a small compound tyrosine kinase inhibitor of VEGFR2, 
MET and RET and has been shown to block tumor development in the RipTAG2 mouse 
model of pancreatic carcinogenesis more effectively than blockade of MET or VEGFR2 alone 
[165, 174, 175]. Cabozantinib was recently FDA-approved for treatment of medullary thyroid 
cancer.
 The aim of the current work was therefore to test the effects of cabozantinib in mice 
carrying highly aggressive orthotopic E98 glioma xenografts [92]. We show that cabozan-
tinib blocks vascular leakage in this MET positive tumor model and gives a significant surviv-
al benefit which was not observed in previous experiments from our lab with bevacizumab or 
other VEGFR2 inhibitors [51, 127]. Interestingly, whereas cabozantinib completely blocked 
MET tyrosine phosphorylation in vitro in E98 cell cultures, phosphorylated MET was still pres-
ent in remaining diffuse infiltrative tumor areas in treated mice. We propose that the anti-VEG-
FR2 activity of cabozantinib results in a restoration of the blood-brain barrier (BBB), thereby 
precluding an efficient distribution of the compound to the tumor cells and reducing MET 
inhibitory activity. 
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Materials and Methods
Cell culture 
 E98NT cells (cell line derived from E98 xenografts, described in [176]) were cul-
tured in DMEM supplemented with 10% FCS and pen/strep in the presence of 5% CO2 at 
37°C. HUVECs were cultured in EBM medium, supplemented with FCS, bFGF and VEGF 
(Lonza) according to the manufacturer’s instructions.
Protein expression analysis
 E98NT cells or HUVECs were plated in 6 well dishes in appropriate media at a 
density of 5x105 cells per well. The following day cabozantinib (0, 0.01, 0.1, 0.5, 1 and 10 
μM in DMSO) was added. After a 30 min incubation, cells were washed with ice-cold PBS 
and protein extracts were generated using RIPA buffer supplemented with protease and 
phosphatase inhibitors (Roche Applied Science). Similarly, extracts were generated from 
E98NT cells treated for 24 h with 1 and 10 μM cabozantinib (for assaying apoptosis) and 
sections of snap frozen xenograft brains (approximately 20 mg of tissue). Protein lysates 
were cleared by centrifugation and protein concentrations were measured using the BCA 
Protein Assay Kit (Thermo Scientific) according to manufacturer’s instructions. Proteins (20-
40 µg/lane) were subjected to SDS-PAGE and Western Blotting using antibodies directed 
against MET (clone EP1454Y, Epitomics and clone D1C2, Cell Signaling Technology (CST)), 
phospho-MET (Y1234/1235, clone D26, CST), phospho-AKT (S473, clone D9E, CST) phos-
pho-ERK1/2 (Thr202/Tyr204, clone 20G11, CST), anti-U1-70 (to detect apoptosis, [177]) and 
α-tubulin (clone 236-10501, Molecular Probes) or γ-tubulin (clone C20, goat, Santa Cruz 
Biotechnology) as internal control. Antibodies were detected using appropriate secondary 
antibodies, labeled with IRDye700 or IRDye800 infrared dyes. Signals were visualized and 
quantified when appropriate, using the Odyssey Infrared Imaging System (LI-COR Biosci-
ences Odyssey Application Software version 3.0.30). 
Dose response analysis
 IC50 of cabozantinib was determined as follows: cells were plated at a concentration 
of 2x104 cells per well in 96-wells plates. The next day increasing concentrations of cabozan-
tinib (in DMSO) were added to the medium. Each condition was tested in quadruplicate in at 
least three independent experiments. Metabolic activity of the cells was determined 4 days 
following start of TKI treatment by incubation with 0.5 mg/ml MTT in PBS (Sigma-Aldrich, St. 
Louis, MO). After a 3.5 hr incubation at 37˚C formazan crystals were dissolved in MTT solvent 
(0.1% NP40 and 3.4 mM HCl in isopropanol) and optical densities were measured at 560 
nm.  IC50 concentrations were determined using sigmoidal dose-response (variable slope) 
statistics and normalized in GraphPad Prism. 
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Cell migration assays
 E98NT spheroids were generated by the hanging drop method. In brief, 0.7 ml 
methylcellulose (Sigma M6385, final concentration 1.68 mg/ml) was added to 4.3 ml E98 
cell suspension in normal culture medium (500,000 cells total) and drops of 25 µl containing 
approximately 2,500 E98 cells were seeded in a dry culture dish. The dish was then invert-
ed and incubated overnight at 37°C in the presence of 5% CO2. The next day, individual 
spheroids were seeded in a matrigel-coated 96-well imaging culture dish (Matrigel: BD cat 
356237, 96-well plates: BD falcon imaging plates cat 353219) and grown further at 37°C and 
5% CO2. Individual spheroids were photographed at t=0 h in a culture system which allows 
for live cell imaging, after which they were incubated with 0, 1 or 10 µM cabozantinib. After 
24 h, wells were washed with PBS and cells were fixed with 4% PFA in 0.1M phosphate buf-
fer, followed by DAPI staining. Fluorescent and phase-contrast images were then taken and 
Image J software was used to quantify spheroid outgrowth. Briefly, cells which had migrated 
from the spheroids were selected automatically using a cell mask. Numbers of cells that had 
migrated out of the spheroids (n=at least 32 for each condition) were measured. Statistical 
analyses involved ANOVA and post-hoc Tukey’s Multiple Comparison Test.
Animals 
 Athymic female BALB/c nu/nu mice (18-25 gram, age 6-8 weeks) were kept under 
specified pathogen free conditions and received food and water ad libitum. The local Animal 
Experimental Committee of the Radboud University Nijmegen Medical Center approved all 
experiments. E98 GBM cells derived from subcutaneous xenograft tumors were injected 
intracranially under isoflurane anesthesia as described previously [92]. All efforts were made 
to minimize suffering. Animals were closely monitored by visual inspection and weighed daily 
from start of treatment (see below) and sacrificed when evident signs of tumor burden (es-
pecially weight loss >20%, severe neurological dysfunction) were observed. Brain, liver and 
kidneys were harvested, and parts were formalin fixed and paraffin embedded or snap-fro-
zen in liquid nitrogen for further analysis.
Therapy 
 Animals carrying E98 tumors were randomly divided into placebo and cabozantinib 
treatment groups. Treatment was started at day 12, when signs of tumor growth became 
apparent, as evidenced by the presence of edema in T2 weighted MR imaging. Water-sus-
pended cabozantinib (XL184, Exelixis, South San Francisco) was given daily by oral gavage 
in doses of either 60 mg/kg (n=3) or 100 mg/kg (n=10) in a volume of 100 μl. A control group 
(n=10) received water daily by oral gavage. 
Immunohistochemistry  (IHC)
 Immunohistochemical stainings were performed as described before [127]. In 
short, after epitope retrieval by boiling in citrate buffer (pH 6.0), 4 µm tissue sections were 
incubated with primary antibodies against GLUT1 (Neomarkers), CD34 (clone MEC14.7, 
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Hycult biotech), MET (clone EP1454Y, Epitomics), phospho-MET (Y1234/1235, clone D26, 
CST), MCT4 (clone H90, Santa Cruz), cleaved caspase 3A (clone C92-605, BD Pharmingen) 
and Ki-67 (clone Sp6, Thermo Fisher Scientific). Appropriate biotinylated secondary anti-
bodies were used for detection using the Avidine Biotine Complex (ABC) method (Vector 
Laboratories). Specific signals were visualized by staining with 3-amino-9-ethyl-carbazole 
(AEC, Scytek Laboratories) or 3,3’-diaminobenzidine (Power-DAB, ImmunoLogic) solution. 
All sections were counterstained with haematoxylin and mounted in Imsol Mounting medium 
(Klinipath B.V.). 
Image analysis
 Cell proliferation, hypoxia and vessel densities were quantified using KS400 soft-
ware (Carl Zeiss AG, Germany) with a custom-written macro on images acquired on a Zeiss 
Axioskop II microscope coupled to a CCD-RGB camera. For proliferation, five random 
non-overlapping diffuse infiltrative or compact tumor containing microscopic fields (magni-
fication x200) were analyzed per section. Compact and diffuse areas were recognized by 
gross histology, with compact areas being present in the ventricles or leptomeninges, and 
diffuse areas defined by the intermittent presence of white matter tracts in H&E staining.  The 
proliferative fraction was defined as the number of proliferative cells (based on Ki-67 positiv-
ity) divided by the total number of nuclei in a tumor region. Ratios were determined and the 
average value for the different fields per slide was used in further calculations. 
 For hypoxia quantification, compact tumor areas, defined as sharply bordered re-
gions lacking normal brain parenchyma in between the tumor cells, and hypoxic regions 
(based on MCT4 positivity) were selected interactively. The hypoxic fraction was defined as 
the total hypoxic area divided by the total tumor area. 
 Vessel densities were measured in GLUT1 immunostainings and counted in 5 high 
power fields per section in both compact and diffuse areas. Since neovasculature in com-
pact areas often lack BBB characteristics (e.g. GLUT1 expression), also CD34 stainings 
were performed.
 Statistical comparisons were done by normality analysis, followed by a Student’s 
t-test (two-sided) using GraphPad Prism v4. For both control and 100 mg/kg cabozantinib 
treated brains, n=10. A p value of ≤0.05 was considered as statistically significant.
Contrast-enhanced Magnetic Resonance Imaging 
 CE-MRI was performed in a 7T MR system (ClinScan, Bruker BioSpin, Ettlingen, 
Germany) equipped with a clinical user interface (syngo MR, Siemens, Erlangen, Germany). 
When tumor-related symptoms became apparent, animals were anesthetized using 1-2% 
isoflurane in a 70% N2O and 30% O2 mixture and placed in a prone position in an MR cradle. 
Breathing was monitored throughout the MR experiment and the animals’ core temperature 
was maintained at 37.5°C using a continuous flow of warm air (SA Instruments, Inc., Sunny 
Brook, NY, USA). Anatomical references were acquired using a multi-slice localizer with 
slices in the three main orthogonal directions. A turbo spin echo sequence with following 
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settings were used: repetition time (TR) 3880 ms, echo time (TE) 43 ms and a turbo factor of 
7. The scans had a resolution of 98 μm in-plane and a thickness of 0.7 mm per slice. A bolus 
of 0.2 ml of Gd-DTPA (20 mM, Magnevist®, Schering, Germany) was injected intravenously 
via a pre-inserted tail vein catheter and additional sets of T1-weighted images were acquired 
2-3 minutes after injection.
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Results
 Elevated expression of MET in glioma specimens has been documented by sev-
eral groups. Whereas up to 35% of primary gliomas overexpress this RTK, this percentage 
increases to up to 75% in recurrent GBMs [178]. Often, heterogeneity in MET expression is 
found between tumor cells [179] and some papers have reported on the expression of MET 
on endothelial cells too [180]. This is especially interesting since multi-targeted tyrosine ki-
nase inhibitors such as cabozantinib have been developed that have specificity against both 
VEGFR2 and MET. 
 In the past we have established a number of GBM xenograft lines by either subcuta-
neous or direct intracerebral implantation of surgically derived tumor cell suspensions in im-
munodeficient mice, which are subsequently maintained by serial transplantation [92]. One 
xenograft line that has been extensively analyzed for its response to anti-angiogenic treat-
ment is E98. This line routinely presents with diffuse tumor growth in the brain parenchyma, 
using co-opted blood vessels and white matter tracts as scaffold. The presence of additional 
areas of angiogenesis-dependent growth makes this model of high translational relevance 
for testing of targeted therapies. Western blot analysis using MET and phospho-MET specific 
antibodies (recognizing the phospho-tyrosines Y1234 and Y1235) revealed that only E98 
xenografts express significant amounts of the activated receptor, consistent with our obser-
vation that chromosome 7 is amplified in this xenograft line  (Figure 1A and [92]). IHC anal-
ysis confirmed MET expression in E98, showing expression in all tumor cells (note that the 
non-stained structures in Figure 1D correspond to white matter tracts, as is clear from H&E 
staining of the serial section in Figure 1B). IHC using the phospho-specific anti-MET antibody 
also confirmed the presence of activated MET, although in a heterogeneous fashion, being 
present predominantly in diffuse infiltrating tumor cells in the corpus callosum and adjacent 
white matter (Figure 1E, arrow and 1F). Furthermore, activated MET was detected in a rim of 
non-infiltrative tumor cells (routinely present in this model in the leptominges and ventricles) 
at the interface with normal brain parenchyma (inset in Figure 1E and not shown). In central 
regions of compact growing tumor areas MET was not activated (arrowhead in Figure 1E). 
 We reasoned that the partially angiogenic character of the E98 xenograft model, in 
combination with high MET expression and activation in diffuse infiltrative areas makes this 
model highly relevant to study simultaneous inhibition of VEGFR2 and MET signaling. First, 
we investigated whether cabozantinib therapy blocked MET activation in vitro. Treatment of 
the E98NT cell line, derived from the E98 xenograft model [176] resulted in an efficient and 
dose-dependent inhibition of MET phosphorylation after 30 minutes (Figure 2A). Downstream 
signaling via AKT was also significantly inhibited by cabozantinib (note the ~82% reduc-
tion of phosphorylated AKT and the accompanying decrease in phosphorylated ERK1/2 at 
concentrations higher than 0.5 µM). Consistently, cabozantinib caused a dose-dependent 
inhibition of proliferation in E98NT cells (Figure 2B, IC50 ~ 89 nM). Cabozantinib did not in-
duce apoptosis in vitro as demonstrated by Western blot staining with anti-U1-70 antibody 
(Figure 2F). In an in vitro spheroid-based cell migration assay, we observed that cabozan-
tinib significantly reduced the number of E98 cells that are able to migrate away from the 
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spheroids (Figure 2C-D, p<0.001, Post-hoc Tukey’s Multiple Comparison Test). Thus, MET 
signals have bearing for E98 tumor cell migratory potential as well. These inhibitory effects 
can be attributed to MET inhibition since E98 cells do not express VEGFR2 (Figure 2E). The 
inhibitory activity of cabozantinib on VEGFR2 [174] was confirmed on cultures of HUVECs 
and was complete at concentrations of 10 µM (Figure 2E). 
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Figure 1. MET is activated in E98 xenografts. Panel A shows a Western blot containing protein extracts 
of different xenografts as indicated (40 µg/lane) and stained with a pan and an Y1234/1235 phosphor-
ylated (P-) MET specific antibody. As a loading control, γ-tubulin was included. Immunohistochemical 
analysis reveals prominent MET expression and activation in orthotopic E98 xenografts (C-F). Gross 
appearances of an E98 tumor are shown in C and E, while D and F show magnifications of the boxed 
areas in C and E. The H&E section in B illustrates the diffuse nature of these tumors, arrows pointing 
at white matter tracts and comparison with D shows homogeneous expression of MET by tumor cells. 
Arrow in E points at diffuse infiltrative tumor cells in white matter with activated MET, while the arrowhead 
points at a more compact paraventricular tumor area. The inset in E represents an area with compact 
leptomeningeal growth partly positive for activated MET. The pictures shown are representative for this 
xenograft model. Size bars: B, D, F 200 µm; C 1 mm and E 500 µm. 
71
4
 We next subjected mice carrying established orthotopic E98 xenografts, as deter-
mined by visibility of edema on T2-weighted MR imaging (see Figure 3A for an example) to 
treatment with cabozantinib. An initial pilot experiment with 60 mg/kg cabozantinib (n=3) 
resulted in a full radiologic response using Gd-DTPA enhanced MRI, similar to our previous 
observations with bevacizumab, vandetanib and sunitinib [50, 51, 127]. However, large inva-
sive tumors with hypoxic compact regions (identified by MCT4 expression) remained present 
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Figure 2. In vitro effects of cabozantinib on MET and VEGFR2 signaling. Panel A shows a West-
ern blot of E98NT cell extracts (20 μg per lane) treated for 30 minutes with different concentrations of 
cabozantinib as indicated. Protein extracts were analyzed for MET, phospho-MET, AKT, and ERK1/2, 
using α-tubulin as a loading control. B) MTT assays were done to determine the IC50 concentration of 
cabozantinib on E98NT cells. Experiments were performed at least in triplicate. C) Effects of cabozan-
tinib on cell migration. Shown are representative examples of DAPI-stained spheroids after 24 hr incuba-
tion with indicated concentrations. Number of outgrowing and migrating cells per spheroid are shown in 
panel D (***: p<0.001). Number of migrating cells were significantly different between groups (one-way 
ANOVA, p<0.0001). Post-hoc Tukey's Multiple Comparison Test revealed significant differences groups 
as indicated (***: p<0.001). E) Western blot of cell lysates of E98NT and HUVEC extracts, treated with 
10 ng/ml VEGF with or without cabozantinib, and stained for VEGFR2, phospho-VEGFR2 and α-tubulin 
as an internal control. Note the absence of VEGFR2 in E98NT cells. F) Western blot of treated E98NT 
cell extracts with the anti-apoptotic antibody U1-70. Control sample consists of Jurkat cells treated with 
anisomycin. 
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after treatment while no signs of hypoxia were seen in the diffuse tumor areas (not shown). 
There was a non-significant trend towards increased survival (mean survival of 19 days in 
control vs. 23 days in 60 mg/kg cabozantinib treated animals). A larger group of animals 
(n=10) was therefore treated with 100 mg/kg cabozantinib, which did result in significant-
ly prolonged survival compared to control-treated mice (median survival of tumor-bearing 
control mice was 20 days vs. 32 days for the 100 mg/kg cabozantinib group, log rank test 
p<0.0001, Figure 3B). All further experiments refer to this group. Prior to sacrifice, mice were 
subjected to Gd-DTPA-enhanced MRI. Treatment with 100 mg/kg cabozantinib resulted, as 
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Figure 3. Cabozantinib prolongs survival of mice bearing orthotopic E98 xenografts. Mice were 
treated with 100 mg/kg cabozantinib from day 12 post tumor inoculation, when tumor was detected 
via abnormalities in T2 images (see panel A for a representative example). B) Survival curves for pla-
cebo (n=10) and cabozantinib (n=10) treated animals. Note that, for ethical reasons, mice were sac-
rificed when excessive weight loss and signs of neurological dysfunction occurred. Median survival 
was significantly different between the groups (20 and 32 days respectively, log rank test, p < 0.0001). 
C) Representative examples of T1-weighted MRI of control (upper row) and treated (lower row) E98 
bearing animals before (pre) and 2-3 minutes after (post) Gd-DTPA injection. [Post-pre]/pre represents 
subtracted images. Note the complete loss of contrast enhancement in treated animals. Panel D shows 
H&E staining of sections, corresponding to the slices shown in the MR images.  Bars: overviews 2 mm, 
zoom 200 μm.
73
4
expected, again in a complete absence of contrast enhancement (Figure 3C, lower panels) 
despite clear presence of extensive tumor (H&E staining in figure 3D, note that these sec-
tions correspond to the MR scans). Upon 100 mg/kg cabozantinib treatment, tumors gen-
erally had converted to a mainly diffuse infiltrative phenotype (see figure 3D, lower panels) 
similar to our previous findings with vandetanib and sunitinib [51, 127]. In all animals limited 
areas of compact tumor were present to varying extent and these areas were significantly 
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Figure 4. In vivo effects of cabozantinib treatment in E98 xenografts. Panels A and B show rep-
resentative examples of IHC for the hypoxia marker MCT4 in control and cabozantinib-treated tumor 
bearing animals. Hypoxia in compact tumor regions is significantly increased after treatment (Students 
t-test, p=0.003, panel C). D and E show examples of Ki67 stainings in compact tumor areas. Prolifera-
tion indices were significantly different in these regions (Students t-test p=0.04), but no difference was 
detected in diffuse tumor areas (panel F).  Panels G and H show representative examples of GLUT1 
vessel staining. Automated quantification revealed no differences between vessel densities of diffuse 
tumor areas in control vs treated mice (I). Numbers of CD34-positive vessels were lower in cabozantinib 
treated mice (see panels J and K, arrows point at blood vessels), but these data were not quantified 
because vessels without CD34 expression were also observed in these mice. L: Western blot analysis of 
protein extracts (50 μg protein/lane), derived from cabozantinib-treated xenografts reveals a substantial, 
though not complete, reduction of MET phosphorylation. As a loading control, γ-tubulin was included. 
Immunohistochemistry for phospho-MET (Y1234/1235) also shows the presence of phosphorylated MET 
in treated animals, as visualized in panel K. Size bars: A-B 2 mm, D-E 100 μm, G, H, J, K 200 μm. 
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more hypoxic than in control animals (p=0.003, see IHC for hypoxia induced monocarbox-
ylate transporter-4 (MCT4, Figure 4A-C) confirming previous observations with other angio-
genesis inhibitors [127]. Staining for GLUT1, another marker for hypoxia, gave similar results 
(not shown). 
 Diffuse infiltrative tumor regions did not show signs of hypoxia in control and treat-
ed tumors and based on caspase stainings apoptotic cells were very infrequent, also in 
treated tumors (not shown). Both compact and more invasive tumor areas were analyzed for 
proliferation differences, based on Ki-67 positivity in IHC. The proliferative fraction did not 
differ between controls and treated tumors in diffuse infiltrative regions, but proliferation was 
significantly less in compact tumor regions after treatment (p=0.04, Figure 4D-F).  
GLUT1 is, except for hypoxic cells, also expressed on brain capillaries and can be utilized as 
a blood vessel marker in the CNS. Tumor vessel densities were quantified and did not differ 
in diffuse areas between treatment and placebo groups (Figure 4G-I). Vessel densities in 
compact areas were difficult to quantify based on GLUT1 staining because neovasculature 
often does not express this differentiation marker. Based on CD34 stainings (a marker of ac-
tivated (neo)vasculature), vessel densities appeared lower in cabozantinib treated animals 
(compare Figure 4J and K), but as this treatment may also result in a downregulation of CD34 
expression on vessels, these data are difficult to interpret in terms of vascular densities. It is 
important to realize that our studies were not time-matched, making it impossible to compare 
tumor volumes in treated and control animals.
 To investigate whether the remaining diffuse infiltrative tumor might be the result 
of incomplete MET inhibition, we prepared tumor extracts from treated and control animal 
brains and prepared Western blots. As opposed to our in vitro data, even dosing as high 
as 100 mg/kg cabozantinib (resulting in plasma levels of 30 µM [175]) was not able to fully 
prevent MET phosphorylation (Figure 4L) and this finding was confirmed with IHC for phos-
pho-MET (Y1234/1235, Figure 4M). 
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Discussion
 The proposed functional role of MET in tumor cell migration makes this receptor an 
attractive therapeutic target in MET positive GBM. The high expression and activation levels 
of MET in diffuse E98 tumor areas supports the notion that MET is actively involved in tumor 
cell migration [166]. Targeting of MET may further be beneficial as signaling from this recep-
tor may induce and maintain the GBM stem cell-like phenotype and therefore resistance to 
chemotherapy and radiotherapy [181].  
 Cabozantinib treatment of in vitro cultures of E98 cells greatly reduced phosphory-
lation of AKT and ERK. This was accompanied by a 50% inhibition of cell growth at concen-
trations as low as 89 nM, which is consistent with the involvement of these signal transducers 
in PI3K and MAPK signaling. In vitro migration assays showed potent effects of cabozantinib 
on single cell migration, further strengthening a role of MET in cell migration as well.
 E98 tumors became largely invisible in CE-MRI under cabozantinib therapy, and 
similar phenomena have been observed in clinical studies, with a radiological response as 
early as one day after start of therapy [145]. This effect of vascular normalization, rendering 
capillaries in brain tumors impermeable to MR contrast agents by restoring the BBB, is a well 
known phenomenon which is the result of VEGFR2 inhibition [35, 44, 50]. A reduced vessel 
density in compact tumor areas in cabozantinib treated mice may also have contributed to 
some extent to the reduced visibility in CE-MRI. The persistent presence of MRI-invisible tu-
mor confirms our earlier finding that the high blood vessel density in brain can accommodate 
tumor growth via vessel cooption [119], i.e. without the necessity for neovascularization.
 High dose cabozantinib treatment in our study resulted in a significant improvement 
of survival. Kamoun et al. have shown that anti-angiogenic treatment of mice carrying orthot-
opic glioma may result in improved survival by a sole reduction of edema [46]. In previous 
experiments, we examined the effects of VEGFR2 inhibition by bevacizumab, vandetanib 
and sunitinib, alone or in combination. Even combinations of these compounds did not result 
in improved survival of E98-carrying mice, although there seemed to be a complete BBB 
restoration [127]. Therefore, it is likely that improved survival is the result of additional MET 
targeting.  Of note, a phase II trial of cabozantinib for recurrent GBM also revealed clinical 
activity of this compound [145]. 
 The high efficacy of cabozantinib to E98 cells in vitro contrasts with our in vivo 
results. Although the increased survival was unprecedented compared to previously used 
angiogenesis inhibitors, tumors could still escape therapy via diffuse growth. The exact con-
tribution of MET during tumor progression in E98 xenografts is somewhat difficult to assess. 
In a recent paper an interesting explanation for increased invasiveness of GBM in response 
to VEGF inhibition has been proposed [166]. These authors demonstrated that MET activa-
tion is inhibited in GBM cells that also express VEGFR2 in the presence of VEGF. This was 
suggested to be the result of activation of the VEGFR2-associated protein tyrosine phospha-
tase PTP1B, resulting in dephosphorylation of its target MET. According to this hypothesis, 
inhibition of VEGF-A releases PTP1B from the multi-receptor complex, unleashing MET and 
resulting in increased diffuse infiltrative tumor growth. This might complicate the use of com-
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pounds like cabozantinib, as it may bear antagonistic activities in itself. However, it must be 
realized that this is only relevant for GBMs that are positive for both MET and VEGFR2. As 
E98 tumor cells do not express VEGFR2 this hypothesis is not applicable to this model and 
other explanations must be found for the escape from therapy. 
One such alternative explanation comes from our finding that cabozantinib plasma con-
centrations of approximately 30 µM [175] did not entirely annihilate MET activation whereas 
in vitro, concentrations as low as 0.5 µM sufficed to achieve complete inhibition. Reduced 
penetration of the drug into the tumor and surrounding tissue, as well as reduced free con-
centrations of drug due to protein-binding in blood and tissue, may account for the apparent 
reduction in potency. Pharmacokinetic studies and measurement of steady-state levels in 
brain would be appropriate.
 The difference between the apparent in vitro and in vivo potency of cabozantinib 
with respect to MET inhibition poses us with an interesting dilemma. We demonstrated in a 
previous study that the combination of vandetanib and the DNA-alkylating agent TMZ was 
less effective than TMZ alone [51]. This was attributed to vessel normalization and concom-
itant ‘restoration’ of the BBB, resulting in a hampered distribution of the chemotherapeutic 
agent to the tumor cells. To what extent cabozantinib can pass the BBB is not exactly known. 
If passage would be inefficient, it may be envisioned that a short period of cabozantinib 
treatment, enough to restore the BBB, will result in inhibition of distribution of the compound 
to tumor cells in later stages of treatment. According to this hypothesis, only during the initial 
cabozantinib administrations, the compound will reach tumor cells and have anti-migratory 
and anti-proliferative effects. In later stages of tumor growth, tumor access may be limited 
by the restored BBB, although it is likely that this block is not 100%, given that phospho-MET 
is still significantly reduced in treated tumors. This may indeed explain the significant delay 
in tumor growth that we observed. In this respect it would be very worthwhile to investigate 
whether sequential targeting of MET and VEGFR2 with monotargeted compounds would 
be more effective. Such schemes may involve giving intermittent cycles of MET inhibitor, 
followed by VEGFR2 inhibitors, which would effectively result in locking up the MET inhibitors 
in the tumor cell compartment. Such studies are underway in our lab.
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Abstract
 MET has gained interest as a therapeutic target for a number of malignancies be-
cause of its involvement in tumorigenesis, invasion and metastasis. At present, a number of 
inhibitors, both antibodies against MET or its ligand hepatocyte growth factor (HGF), and 
small molecule MET tyrosine kinase inhibitors are in clinical trials. 
 We here describe a novel variant of MET that is expressed in 6% of high-grade 
gliomas. Characterization of this mutation in a glioma cell line revealed that it consists of an 
intronic deletion, resulting in a splice event connecting an intact splice donor site in exon 6 
with the next splice acceptor site being that of exon 9. The encoded protein lacks parts of 
the extracellular IPT-domains 1 and 2, encoded by exons 7 and 8, resulting in a novel pseu-
do-IPT and is named METΔ7-8. METΔ7-8 is located predominantly in the cytosol and is constitu-
tively active. The auto-activating nature of METΔ7-8, in combination with a lack of transmem-
brane localization, renders METΔ7-8 not targetable using antibodies, although the protein is 
efficiently deactivated by MET-specific tyrosine kinase inhibitors. Testing of MET-expressing 
tumors for the presence of this variant may be important for treatment decision making. 
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Introduction
 The MET proto-oncogene (chromosome 7q31.2) encodes the tyrosine kinase mem-
brane receptor MET (also called Scatter Factor Receptor), which is essential during devel-
opment. Signaling from the receptor controls epithelial-to-mesenchymal transition (EMT) of 
myogenic precursor cells during differentiation into skeletal muscle cells [182], a process 
that involves migration over long distances in the embryo. In adults, MET is involved in tissue 
regeneration upon injury [183]. 
 MET is produced as a glycosylated single chain precursor protein of ~190 kDa 
which, during transport to the membrane, undergoes furin-mediated cleavage in the 
trans-Golgi network [184, 185]. The resulting mature receptor consists of an extracellular 
50 kDa α-chain, covalently attached via a disulfide bond to a membrane-spanning 140 kDa 
β-chain [186, 187]. The extracellular segment consists of an N-terminal Sema-domain that is 
involved in ligand binding, a small cysteine-rich domain, and four IPT (Immunoglobulin-like 
fold shared by Plexins and Transcription factors) domains, which connect the Sema and 
cysteine-rich domains with the C-terminal β-subunit [188]. 
 Upon binding of the ligand Hepatocyte Growth Factor (HGF, Scatter Factor), re-
ceptor dimerization occurs followed by trans-phosphorylation in the intracellular tyrosine ki-
nase (TK) domain at tyrosine (Y) residues 1230, 1234 and 1235 [189, 190]. The TK domain 
subsequently induces auto-phosphorylation of Y1349 and Y1356 which act as docking sites 
for signal transduction molecules including GAB1, GRB2, phospholipase-C and SRC [167]. 
Phosphorylated GAB1 interacts with molecules like PI3-K and SHP2, which together induce 
several downstream signaling pathways. MET signaling is mediated by, among others, the 
PI3-K/AKT and RAS/MAPK pathways, which induce cell cycle progression, survival, cyto-
skeletal changes and invasion (reviewed in [75]). In addition to its role downstream of HGF, 
MET can also be involved in signaling of other transmembrane receptors, including VEGFR2, 
CD44v6, EGFR and Plexin B1 [166, 191-193]. Upon ligand-induced receptor dimerization, 
MET is internalized via endocytosis and may be recycled [194]. Phosphorylation of Y1003 
in the juxtamembrane (JM) domain of the receptor leads to ubiquitination and subsequent 
proteasomal degradation [195]. Thus, levels of MET in the cell are tightly regulated. 
 Aberrant activation of MET signaling is a tumor promoting event in a variety of ma-
lignancies and can be induced by several mechanisms, including alternative mRNA splicing, 
exon skipping and crosstalk with other receptors [73]. In high-grade gliomas, the frequently 
occurring oncogenic EGFR mutant EGFRvIII can induce overexpression of both MET and 
HGF, a process that is balanced by wild type EGFR activation [196]. MET amplifications have 
been found in a number of tumor types including glioblastoma (GBM) [197, 198] and mis-
sense mutations in the Sema, the TK and the JM domain have been reported to affect HGF 
binding, kinase activation and receptor degradation, respectively [199-206]. Recently, gene 
fusions between the protein tyrosine phosphatase PTPRZ1 and MET, resulting in constitutive 
activation of MET were described in 16% of secondary GBMs [207]. Activation of MET sig-
naling has been proposed as a mechanism of resistance to EGFR inhibitors, likely a result of 
the similarities in downstream signaling events from both receptors [208].
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 The significant role that MET plays in tumor progression and metastasis has made 
it a prime therapeutic target in oncology. MET tyrosine kinase inhibitors and therapeutic an-
tibodies against the extracellular domain of MET and against HGF, all preventing HGF-medi-
ated MET activation, are currently in clinical trial (www.clinicaltrials.gov). In a previous study 
we have shown that the combined VEGFR2/MET tyrosine kinase inhibitor cabozantinib (XL-
184, CoMETRIQ) potently inhibits MET phosphorylation, cell proliferation and migration and 
consequently prolongs survival of mice carrying orthotopic E98 glioma xenografts [140]. 
Here we identify a novel intragenic MET deletion in E98 cells, which results in a truncated 
protein that is constitutively active and lacks membranous expression, thereby having im-
portant implications for therapeutic strategies targeting MET. We show that this mutation oc-
curs in 6% of glioblastomas and, like the EGFR mutation EGFRvIII [209], is relatively specific 
for this tumor type.
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Materials and Methods
Immunohistochemistry
 Immunohistochemistry on formalin fixed paraffin embedded (FFPE) tissue sections 
was performed as previously described using antibodies against MET and P-MET (clone 
D1C2 and D26 respectively, both CST) [140]. Antibodies were visualized via sequential in-
cubations with biotinylated secondary antibodies, avidin-biotin complexes (Vector laborato-
ries, Burlingame, CA, USA) and 3,3’-diaminobenzidine solution (Power-DAB, ImmunoLogic, 
Duiven, The Netherlands).
Cell lines 
 The E98 cell line and xenograft model and genetic analysis thereof have been 
described before [92, 140]. E98, U87, A549, HEK-293T and TOV-112D or TOV-112D-MET 
cells [210] were cultured in DMEM + 4.5 g/L glucose medium (PAA Laboratories, Pasching, 
Austria) supplemented with 10% fetal calf serum (FCS) (PAA) and gentamycin (40 μg/mL). 
All cell lines were maintained at 37°C in the presence of 5% CO2. To examine HGF-induced 
MET activation, E98 and A549 cells were seeded in 6 wells plates. The next day, cells were 
serum-starved overnight, followed by a 10 minutes treatment with 50 ng/ml HGF (Miltenyi 
Biotec, Bergisch Gladbach, Germany). In some experiments, prior to HGF incubation cells 
were incubated with the anti-MET llama VHH G2 [210] or cabozantinib (XL-184, Exelixis, San 
Francisco, CA) for 60 min. 
Genetic analysis of E98
 Genomic DNA from E98 cells was analyzed by semi-conductor sequencing (Ion-
PGM, Life Technologies) using the comprehensive cancer panel (Life Technologies) that 
targets 409 cancer-related genes. The IonPGM E98 library generation was performed ac-
cording to the manufacturer’s protocol. In short, 10 ng of DNA per pool was amplified in 
21 cycles by PCR using the Ion AmpliSeqTM mastermix, followed by barcode and adapt-
er ligation. Amplified products were purified with Agencourt AMPure XP beads (Beckman 
Coulter Genomics, High Wycombe, UK). The library was diluted to 20 pM. Emulsion PCR 
was performed using the Ion OneTouchTM 200 Template kit following the protocol of the Ion 
OneTouchTM System. Next, Ion Sphere Particles (ISPs) were recovered and enriched for 
template positive ISPs using Dynabeads MyOne Streptavidin C1 beads (Life Technologies) 
in the Ion OneTouchTM ES instrument (Life Technologies). ISP enrichment was quantified us-
ing the Qubit 2.0 fluorometer (Life Technologies). Sequencing primer and polymerase were 
added to the final enriched spheres before loading onto an Ion 318 chip according to the 
Ion PGMTM 200 sequencing kit protocol. The gene copy number analysis was performed as 
follows. The relative number of sequence reads aligned to a specific gene was determined 
by dividing by the total number of aligned reads of E98, and was divided over the relative 
number of sequence reads of the same gene in non-neoplastic blood cells. The relative ra-
tios are plotted in a graph based on the genomic position of the gene.
 To perform confirmative mapping of the intronic deletion in MET on the nucleotide 
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level, genomic DNA was isolated from E98 and U87 cells using the DNeasy Blood & Tis-
sue Kit (QIAGEN), according to the manufacturer’s protocol. 10 ng was subjected to PCR, 
using primer MET1997Fw (5’-CTCCTTGGAAATGAGAGCTG-3’, forward, exon 6, genome 
location chr7q;g.116395517-36) and reverse primer MET2414Rev (5’-GGGATCTTCACGG-
TAACTG-3’, located in exon 9, CHR7q; g.116398565-45). Human genome sequence anno-
tations are in all cases based on assembly hg19. 
FISH
 FFPE sections (4 μm) on SuperFrost glass (dried > 45 min at 56°C) were deparaf-
finized and rehydrated in ddH2O. After boiling in a microwave in sodium citrate buffer (pH 6), 
slides were allowed to cool to RT, washed in ddH2O and incubated for 5 min in 10 mM HCl. 
Proteins were digested with pepsin (200 U/mL, Sigma) for 15 min at 37°C. Subsequently, 
slides were rinsed in 10 mM HCl and PBS and postfixed for 5 min in 1% paraformaldehyde 
(PFA, Merck)/PBS. Sections were washed in ddH20, dried and hybridized with 10 μl probe 
mix (1 μl cep7 Spectrum Green (06J37007) + 1 μl LSI MET Spectrum Red (06N05-001) + 7 μl 
hybridization buffer in MQ, all Vysis) under a cover slip. Sections were denatured at 80°C for 
10 min, followed by hybridization o/n at 37°C in a Hybridizer (Dako). After removing the cov-
erslip by soaking for 5 min in 2x SSC buffer (Maxim Biotech) at 42°C, slides were washed 3 
times in 2x SSC buffer at 73°C, once in 2xSSC (5 min) and once in ddH2O. After dehydration 
in EtOH, slides were air-dried in the dark and mounted in Vectashield/DAPI (3 parts Vecta-
shield/DAPI + 1 part Vectashield, all Vector). Slides were analyzed on a Leica Fluorescence 
microscope.
RT-PCR and cloning  
 RNA was isolated from cell lines E98 and TOV112D-MET [210] using TRIzol Re-
agent (Life Technologies) and reverse transcribed with MMLV-RT (New England Biolabs) 
using oligo-dT primers, according to the manufacturer’s instruction. HGF was PCR-ampli-
fied from cDNA using Phusion High-Fidelity DNA polymerase (Finnzymes, ThermoFisher 
Scientific, Waltham, USA) and primers HGF-Fw204 (5’-CTGCAGCATGTCCTCC TGCA-3’) 
and HGF-Rv504 (5’-GAGGTCAAATTCATGGCCAA-3’) (30 cycles, annealing at 55°C, 20 sec; 
extension at 72°C, 20 sec). Control PCR reactions were performed for housekeeping gene 
HMBS (Hydroxymethylbilane Synthase) using primers p361-Fw (5’-TGCCAGAGAAGAGT-
GTGGTG-3’) and p425-Rv (5’-GTTAAGCTGCCGTGCAACATC-3’). 
 MET open reading frames were PCR amplified from cDNA using Phusion DNA poly-
merase and primers flanking start and stop codons (MET173EcoR1-Fw: 5’-CGAATTCGA-
TAAACCTCTCATAATGAAGG-3’ and MET4421NotI-Rv 5’-AGCGGCCGCCTATGATGTCTC-
CCAGAAGG-3’). PCR products were purified on agarose gel, digested with NotI and cloned 
as blunt-NotI fragment in pIRESneo-EcoRV-NotI (Clontech Laboratories, Inc, CA, USA) to 
yield pIRESneo-MET and pIRESneo-METΔ7-8. Full sequences were obtained by Sanger se-
quencing via the sequencing facility of Radboud UMC.
 The extracellular parts of MET were PCR-amplified from E98 and TOV-112D-MET 
cDNA using primers MET173EcoR1-Fw and MET3028NheI-Rv (5’-CGCTAGCCTGATCTG-
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GTTGAACTATT AC-3’), and cloned in vector pHLsec-BAPHIS, a derivative from pHLsec-HIS 
(Addgene, Cambridge, MA, USA). The resulting vector adds a biotin-acceptor peptide and 
His-tag to the carboxyterminus of the MET extracellular domains, resulting in pHLsec- MET-
ED-BAPHIS and the E98-derived variant pHLsec- METΔ7-8ED-BAPHIS.
Transfection and protein purification
 pIRESneo-MET or pIRESneo-METΔ7-8 were transfected into HEK-293T or TOV-112D 
cells in 6-well culture dishes (Greiner Bio-One, Krëmsmunster, Austria) using Fugene HD 
transfection reagent (Promega, Fitchburg, WI, USA) according to the manufacturers’ instruc-
tions. After 48 hrs, cell monolayers were washed with PBS and cell extracts prepared in RIPA 
buffer containing protease and phosphatase inhibitors (Cell Signaling Technology, CST, 
Danvers, MA, USA).
 In separate experiments, pHLsec-METΔ7-8ED-BAPHIS or pHLsec-METED-BAPHIS 
were cotransfected in a 1:1 ratio with the biotin-ligase expression construct pDISPLAY-Bi-
rA-ER (Addgene) in HEK293T cells and cells were cultured in the presence of 10 μM biotin 
(Sigma-Aldrich, St Louis, MO, USA). After 48 hours cytosolic extracts were made in RIPA 
buffer, and medium (1 ml) was mixed with 100 ul Ni-NTA sepharose slurry (IBA, Goettingen, 
Germany). After a one hour incubation at 4°C, Ni-beads were washed with buffer (500 mM 
NaCl, 50 mM phosphate buffer, pH 7.4) and loaded onto a Poly-Prep column (Bio-Rad, Her-
cules, CA, USA). After washing off aspecifically bound proteins with 2 ml 10 mM imidazole, 
His-tagged an biotinylated MET extracellular domains were eluted with 0.5 ml 0.5 M imidaz-
ole, and dialysed o/n at 4°C to 50 mM TRIS/150 mM NaCl pH 7.5.
MET downregulation via short hairpin RNAs
 To create MET knock-down constructs, shMET1 (GTATGTCCATGCCTTTGAA) and 
shMET2 (GTATGTCCATGCCTTTGAA) oligonucleotide heteroduplexes were ligated in pEN-
TR/U6 vector and subsequently Gateway-cloned into pLenti6/ BLOCK-iT-DEST- TagRFP ac-
cording to the manufacturer’s protocols (Invitrogen). Generation of lentiviruses was done in 
HEK293FT cells as described previously [211].
Protein analysis
 RIPA extracts (20-40 µg protein per lane) and purified His-tagged proteins from 
conditioned media (equivalent of 20 µl conditioned medium) were subjected to PAGE on 
8-10% polyacrylamide gels and western blotting according to standard procedures. Nitro-
cellulose blots (Whatman Optitran BA-S85, GE Healthcare, Little Chalfont, UK) were blocked 
with PBS/Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln, NE, USA) (1:1), followed 
by overnight incubation with primary antibodies at 4˚C. Antibodies used were against MET 
N-terminus (clone EP1454Y, Epitomics, Abcam, Cambridge, UK), MET C-terminus (clone 
D1C2), phosphorylated (P)-MET (Y1234/1235, clone D26), P-AKT (S473, clone D9E), 
P-ERK1/2 (T202/Y204, clone 20G11) (all CST), GAPDH (clone 6C5, Abcam), and α-tubulin 
(clone 236-10501, Molecular Probes, Life Technologies). Biotin groups and primary antibod-
ies were visualized using respectively streptavidin-680 (Molecular Probes, Life Technology) 
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and appropriate secondary antibodies [goat-anti-rabbit-IRDye800 (Rockland Immunochem-
icals, Gilbertsville, PA, USA) or Alexa Fluor 680 goat-anti-mouse IgG (Molecular Probes, Life 
Technologies)]. Blots were scanned on the Odyssey imager (LI-COR Biosciences).
Protein domain modeling 
 A homology model for the new hybrid IPT-domain using the WHAT IF & YASARA 
Twinset was generated [212, 213]. We used the experimentally solved 3D-structure 2uzx, 
which contains the human tyrosine kinase MET. The first 60 residues of the hybrid domain 
are identical to this structure, whereas the following 38 residues were modeled based on 
homology between the 2 domains.
Confocal microscopy
 E98NT and U87-MG cells, grown on Nunc Lab-Tek chamber slides (Sigma-Aldrich) 
to 40% confluence, were fixed with 2% PFA in 0.1 M phosphate buffer (pH 7.4) for 15 min 
at RT, followed by three washes with PBS, 30 min glycine incubation (100 mM in PBS) to 
quench PFA-induced autofluorescence, three PBS washes and permeabilization with dig-
itonin for 10 min (100 μM in PBS). Aspecific binding was blocked by incubation with 20% 
normal goat serum in PBS/1%BSA for 20 min, and cells were incubated overnight at 4˚C in 
a humidified chamber with PBS/1%BSA containing (combinations of): mouse monoclonal 
anti-CD44 antibody (as a surface marker, clone Hermes-1, ThermoFisher Scientific); rabbit 
anti-MET (clone D1C2, CST); rabbit anti-P-MET (clone D26, CST); mouse anti-EEA-1 (clone 
14/EEA1, BD Biosciences, early endosome marker); anti-CLIMP-63 (clone G1/296, rough ER 
marker, a kind gift of J. Fransen). Primary antibodies were detected using Alexa Fluor 488- or 
594-labeled secondary goat-anti-mouse and Alexa Fluor 488- or 568-labeled goat-anti-rabbit 
IgGs (all Life Technologies), 1:200 diluted in PBS/1%BSA. Q-nuclear deep red (1:200, Life 
Technologies) was used to stain nuclei, and cells were mounted in Fluoromount G with DAPI 
(Southern Biotech, Birmingham, AL, USA). Cells were analyzed using a confocal laser scan-
ning microscope (Leica SP2 CLSM) and Leica confocal software.
Biotinylation assay
 E98NT and A549 cells were allowed to adhere and grown to 80% confluence in a 
6-wells plate (Cellstar, Greiner Bio-One, Kremsmünster, Austria). Cells were washed 3 times 
with ice cold PBS and incubated for 30 min at 4°C with 0.5 mg/ml EZ-Link Sulfo-NHS-LC-
Biotin (ThermoFisher Scientific). This compound does not penetrate cells and biotinylation is 
therefore confined to exposed membrane proteins.  In parallel, Tris-free RIPA extracts, pre-
pared from equivalent numbers of E98 or A549 cells by repeated washing over Amicon Ultra 
K10 centrifugal filters (Merck Millipore, Billerica, MA, USA), were treated similarly to bioti-
nylate all cellular proteins. The reaction was quenched by washing cells or cytosolic proteins 
three times with 100 mM glycine/PBS and two times with PBS (using K10 columns in the case 
of protein lysates). Intact biotinylated cells were then subjected to lysis with RIPA buffer. Pro-
tein concentrations in all lysates were determined using the BCA protein concentration assay 
(ThermoFisher Scientific). MET was immunoprecipitated from 200 µg total protein in a volume 
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of 200 μl using anti-MET (1:50, clone D1C2, CST) for 1 hour at 4˚C. Immune complexes were 
captured by incubation for 30 min at 4˚C with 10 μl prot A agarose slurry (Roche Diagnostics, 
Basel, Switzerland), followed by centrifugation (14.000 rpm, 4 min) and three PBS washes. 
Immune complexes were solubilized by heating (5 min 95°C) in 30 μl 2x SDS-PAGE sample 
buffer (0.2% SDS, 62.5 mM Tris-HCl pH 6.8, 10% glycerol and 0.2 μM DTT). Samples were 
subjected to 10% SDS-PAGE and western blotting as described above.
RT-PCR analysis
 Glioma tissues (n=80) were obtained from the Radboud UMC and from the Univer-
sity of Cologne. Sarcoma (n=25) and castration-resistant prostate cancer (CRPC) tissues 
(n=43) were obtained from Radboud UMC. RNA was isolated from tissues using the mir-
VANA RNA isolation kit (Life Technologies) according to standard procedures. For cDNA 
synthesis, 1 μg RNA was reverse transcribed using the Quantitect Reverse Transcription Kit 
(QIAGEN, Venlo, The Netherlands) using hexanucleotides. To distinguish wtMET from METΔ7-
8-transcripts, a PCR was performed in AmpliTaq Gold 360 mastermix (Applied Biosystems, 
Life Technologies) using primer MET1997Fw (5’-CTCCTTGGAAATGAGAGCTG-3’, forward, 
located in exon 6), and primer MET2342Rv (5’-CAGTTGAAATGGTTTGGGCTG-3’, reverse, 
located in exon 9). This PCR results in a 105 bp product for METΔ7-8 and a 345 bp product 
for wtMET. Conditions were: denaturation 95˚C, followed by 35 cycli of 95˚C denaturation; 
annealing at 58˚C, 30 sec; elongation at 72°C, 1 min. A final elongation step of 7 min was 
done at 72˚C.
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Results
E98 MET protein is auto-activated in an HGF-independent fashion 
 Our previous experiments have shown that MET in orthotopic E98 xenografts is 
phosphorylated in tumor cells in a homogeneous fashion (Figure 1A, see also [140]). In vitro, 
E98 cells also show high levels of phosphorylated MET when grown under serum-free con-
ditions (Figure 1B). HGF treatment did not further increase phosphorylation levels of MET, in 
contrast to A549 control cells in which HGF was required for MET activation. MET phosphor-
ylation in E98 cells was not the result of endogenous HGF expression as revealed by RT-PCR 
analysis (Figure 1C), while analysis of E98 xenograft RNA revealed the presence of mouse 
HGF only, as determined by Sanger sequencing (not shown). Since mouse HGF is not an 
activating ligand for human MET [214] we conclude that constitutive activation of MET in E98 
cells and xenografts is not the result of an autocrine HGF-activation loop.
E98 cells express a truncated version of an amplified MET gene 
 To examine the underlying mechanism of MET auto-activation in this model, we 
PCR-cloned MET cDNA from E98 cells, using primers flanking the open reading frame (ORF, 
NM_000245.2). The MET PCR product from E98 was 240 bp smaller than that from U87 
and CaCo2 cDNA (Figure 2A), and Sanger sequencing analysis revealed an in-frame de-
letion of nt 2050-2289 in the coding sequence, corresponding to exons 7 and 8. The same 
transcript was also found in E98 xenografts (not shown). Genomic analysis of E98 cells us-
ing semi-conductor sequencing revealed high copy MET amplification (Figure 2B). Average 
amplification of MET (except for exons 7/8) was about 14-fold. FISH analysis using probes 
specific for MET and chromosome 7 centromere confirmed the amplification (Figure 2C). 
E9
8
TO
V-
11
2D
HE
K2
93
T
HGF
HMBS
C
B
200 �m α-tub
P-MET
MET
E98 A549
HGF: +- +-A
Figure 1. MET is constitutively acti-
vated in the E98 cell line and xeno-
graft model. A) Sections of an intracra-
nial E98 xenograft were subjected to 
immunohistochemistry for P-MET (up-
per panel, brown staining). A matching 
H&E staining is shown as reference. 
Note that tumor shows diffuse infiltration 
in the brain parenchyma and that the tu-
mor cells are highly positive for this ac-
tivated MET. B) Western blot analysis of 
MET expression in serum-starved E98 
and A549 cells in absence of presence 
of HGF. Note that the processed form 
of MET (arrowhead) in E98 is some-
what smaller than that of A549 while 
the preform is predominantly present 
in E98 (arrow). α-tubulin was used as 
a loading control. C) RT-PCR for HGF 
on E98, TOV-112D and HEK-293T cell 
line cDNA. HMBS was used as a control 
housekeeping gene.
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Consistent with Sanger sequencing, amplicons in exon 7 and the first part of exon 8 were 
absent (see insert in Figure 2B), suggesting that the lack of exons 7 and 8 results from a 
genomic rearrangement (similar to the EGFR variant III [215]) instead of alternative splicing. 
PCR on genomic DNA using exon 6 and 9-specific primers resulted in amplification of a 910 
bp fragment (predicted size from the wild-type allele, present in U87, is 3,014 bp, see Figure 
2D). Sequencing of this product revealed an intronic deletion of 2,114 bp (between position 
g.116 395 653 located in intron 6, and 116 397 766, located in exon 8). This deletion results 
in an intact splice donor site from exon 6, juxtaposed to the exon 9 splice acceptor site, and 
explains the lack of exons 7 and 8 in the resulting mRNA (Figure 2E). Of note, a wtMET allele 
E
HMBS
ﬂ-MET
E9
8
U8
7
Ca
Co
2
E9
8
U8
7
925-
831-
564-
1375-
1584-
2027/1904-
21226-
exon 6 exon 7 exon 8 exon 9
human 
MET 
NM 000245.2
intron intron intron
deletion
METΔ7-8
wt MET
2049 22902050 2152 2153 2289
6641 
bp
A B 
C 
D 
MET exon 
structure
Figure 2. E98 MET contains an intronic deletion, resulting in a truncated transcript. A) RT-PCR on 
cDNA from different cell lines using full length MET primers, using HMBS as a housekeeping gene for 
reference. B) Ion-torrent sequencing analysis exposes a high-copy amplification of MET in E98 DNA. 
Plotted on the x-axis are all 409 genes sequenced, in chromosomal order. The number of reads per gene 
was compared to blood-obtained DNA from a glioma patient as a reference. The dotted line represents 
the level of heterozygous losses, as can be seen for the X-chromosome (the reference blood sample 
was female, while the tumor DNA was male). The inset shows the relative number of reads per MET 
exon. Note the loss of exon 7 and part of exon 8. C) FISH analysis of the number of MET (red) and chr.7 
centromere (green) copies in the genome of an E98 xenograft. D) Amplification of MET using exon 6 and 
9-specific primers on genomic DNA of E98 and U87 cells. METΔ7-8 and wtMET amplification leads to 
910 and 3041 bp products in E98 and U87 respectively. D) Schematic overview of the METΔ7-8 deletion 
found in E98 cDNA. Splicing of exon 6 to exon 9 is indicated with the dotted orange lines. The orange 
solid line represents the deletion.
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could not be detected in E98 cells (Figure 2D).
 In the MET protein this rearrangement leads to loss of the C-terminus of IPT1 and 
the N-terminus of IPT2 (Figure 3A). Yasara modeling, using X-ray crystallographic data of the 
MET ectodomain, predicts the formation of a novel IPT, composed of the remaining parts of 
IPT1 and 2. Interestingly, in the new IPT1/2 fusion a small stretch of 5 extra amino acids loops 
out towards the Sema domain (Figure 3B, arrow).
METΔ7-8 is aberrantly processed 
 MET is synthesized as a 190 kDa precursor protein which is proteolytically cleaved 
by furin between residues 307 and 308, to yield an extracellular α-chain of approximately 
45 kDa, covalently linked via a disulfide bridge to the transmembrane β-chain. Reducing 
SDS-PAGE, followed by western blot analysis of E98 cell extracts showed that the majority 
of MET protein was in a 180 kDa phosphorylated form, corresponding to the uncleaved 
truncated preform (Figure 1B, arrow). In contrast, in A549 cells the matured cleaved MET 
protein was the predominant form (arrowhead in Figure 1B). To investigate whether this was 
a specific feature of E98 cells, we analyzed the protein structure in cells after transfection 
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Figure 3. Predicted protein structure of METΔ7-8. A) Schematic overview of MET and METΔ7-8. The 
red lined box represents the deletion, comprising parts of the IPT1 and 2 domains (represented by the 
red and yellow boxes respectively in METΔ7-8). Other domains present are the SEMA, a cysteine-rich 
(CR), transmembrane (T), the junxtamembrane (JM) and kinase (K) domains. B) Yasara modeling of the 
remaining IPT1 and 2 domains in METΔ7-8 was performed based on wtMET IPT1. The wtMET SEMA 
domain and IPTs are shown in blue, with the novel putative IPT domain consisting of IPT1 (red) and 2 
(yellow) of METΔ7-8, superimposed on wtMET. An enlargement of the fusion part in the overview figure 
(arrow) is shown in the right panel. The arrow indicates the additional loop in red that is formed by the 
novel IPT domain. 
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Figure 4. Aberrant processing and localization of METΔ7-8. A) Western blot analysis of MET expres-
sion in HEK-293T and TOV-112D cells, transfected with pIRESneo-MET or pIRESneo-METΔ7-8. Note 
that HEK-293T cells have endogenous MET expression. As a loading control, α-tubulin was used. B) 
Analysis of MET localization in E98 by confocal microscopy, using CD44 as a membrane marker (green) 
in combination with C-terminal MET antibodies (red), or phosphorylated MET (1234/1235, red) as indi-
cated. U87 cells were also analyzed for MET/CD44 colocalization for comparison. Q-nuclear deep red 
stain was used to stain all nuclei. C) Subcellular localization of MET (green) with early endosome and 
RER markers EEA-1 and CLIMP-63 (both in red) in E98 cells. D) Western blots of biotinylated intact E98 
and A549 cells or of biotinylated cell lysates. MET was immunoprecipitated and analyzed on western 
blot for biotinylation, as described in the materials and methods section. The α-chain of MET is shown. E) 
His-tagged ectodomains of both wildtype MET and METΔ7-8, biotinylated via a biotin-acceptor peptide 
at the carboxyterminus, were expressed in HEK-293T cells. Ni-purified culture media and extracts of 
the transfected cells were used to analyze MET localization. Both fractions were subjected to western 
blotting using N-terminal MET antibodies, recognizing both the preform and the cleaved α-portion of the 
ectodomain, and directly labeled streptavidin to visualize the preform and the β-chain. GAPDH was used 
as a loading control for the RIPA extracts (red signal at 36 KDa). 
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with the full-length cDNAs encoding METwt or METΔ7-8. In both HEK-293T and TOV-112D 
cells, wtMET was properly processed to an α- and β-chain, indicating that these cells are not 
defective in furin-mediated processing. In contrast, METΔ7-8 was predominantly present in 
the uncleaved preform in both cell types (Figure 4A, arrow). Thus, improper MET cleavage 
is an intrinsic property of METΔ7-8. Overexpression studies in HEK-293T and TOV-112D 
cells resulted in phosphorylated Y1234/1235 residues in both METwt and METΔ7-8 proteins 
(Figure 4A, P-MET). Because both cell lines produce HGF (Figure 1C) this may be a result of 
HGF-dependent autocrine activation. 
 MET is cleaved by the endoprotease furin, which is localized predominantly in the 
trans-Golgi network, but also in vesicles and near the plasma membrane [184, 185, 216]. To 
test whether the inefficient cleavage of METΔ7-8 in E98 cells is related to intracellular transport 
defects, we analyzed the subcellular localization of METΔ7-8 in detail via confocal microsco-
py. METΔ7-8 did not co-localize with the cell surface marker CD44 and was confined to the 
cytosol (Figure 4B). In contrast, in U87 cells METwt did co-localize with CD44. Additional in-
tracellular staining in U87 cells reflects de novo synthesized material that is being processed 
for constitutive secretion. Immunostainings with the early endosome marker EEA-1 and the 
rough endoplasmic reticulum (RER) marker CLIMP-63 suggested that METΔ7-8 in E98 cells is 
predominantly retained in the RER (Figure 4C).
 To confirm the absence of cell surface expression of METΔ7-8 on E98 cells, we la-
beled intact E98 cells or cell lysates with NHS-biotin and immunoprecipitated MET using 
specific antibodies, followed by SDS-PAGE/western blot and staining for biotin and MET. 
Whereas METs’ N-terminal α-chain was readily biotinylated in E98 cell lysates, no detectable 
MET biotinylation occurred when intact cells were labeled (Figure 4D, lane 1). In contrast, 
biotinylated MET was readily detected in A549 cells upon labeling of intact cells, as shown 
by the biotin-labeled α-chain (Figure 4D, lane 3). Thus, these data confirm that METΔ7-8 is 
predominantly localized intracellular and is poorly exposed on the cell surface of E98 cells.
 To further confirm a defect in intracellular trafficking of METΔ7-8 we analyzed secre-
tion patterns of extracellular domains of wtMET or METΔ7-8 (ending with residue D929, number-
ing according to MET variant 2 (NP_000236.2), containing a C-terminal biotin tag. Whereas 
the extracellular domain of wtMET was properly processed and secreted into the culture 
medium (as illustrated by the presence of the 309-929 biotinyated extracellular β-chain and 
the MET25-308 α-chain, Figure 4E, lane 4), no secreted MET products were found in medium 
of cells, transfected with the METΔ7-8 ectodomain (Figure 4E, lane 3). Instead, all biotinylated 
MET products were located intracellularly (Figure 4E, lane 1).
185 kDa METΔ7-8 is not affected by antagonistic anti-MET antibodies but is inhibited 
by cabozantinib  
 It was previously reported that incubation of A549 cells with VHH G2, a recombi-
nant single domain llama antibody against MET, results in low MET activation levels, while 
inhibiting the strong activation which is induced by HGF [210]. To test whether and how G2 
affects phosphorylation of METΔ7-8, we treated serum-starved E98 cells with G2, either or not 
followed by HGF, using A549 cells as control. As shown in Figure 5, HGF did not increase 
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overall MET phosphorylation levels, although, interestingly, a slight activation was seen in the 
minority of processed β-fragment of MET. For G2 a similar effect was observed. Consistent 
with high overall MET phosphorylation levels in all samples, neither G2 nor HGF treatment 
resulted in altered levels of P-AKT and P-ERK1/2, both targets of MET. In A549 cells G2 and 
HGF induced MET phosphorylation, which increased levels of P-AKT and P-ERK1/2. Thus, in 
contrast to A549 cells that express METwt, E98 cells are not responsive to antibodies against 
or ligands of MET. However, both E98 and A549 cells responded well to the MET tyrosine 
kinase inhibitor cabozantinib (Figure 5).
Prevalence of METΔ7-8
 Data mining of the COSMIC and TCGA databases did not uncover the intronic de-
letion in gliomas and other tumor types (not shown). Intra-gene deletions spanning multiple 
exons are however in general more difficult to recognize in whole exome sequencing (WES). 
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Figure 5. METΔ7-8 is blocked by TKIs 
but not by inhibiting antibodies. 
E98 and A549 cells were left untreat-
ed or treated with the MET VHH G2, 
cabozantinib (XL; MET/VEGFR2 in-
hibitor), or HGF. Protein lysates were 
analyzed for MET, AKT and ERK1/2 
(p42/44) phosphorylation. GAPDH was 
used as a loading control. Note the 
prominent uncleaved MET protein in 
E98, which is absent in A549 cells. 
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Figure 6. METΔ7-8 is expressed in glial tumors. A) PCR analysis of cell line cDNAs using primers 
located in exon 6 and exon 9. This PCR results in a product of 105 bp for the METΔ7-8, while wtMET gives 
a 345 bp product. B) Immunohistochemical staining for MET of the patients’ tumor from which the E98 
cell line has been generated. C) FISH analysis of the number of MET (red) and chromosome 7 (green) 
copies in the original E98 patient tumor. D) PCR analysis for METΔ7-8 on a random set of glioma biopsies. 
Note that in tumors with METΔ7-8 expression, also wtMET is observed. 
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Furthermore, the coverage of the exact location of the deletion is poor in the mostly used 
WES protocols, and as can be seen in figure 2B, even targeted sequencing reveals the muta-
tion only after detailed bio-informatic analysis. We therefore assume that detection of METΔ7-8 
requires dedicated PCR protocols.
 PCR with deletion-spanning primers revealed the presence of the deletion-specific 
105 bp fragment in E98 cDNA, while a number of other cell lines presented with the wt 345 
bp amplicon only (Figure 6A). Since frozen material from the patient tumor that was used 
to generate E98 is unavailable, we could unfortunately not obtain genomic DNA and cDNA 
of sufficient quality to confirm the presence of the mutation in the originating tumor. We did 
however perform immunohistochemistry on formalin-fixed, paraffin-embedded tumor materi-
al from this patient and observed a highly heterogeneous staining for MET, with only a small 
percentage of strongly positive tumor cells, apparently with intracellular staining (Figure 6B). 
Of note, such immunostainings cannot discriminate between METwt and METΔ7-8. FISH analy-
sis confirmed the presence of the MET amplification in the original tumor (Figure 6C).
Table I. METΔ7-8 expression in glioma, sarcoma and CRPCs 
Tumor type Δ7/8 occurrence
Glioma 6/102 (5.8%)
        O-II 0/3
        A-II 0/7
        OA-II 0/5
        O-III 2/5 (40%)
        A-III 2/16 (12.5%)
        OA-III 0/5
        GBM 2/61 (3.3%)
Sarcoma 0/25
        Ewing tumor 0/5
            Cell line 0/3
        Rhabdo tumor 0/15
            Cell line 0/2
CRPC 0/43
 
 To investigate the prevalence of the METΔ7-8 mutation further, we performed the 
exon 6-9 PCR on cDNA, generated from a series of gliomas (n=102) and a number of other 
tumor types in which MET has been suggested to play an important role (castration resistant 
prostate carcinomas, n=43; Ewing sarcoma, n=21; rhabdomyosarcoma, n=22) [217, 218]. 
METΔ7-8 was found in 6 out of 102 gliomas, both grade III and IV (5.8%; 2 out of 5 anaplastic 
oligodendrogliomas, 2 out of 16 anaplastic astrocytomas and 2 out of 61 glioblastomas), and 
was not detected in the other tumor types tested (Table I). All grade III tumors with METΔ7-8 
were IDH1-R132H mutated. Most tumors that contained the mutation were heterozygous, 
containing also the wild-type transcript (example in Figure 6D).  Further research with higher 
The incidence of METΔ7-8 in different subtypes 
and malignancy grades of diffuse glioma, sarco-
mas and castration resistant prostate carcinomas 
(CRPC). Abbreviations: O-II, oligodendroglioma WHO 
grade II; O-III, oligodendroglioma (WHO grade III); 
A-II, astrocytoma WHO grade II; A-III, anaplastic as-
trocytoma, WHO grade III; GBM, glioblastoma.
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numbers of patients is needed to investigate any correlations between METΔ7-8 and other 
molecular aberrations.
 Sanger sequencing of the smaller PCR products of one patient with glioma con-
firmed the deletion of exons 7 and 8 (not shown). Of note, due to the lack of high quality ge-
nomic DNA from these clinical samples we could not discriminate in these samples whether 
METΔ7-8 resulted from a mutation or from exon skipping or alternative splicing, such as sug-
gested for MET variants lacking exon 10 or 14 [219]. 
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Discussion
 A major problem in glioma treatment is diffuse growth in the neuropil, and it has 
been suggested that the MET oncogene is causally involved in this phenotype in subsets of 
tumors [220]. Several signal transduction pathways that are induced by MET activation are 
shared with other tyrosine kinase receptors and it is increasingly recognized that activation of 
MET bypasses the need for EGFR activation, generating resistance to EGFR-targeted thera-
pies [73]. Also, there is an interesting cross-talk between MET and EGFR: the EGFR variant 
III (EGFRvIII) stimulates expression of both MET and its ligand HGF, possibly contributing 
to oncogenicity of EGFRvIII [220], but this phenomenon is counteracted by EGF mediated 
activation of wild type EGFR in the same complex [196]. 
 We previously reported that MET is crucially implicated in proliferation, survival and 
migration of (EGFR-negative) E98 glioma cells in vitro. To further investigate the involvement 
of MET in the biological behavior of E98 cells we attempted to knock down the protein by 
a lentiviral shRNA approach. Attempts to generate stable MET knock downs using 2 differ-
ent MET shRNAs failed since both shRNA encoding lentiviruses were lethal to E98 cells, in 
contrast to control viruses (data not shown). In agreement with a crucial role of MET for cell 
survival, we showed that treatment with the MET tyrosine kinase inhibitor cabozantinib pro-
longs survival of mice carrying orthotopic E98 xenografts [140]. Based on the observation 
that the pattern of MET phosphorylation in E98 xenografts was remarkably homogeneous 
in the absence of its ligand HGF, we analyzed the MET product in E98 cells in more detail 
and found that the protein is expressed as a truncated product, which lacks effective furin 
cleavage and is predominantly retained intracellular in its active, phosphorylated form. The 
truncation generates a novel IPT domain consisting of a fusion between the carboxyterminus 
of IPT1 and the amino terminus of IPT2. Modeling of the novel fusion IPT domain suggests 
that it adopts a similar structure as the IPT domains in wild type MET, although a small stretch 
of extra amino acid residues is accommodated in a loop, extending towards the Sema do-
main. Since this loop approaches the furin-cleavage site in the Sema domain, it may directly 
impact on furin cleavage. Interestingly, the colorectal adenocarcinoma cell line Lovo lacks 
furin protease and consequently cannot properly process MET [221]. In this cell line, the 
unprocessed preform is still expressed on the cell surface, binds HGF and is capable of 
signaling. Thus, defective processing alone does not explain intracellular retention of METΔ7-8 
and we therefore hypothesize that the novel IPT1-2 fusion domain in METΔ7-8 is involved in 
defective furin cleavage, intracellular retention of the uncleaved perform and auto-activation 
of the uncleaved preform. 
 Recently, effects of various activating mutations in the MET TK domain have been 
analyzed in detail. These mutants are expressed on the cell surface but are subject to in-
creased rates of turnover, resulting in accumulation in early endosomes where they can still 
signal [194]. METΔ7-8 did not accumulate in early endosomes, suggesting that the under-
lying mechanism of intracellular retention is different [222]. Our confocal microscopy and 
biotinylation experiments strongly suggest that only the very small fraction of METΔ7-8 that is 
cleaved reaches the cell membrane, but this fraction is insignificant with respect to the au-
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to-active component in the cytosol.
  From a genetic perspective, the METΔ7-8 mutant resembles the auto-active EGFRvIII 
variant which occurs concomitant with EGFR amplification in 25-64% of all GBMs [223, 224]. 
This variant results from a genetic deletion of exons 2-7 and its activation is also independent 
of the ligands EGF or TNFα. Like the EGFRvIII mutation [215], the METΔ7-8 alteration appears 
to be restricted to only few cancer types, as we detected it in glioma but not in a number of 
other tumor types. The mutation was detected in grade III gliomas of both oligodendroglial 
and astrocytic origin and GBMs. Investigations of METΔ7-8 expression in other tumor types is 
however warranted and is ongoing in our lab.
Another example of a tyrosine kinase receptor which often carries deletions in GBM is PDG-
FRA. Forty percent of the GBMs with amplified PDGFRA contain an in-frame deletion in the 
ectodomain, leading to constitutive activation of the TK domain [225]. Recently also in pe-
diatric high-grade gliomas, ligand-independent and tumorigenic in-frame PDGFRA deletion 
variants have been reported [69, 226]. Data on the subcellular localization of such mutated 
oncoreceptors is frequently lacking, and our data call for in-depth analysis of the cellular 
localization of receptors that are considered targetable. Interestingly, activating mutations in 
the RON tyrosine kinase receptor have been identified which resemble the METΔ7-8 mutation 
in that it also involves the first IPT domain [227]. Of note, these alterations do not lead to a 
loss of expression at the cell surface.
 Importantly we did not detect a METwt transcript in E98 cells, in contrast to the 
clinical gliomas which were analyzed in this study and which all showed abundant wtMET, 
also in METΔ7-8 tumors. We formally cannot exclude that the wild type MET amplicons in our 
PCR derive from ‘contaminating’ non-neoplastic stromal cells in the tumor biopsies that were 
tested. There may however be another explanation for the relatively low levels of METΔ7-8 in 
clinical tumors: in the patient tumor from which the E98 model was generated, a low per-
centage of MET-expressing tumor cells was detected, although it is impossible to determine 
whether these cells carry the METΔ7-8 mutation because the antibodies used do not discrim-
inate between MET and METΔ7-8. It is tempting to speculate that during the generation of the 
E98 model, a small subset of METΔ7-8- tumor cells in the primary tumor experienced a growth 
advantage, ultimately resulting in clonal outgrowth during xenograft formation. This scenario 
fits with the notion that clinical tumors not only show inter- but also intratumoral heterogeneity 
[228], and derived preclinical tumor models may only be representative for the most malig-
nant population of tumor cells.
 Expression of METΔ7-8 may have important consequences for choice of therapy. 
MET is increasingly recognized as an important target in multiple tumor types, including 
glioma, and therapeutic antibodies against HGF or the HGF binding site on MET have been 
developed. Since HGF is not involved in METΔ7-8 activation and METΔ7-8 is retained intracel-
lular, MET-mutated cells will not be responsive to these therapies. Indeed we were able to 
show that E98 cells do not respond to the anti-MET VHH G2. Selection of MET-mutated cells 
in tumors that initially respond to antibody-based MET-directed treatment is expected to 
result in recurrence of treatment-resistant clones. In this respect, it will be important in future 
studies to assess the occurrence of the Δ7-8 mutation in paired samples of primary and re-
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current tumors after MET-antibody-based therapies, but also anti-EGFR therapies since cells 
may use METΔ7-8 to bypass EGFR signaling [208, 229]. With this in mind, the use of specific 
tyrosine kinase inhibitors of MET may have preference over antibody-based therapy for re-
sistant tumors, at least in the ones that are KRAS and RAF wild type, [208, 230-232] since 
METΔ7-8 is sensitive to these inhibitors [140]. Such inhibitors have already shown to improve 
overall survival of patients with non-small cell lung carcinoma with MET amplification and re-
nal papillary carcinoma with MET mutations [233, 234]. A recent clinical study with anti-MET 
antibody MetMab for lung cancer failed to meet the primary end point of prolonged survival 
[235]. A study of MET mutations and intracellular localization patterns in this patient group 
may be highly informative for future therapeutic directions [236]. 
 In conclusion, we describe a highly active, non-ligand dependent mutant of MET in 
6% of gliomas, which is not exposed on the cell surface and is predicted to be non-targeta-
ble with therapeutic antibodies against MET and/or HGF. 
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Abstract
 Gliomas are primary brain tumors for which surgical resection and radiotherapy 
is difficult because of the diffuse infiltrative growth of the tumor into the brain parenchy-
ma. For development of alternative, drug-based, therapies more insight in the molecular 
processes that steer this typical growth and morphodynamic behavior of glioma cells is 
needed. Protein tyrosine phosphatase PTPRZ-B is a transmembrane signaling molecule that 
is found to be strongly up-regulated in glioma specimens. We assessed the contribution of 
PTPRZ-B protein domains to tumor cell growth and migration, via lentiviral knock-down and 
over-expression using clinically relevant glioma xenografts and their derived cell models. 
PTPRZ-B knock-down resulted in reduced migration and proliferation of glioma cells in vitro 
and also inhibited tumor growth in vivo. Interestingly, expression of only the PTPRZ-B extra-
cellular segment was sufficient to rescue the in vitro migratory phenotype that resulted from 
PTPRZ-B knock-down. In contrast, PTPRZ-B knock-down effects on proliferation could be 
reverted only after re-expression of PTPRZ-B variants that contained its C-terminal PDZ bind-
ing domain. Thus, distinct domains of PTPRZ-B are differentially required for migration and 
proliferation of glioma cells, respectively. PTPRZ-B signaling pathways therefore represent 
attractive therapeutic entry points to combat these tumors.
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Introduction
 Diffuse gliomas comprise a heterogeneous group of glial brain tumors that share 
high migratory potential, as evidenced by diffuse infiltration in the surrounding brain paren-
chyma along white matter tracts and blood vessels [2]. This phenotype severely reduces 
efficacy of conventional therapeutic strategies, i.e. surgery and radiotherapy [6]. A hallmark 
of the highly malignant WHO-grade-IV gliomas, with a very dismal prognosis of less than 
15 months [9], is the additional local occurrence of angiogenesis. This angiogenesis has 
been combated using specific inhibitors in phase III trials, but thus far therapeutic survival 
benefit is lacking because the approach leaves the diffuse infiltrative component unaffected 
or even increases diffuse growth [52, 237, 238]. Additional treatment modalities aiming at 
diffuse tumor cells that escape surgery and radio-chemotherapy, hence knowledge about 
the molecular mechanisms that underpin glioma cell migration and proliferation in the brain 
parenchyma, are therefore urgently needed.
 Aberrant phosphotyrosine-based signaling is a hallmark of cancer, and gliomas are 
no exception; tyrosine kinase membrane receptors like EGFR, ERBB2, PDGFRA, MET and 
VEGFR2 have been implicated in glioma growth, angiogenesis and cell motility [66]. A role 
for the counter-acting protein tyrosine phosphatase (PTP) enzyme family [239, 240] is much 
less studied. There is compelling evidence that PTPs influence cell migration [241], espe-
cially during neuronal development [239, 240]. Several PTPs have been linked to carcinoma 
development [78, 242] and their involvement in glioma biology is gradually being uncovered 
[79]. PTEN, for example, is inactivated or absent in one-third of high-grade gliomas, resulting 
in increased PI3K-mediated cell proliferation and survival [66, 243]. For multiple additional 
PTPs the contribution to glioma etiology, especially the diffuse infiltration in the neuropil, re-
quires further study. 
 Within the receptor-type PTP (RPTP) subfamily there is a number of transmembrane 
enzymes that resemble cell adhesion molecules, having extracellular domains that might 
engage in interactions with neighboring cells or extracellular matrix components [239-241]. 
These characteristics make RPTP genes, including PTPRZ1, potentially important regulators 
of cell motility and growth. PTPRZ1 encodes three isoforms (PTPRZ-A, PTPRZ-B and phos-
phacan) that share a carbonic anhydrase-like (CAH) and a fibronectin type III (FNIII) domain 
at the protein’s N-terminus [244]. Furthermore, a spacer with chondroitin sulfate proteogly-
can attachment sites is present in isoforms PTPRZ-A and phosphacan. PTPRZ-B lacks most 
of this spacer, resulting in a smaller extracellular part. PTPRZ-A and PTPRZ-B have identical 
intracellular parts consisting of a catalytically active membrane-proximal and an inactive 
membrane-distal PTP domain. The phosphacan isoform lacks these PTP domains and rep-
resents a secreted protein [244]. Several PTPRZ-interacting proteins have been identified. 
For instance, the extracellular ligand pleotrophin binds to and inactivates PTPRZ, thereby in-
creasing the phosphorylation of intracellular substrates β-catenin [245], Fyn [246], β-adducin 
[247] and Alk [248]. Additional interaction partners include contactin-1, which binds to the 
CAH domain [249], and tenascin-C and -R that bind to the FNIII domain [250]. It is thought 
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that these proteins form complexes with the extracellular matrix [251] to induce and facilitate 
migration.
 PTPRZ expression, in particular PTPRZ-B [252], is up-regulated in glioma tumor 
specimens [253-255]. PTPRZ1 knock-down in glioblastoma cell lines reduced cell migration 
[254] and tumor growth [256], and PTPRZ overexpression enhanced cell migration [253]. 
However, these cell models produce circumscribed tumors that lack the highly invasive 
phenotype when grown orthotopically [92]. Furthermore, PTPRZ protein domains that steer 
glioma cell behavior still need to be uncovered. Here we investigated the role of PTPRZ and 
its protein domains, exploiting glioma models that faithfully recapitulate diffuse infiltrative 
growth in vivo [92, 127, 176]. Lentivirus-mediated knock-down and subsequent rescue ex-
periments revealed that PTPRZ-mediated effects on migration rely exclusively on its extracel-
lular domain, whereas impact on proliferation depends on the intracellular carboxyl-terminal 
PDZ domain binding site. These findings identify PTPRZ as a dual entry point for glioma 
therapy development.
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Materials and methods
 Experimental details on cell lines and antibodies used, plasmid construction, len-
tiviral transduction, immuno-blotting, -precipitation and -histochemical procedures, peptide 
microarray analysis, and statistical analyses are provided as supplementary material.
Cell proliferation and viability assays
 E98 cells were grown on collagen I-coated (10 µg/cm2; Invitrogen) coverslips to 
60-80% confluency, and incubated for 1hr with culture medium containing BrdU (50 μM; Life 
Technologies, #B23151). Cells were then washed three times with PBS and fixated in 2% 
paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB: 46 mM NaH2 PO4; 354 mM Na2H-
PO4, pH 7.4). Subsequently, coverslips were washed with PBS and quenched with 50 mM 
NH4Cl in PBS. Cells were blocked and permeabilized for 1hr in blocking buffer (5% Normal 
Goat Serum and 0.1% Triton X-100 in PBS) and then incubated for 2.5hrs with anti-BrdU, 
anti-Ki67 or anti-cleaved Caspase 3 antibodies in blocking buffer with added DNAseI (100 
ng/mL; Roche) and MgCl2 (2.5 mM) at 37 °C. Bound antibodies were detected with goat-anti-
mouse Alexa 488 and goat-anti-rabbit Alexa 647 secondary antibodies in PBS. Coverslips 
were mounted on microscope slides in DAPI-containing Mowiol (Sigma-Aldrich) and images 
were collected on a Leica DMRA Fluorescence microscope, equipped with a DFC340 FX 
CCD camera, using 40x and 63x objectives. DAPI- and BrdU-positive nuclei and cleaved 
Caspase 3-positive cells were counted using FIJI software [257].
 For proliferation assays, stably transduced E98 cells were seeded in triplicate in a 
96-well microtiter plate (10,000 cells/well), and cultured in 10% FCS-containing DMEM. At 
various time points, cells were washed with PBS and fixed using 10% trichloroacetic acid 
for 1hr at 4 °C, washed with water and afterwards frozen until all time points were collected. 
Cells were then stained with 1% Sulforhodamine B (SRB; Sigma-Aldrich) in 1% acetic acid 
for 20 minutes. Plates were subsequently washed with 1% acetic acid and dried at 60 °C for 
3 hrs. Protein-bound SRB was then dissolved in 10 mM Tris (pH 10.5) and absorption was 
measured at 510 nm using a micro-plate reader (Bio-Rad). 
Lentivirally transduced E434 spheroids were seeded in a 96-well imaging plate (BD Biosci-
ences, #353219) and allowed to settle overnight. The next day, images were taken using a 
BD Pathway 855 high-content bio-imager (BD Biosciences). Fluorescent images (TagRFP 
or EGFP-based) were taken longitudinally at days 4, 6 and 8 and the average increase in 
spheroid area was calculated automatically using FIJI software. After images had been taken 
on the fourth day, half of the medium was replenished and spheroid growth was continued.
2D and 3D migration assays
 E98 spheroids were generated by the hanging-drop method. In brief, 0.7 mL meth-
ylcellulose (12 mg/mL; Sigma, M6385) was added to 4.3 mL E98 cell suspension in DMEM 
supplemented with 10% FCS (500,000 cells total) and 25 µL drops were seeded in a dry 
culture dish. The dish was then inverted and incubated overnight at 37 °C in the presence of 
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5% CO2. The next day, individual spheroids were seeded in a 96-well imaging culture dish 
(BD Falcon, #353219) coated with Matrigel (30 μg/mL PBS; BD Biosciences, #356237) and 
further incubated in DMEM with 10% FCS, at 37 °C and 5% CO2. For E434, cultured spher-
oids were directly plated onto Matrigel-coated wells containing B27-supplemented neuro-
basal medium. After 24 hrs, wells were washed with PBS and cells were fixed with 2% PFA 
in 0.1 M PB, followed by DAPI staining. Fluorescent images were collected on a high-content 
microscope (Leica DMI6000B) extended with a motorized x-y scanning stage (Leica EL6000 
illumination source), and FIJI software [257] was used to automatically quantify spheroid out-
growth. Briefly, cells which migrated from the spheroids were selected, coordinates of each 
individual cell were determined, and distance from the spheroid border was calculated using 
the coordinates and radius of the spheroid. For each experiment the average cell migration 
distance across all spheroids (n>31) was calculated.
 Cell cultures in solidified Matrigel/Agarose matrices were prepared as follows. 10 
μL Matrigel and 5 μL 2% agarose (Seaplaque Agarose; Lonza #50101 in PBS) were mixed 
with 35 μL 10% FCS-containing DMEM and 50 µL of Matrigel/agarose mix was added to 
the wells of a 96-well microtiter plate which was placed on ice. One minute later, 50 µL cell 
suspension (50,000 cells) was mixed resulting in a 3D environment containing cells. Cells 
were imaged overnight with 10-min intervals on a time lapse system (Nikon Diaphot 300 with 
Hamamatsu C8484-05G CCD Camera, Okolab 4 well CO2 stage incubator and Okolab 2D 
time lapse software) at 37 °C and 5% CO2 with a 10x objective. Cells were manually tracked 
for at least 2 hrs using the FIJI plug-in [257].
Intracerebral injection of spheroid-derived cells
 All animal experiments were approved by the local Animal Experimental Committee 
of the Radboud University Medical Center. Athymic female BALB/c nu/nu mice (18–25 gram, 
age 6–8 weeks) were kept under specified pathogen-free conditions and received food and 
water ad libitum. E98 and E434 cells were grown as spheroids in supplemented neurobasal 
medium for at least two weeks prior to orthotopic injection [127]. A 20 μL cell suspension (107 
cells/mL in PBS) containing a mixture of shSCR/GFP and shPTPRZ1/TagRFP labeled cells 
was injected per animal (n=5 and 4 for E98 and E434 cells, respectively). Prior to injection, 
the ratio of GFP- and TagRFP-positive cells was determined using an EVOS fluorescence im-
aging system (AMG) and FIJI Software. Animals were closely monitored and sacrificed when 
signs of tumor burden (especially weight loss and neurological dysfunction) were observed. 
Brains were harvested, and parts were either formalin-fixed and paraffin-embedded (FFPE) 
or snap-frozen in liquid nitrogen, and stored for (immuno)histochemical analysis.
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Results
Modulation of PTPRZ-B expression levels in glioblastoma cells
 In line with previous reports [253-255], high PTPRZ1 expression levels are detect-
able in glioma tumors (data not shown) and in human xenograft-derived cells in culture (Fig-
ure 1). The two well-characterized glioma xenograft lines E98 and E434 [92] differ in their 
in vitro culture regimen; anaplastic oligodendroglioma-derived E434 cells only propagate 
under neurosphere growth conditions, using serum-free neurobasal medium [98], whereas 
glioblastoma-derived E98 cells additionally grow in standard DMEM/10%FCS as an adherent 
monolayer (Figure 1A). To assess PTPRZ influence on glioma growth and migration, lentiviral 
vectors for PTPRZ-B expression and PTPRZ1 shRNA-mediated knock-down (targeting all 
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Figure 1. PTPRZ1 expression or knock-down in E98 and E434 cells. A) Fluorescent images of glio-
ma cells containing shSCR or shPTPRZ1 knock-down constructs carrying GFP or TagRFP fluorescent 
reporters, respectively. E98 cells were DAPI counterstained. B) PTPRZ1 mRNA levels in lentivirally trans-
duced E98 cells were determined by qRT-PCR. Expression, normalized to β-actin, is given as percent-
age of that in control shRNA-expressing (shSCR) cells. EV; empty vector control. C) Normalized PTPRZ1 
mRNA levels in lentivirally transduced E434 spheroids, determined by qRT-PCR. D) E98 cells were lenti-
virally transduced with expression constructs for PTPRZ-B protein or EV and/or PTPRZ1 or control (SCR) 
shRNAs. After three days, lysates were analyzed on immunoblots using PTPRZ-B (upper) and GAPDH 
(lower) antibodies. Normalized PTPRZ-B levels, relative to that in shSCR control lysates, are depicted 
in between the blot images. Size indications (in kDa) are on the left. E) Immunoblot analysis (as in D) of 
E434 lysates 72 hrs after lentiviral transduction with the indicated constructs.
108
6
three isoforms) were generated (Supplementary Figure S1). We introduced a silent muta-
tion in the PTPRZ-B open reading frame to create an shRNA-insensitive lentiviral PTPRZ-B 
expression construct and used this throughout for validation and rescue purposes. Follow-
ing lentiviral transduction of E98 and E434 cells with PTPRZ1 shRNA, a five- to twenty-fold 
reduction of PTPRZ1 transcript levels (Figure 1B,C) and a five- to ten-fold drop in PTPRZ-B 
protein content (Figure 1D,E) was obtained. As for C6 glioma cells [252], it is the short trans-
membrane variant PTPRZ-B that was detected in E98 and E434 lysates (Figure 1D,E). Use of 
the lentiviral PTPRZ-B expression vector resulted in PTPRZ-B protein levels that were one to 
three times that of the endogenous protein, also in presence of PTPRZ1 shRNA (Figure 1D). 
PTPRZ-B stimulates glioma cell growth in vitro
 PTPRZ-B over-expression and knock-down effects on E98 and E434 cell prolifera-
tion was assessed via direct measurement of cell content and via BrdU incorporation. Sul-
forhodamine B (SRB) proliferation assays revealed that PTPRZ1 knock-down significantly 
inhibited growth of adherent E98 cells, as illustrated by an increased cell doubling time (Fig-
ure 2A). Accordingly, BrdU pulse-labeling showed a significant reduction of the percentage 
of S-phase cells in shPTPRZ1-transduced samples (p<0.05). PTPRZ-B over-expression did 
not significantly affect E98 proliferation, in agreement with the modest increase in PTPRZ-B 
levels on immunoblot. Nevertheless, PTPRZ1 knock-down effects were fully rescued by PT-
PRZ-B re-expression (Figure 2B). 
 To investigate whether observed PTPRZ1 knock-down effects are on the level of cell 
viability, apoptosis or cell cycle progression, BrdU pulse-labeled cells were immunostained 
for BrdU, for the G1-S-G2-M marker Ki-67 and for cleaved Caspase-3. The percentage of 
apoptotic cells was less than 1% for all conditions (data not shown) and, with the exception of 
PTPRZ1 knock-down cells, approximately 20% of cells ended up BrdU-positive. Intriguingly, 
always half of the cells stained positive for Ki-67, even among shPTPRZ1-tranduced cells 
of which 10% is in S-phase (Figure 2B-C). This suggests that the growth impairment upon 
PTPRZ1 knock-down reflects increased duration of cell cycle time. 
 Knock-down of PTPRZ1 also resulted in significantly delayed growth in E434 cells. 
Since these cells can only be propagated as spheroids, we measured proliferation capacity 
by means of the spheroid diameter (Figure 2D-E). Fluorescent protein signals in the lentivi-
rally transduced cells were used to image spheroid size over time. Whereas shSCR-trans-
duced E434 spheroids showed clear signs of growth, shPTPRZ1-transduced spheroids only 
increased a little in size.
PTPRZ-B facilitates migration of E98 and E434 glioma cells 
 We next investigated whether PTPRZ1 influence on cell migration [253, 254] is 
represented in our glioma models. Following PTPRZ1 knock-down, migration of individual 
E98 cells in a 3D Matrigel/agarose environment was significantly reduced (p<0.001), an 
effect that was rescued by expression of the shRNA-insensitive PTPRZ-B transcript in knock-
down cells (Figure 3A-B). To confirm this in a different setting, we generated transduced E98 
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spheroids using the hanging-drop method. Resulting homogeneously sized E98 spheroids 
were subsequently placed on a thin Matrigel layer for 24 hours and migratory performance of 
outgrowing cells, expressed as distance travelled from the edge of the spheroid [140], was 
calculated semi-automatically. Again, PTPRZ1 knock-down cells migrated significantly less 
(p<0.05) than scrambled controls, and restoration of PTPRZ-B levels rescued this phenotype 
(Figure 3C-D). Of note, PTPRZ-B over-expression by itself did not alter E98 motility. In a 
similar fashion, outgrowth of lentivirally transduced E434 spheroids was inhibited by PTPRZ 
knock-down (p<0.05; Figure 3E-F). Interestingly, whereas outgrowing E98 cells presented 
as scattered, amoeboid-like migrating cells, the migrating E434 cells largely remained inter-
connected, suggestive of collective migration [258]. Taken together, the reduced migration 
in vitro due to PTPRZ1 knock-down, which was rescued following PTPRZ-B re-expression, 
corroborates a facilitating role for PTPRZ-B in cell motility.
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Figure 2. PTPRZ1 knock-down impairs glioma cell growth. A) E98 cells expressing shSCR or shPT-
PRZ1 knock-down constructs and non-transduced (E98nt) controls were cultured in microtiter plates, 
total cell mass was determined at various time points, and population doubling times were calculated 
from resulting curves. Error bars indicate SD, asterisk indicates p<0.05 (Student t-test, n=3). B) Trans-
duced E98 cells were grown on coverslips and labeled with BrdU for 1 hr. Percentage of BrdU-positive 
nuclei among DAPI-stained cells was determined (n>3). Error bars indicate SD. Asterisks reflect con-
fidence levels (ANOVA; * p<0.05; ** p<0.01; n.s., not significant). C) Representative images from (B), 
showing DAPI and BrdU (arrowheads) positivity. D) Transduced E434 cells were seeded into a 96-well 
plate and images were collected at indicated time points. Increase in spheroid size relative to day 1 
is depicted. Error bars indicate SEM and asterisks indicate significance levels (* p<0.05; ** p<0.01). 
Repeated measure ANOVA: p<0.0014. E) Representative images from (C), exploiting TagRFP and GFP 
autofluorescence in shRNA vectors.
110
6
A B
PTPRZ-B shPTPRZ1
PTPRZ-B shPTPRZ1
C D
E F
shSCR shPTPRZ1
shS
CR
shP
TP
RZ
1
shP
TP
RZ
1+
PT
PR
Z-B
EV
PT
PR
Z-B
0
25
50
75
100
125
150
M
ig
ra
tio
n 
(A
.U
)
shS
CR
shP
TP
RZ
1
shP
TP
RZ
1+
PT
PR
Z-B
EV
PT
PR
Z-B
shS
CR
shP
TP
RZ
1
***
***
Kruskal-Wallis p<0.0001
0
50
100
150
200
250
Mi
gr
ati
on
 (A
.U
)
Mi
gr
ati
on
 (A
.U
)

..sn
80
60
40
20
  0
Kruskal-Wallis p<0.0001
***
*** *** .s.
n.s.
Figure 3. PTPRZ1 knock-down reduces glioma cell migration. A-B) E98 cells were lentivirally trans-
duced with indicated protein (PTPRZ-B), EV control or shRNA (shPTPRZ1 or shSCR control) expression 
vectors, and seeded in an agarose/Matrigel 3D matrix. A) Migration paths were recorded overnight and 
analyzed by single-cell tracking. B) Averaged migration speeds (arbitrary units, AU) of individual cells, 
normalized to shSCR (n>30), are shown (gray points). Box-plot whiskers represent minimum and maxi-
mum. Asterisks indicate significance (*** p<0.001; n.s., not significant; Kruskal-Wallis p<0.0001). C) E98 
spheroids were seeded on a Matrigel layer and fixed and DAPI-stained 24hrs later. Two representative 
images are shown. D) Pixel distance from the spheroid border was calculate for individual cells and per 
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PTPRZ1 knock-down impairs glioma cell growth in mouse brain 
 To investigate how these PTPRZ-B knock-down effects translate to in vivo tumor be-
havior, we co-injected intracerebrally shPTPRZ1- and shSCR-expressing E98 cells that were 
tagged with TagRFP and EGFP fluorescent marker proteins, respectively. When cultured 
under serum conditions, E98 cells grow to compact non-diffuse tumors upon orthotopic in-
jection, but when cultured as spheroids they display diffuse infiltrative properties (our unpub-
lished results). Stably transduced E98 cells were therefore grown as spheroids in serum-free 
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Figure 4. PTPRZ1 knock-down impairs glioma growth in vivo. Suspensions of E98 or E434 cells 
expressing PTPRZ1 shRNA and TagRFP (shPTPRZ1/TagRFP+) or control shRNA and EGFP (shSCR/
EGFP+) were mixed and injected intracerebrally in immunodeficient mice. TagRFP+/EGFP+ ratios were 
calculated using fluorescent images. A) For E98 this resulted 3-4 weeks later in compact (top pan-
el) and diffuse infiltrative (bottom panel) tumor areas. Representative areas, immunohistochemically 
stained for TagRFP or EGFP and haematoxylin-counterstained, of one out of three animals are shown. 
B) E434 glioma tumor-bearing mice were processed 9 weeks post-injection. Representative pictures of 
one out of two animals are shown. For E434 a 50% transduction efficiency after two consecutive trans-
duction rounds was achieved resulting in also non-transduced cells being injected. C) Quantification 
of TagRFP+/EGFP+ ratios in E98 xenografts, as determined for five different tumor areas per animal, 
averaged and compared to the ratio pre-injection. Error bar represents SD. One-sample Student’s t-test 
yielded p<0.01 (**). D) Quantification of TagRFP+/EGFP+ ratios in E434 xenografts and pre-injection 
mixture. Error bar indicates SD.
spheroid (n>32) average outgrowth was plotted (grey data points). Box-plot whiskers represent mini-
mum and maximum. Asterisks indicate significance (*** p<0.001; n.s., not significant; non-parametric 
ANOVA: Kruskal-Wallis p<0.0001). E) Representative pictures of transduced E434 spheroids, fixed and 
DAPI-stained, after 24hrs on Matrigel. F) Mean pixel distance that cells traveled from the spheroid bor-
der was calculated, and averages per spheroid (n>53) are plotted (grey data points). Box-plot whiskers 
represent minimum and maximum, and asterisks indicate significance (***p<0.001).
 
Figure 6 continued:
112
6
neurobasal medium for at least two weeks prior to injection. E434 cells exclusively grow as 
spheroids in neurobasal medium and were directly injected after dissociation. ShPTPRZ1/
TagRFP and shSCR/EGFP spheroids were processed to single cell suspensions and a 1:1 
mixture of both cell types was injected intracerebrally in immunodeficient mice. Animals were 
sacrificed when symptoms of tumor burden appeared, and brains were examined for the dis-
tribution of EGFP- and TagRFP-containing cells (Figure 4). EGFP-positive control cells great-
ly outnumbered the TagRFP-expressing PTPRZ1 knock-down cells in the tumors (p<0.01), 
in accordance with the low in vitro proliferation rate of the PTPRZ1 knock-down. This in vivo 
proliferation impairment due to PTPRZ1 knock-down likely obscured migratory effects; the 
amount of TagRFP-positive (knock-down) cells relative to haematoxilin-stained nuclei in E98 
tumors was similar in compact and diffuse infiltrative areas (0.11 ± 0.03 SEM versus 0.09 ± 
0.01 SEM, respectively; p<0.61). Also for EGFP-positive (control) cells the relative contribu-
tion to compact and diffuse infiltrative tumor areas was comparable (0.38 ± 0.04 SEM versus 
0.39 ± 0.08 SEM, respectively; p<0.93). Collectively, in vitro and in vivo data demonstrate a 
significant reduction of tumor growth upon PTPRZ1 knock-down, prompting us to address 
the molecular mechanisms by which PTPRZ-B impacts on glioma cell behavior.
The PTPRZ-B PDZ binding domain mediates growth stimulatory signals
 PTPRZ-B may exert its stimulatory effect on E98 glioma proliferation in multiple 
ways, potentially involving extracellular CAH, FNIII and chondroitin sulfate-containing do-
mains or intracellularly the two PTP domains and the C-terminal PDZ domain target site 
(Figure 5A). Only the first, membrane-proximal PTP domain in PTPRZ-B is enzymatically 
active [259]. Because the PTPRZ-B knock-down phenotype in E98-shPTPRZ1 cells could be 
rescued with an shRNA-insensitive full-length expression construct (Figures. 2-3), we tested 
the contribution of the individual PTPRZ-B protein domains using this assay. Three different 
shRNA-resistant PTPRZ-B cDNA versions were generated (Figure 5A). In PTPRZ-B ecto-VSV 
the transmembrane and intracellular PTPRZ-B segments were replaced by a VSV-G epitope 
tag, effectively leading to the secretion of a C-terminally tagged PTPRZ-B extracellular do-
main (Figure 5B). PTPRZ-B C/S represents a cysteine-to-serine catalytically inactive mutant, 
and in PTPRZ-B-VSV the ‘SLVCOOH’ PDZ domain target site is blocked by a C-terminal VSV-G 
tag. Expression of all constructs was readily detected in E98-shPTPRZ1 cells (Figure 5B-C).
 BrdU pulse-labeling experiments revealed that reduction in percentage of cells in 
S-phase, due to knock-down of endogenous PTPRZ, was fully rescued by full-length PT-
PRZ-B and the inactive PTPRZ-B C/S mutant. Expression of PTPRZ-B ecto-VSV or PTPRZ-
B-VSV did not rescue the knock-down phenotype (Figure 5D-E). Thus, PTPRZ-B impacts on 
cell cycle progression through mechanisms that are independent of PTPRZ-B phosphatase 
activity and require interactions with the PTPRZ PDZ domain target site.
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Figure 5. The PTPRZ-B C-terminus is required to rescue the proliferation phenotype in E98 PT-
PRZ1 knock-down cells. A) Schematic representation of PTPRZ-B variants used in the study. CAH, 
carbonic anhydrase-like; FNIII, fibronectin type-III; CS, chondroitin sulfate chain; TM, transmembrane 
region; PD1, phosphatase domain 1; PD2, inactive phosphatase domain 2; VSV, C-terminal VSV-G epi-
tope tag. C/S indicates the mutation of the catalytic site cysteine to serine that renders PD1 inactive. B) 
Conditioned medium from E98 cells expressing PTPRZ-B ecto-VSV or from empty vector (EV) control 
cells was subjected to immunoprecipitation using anti-VSV monoclonal antibody and subsequent im-
munoblot analysis using rabbit antiserum against VSV. Size markers (in kDa) are indicated on the left. 
Arrowhead on the right indicates the chondroitin sulfated PTPRZ-B extracellular part. C) E98 shPTPRZ1 
cells were transduced with the indicated expression constructs and 72 hrs later lysates were prepared 
and analyzed on western blots using PTPRZ-B antiserum. GAPDH staining served as loading control 
and E98 shSCR lysate was included for comparison. Normalized PTPRZ-B levels, relative to that in 
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Extracellular PTPRZ-B interactions impact on glioma cell migration
 Rescuing abilities of PTPRZ-B variants were also assessed in the spheroid migra-
tion assay. Migratory impairment due to PTPRZ1 knock-down in E98-shPTPRZ1 cells was 
effectively rescued upon re-expression of full-length PTPRZ-B, PTPRZ-B C/S and, important-
ly, also by PTPRZ-B ecto-VSV (Figure 6A-B). Moreover, purified VSV-tagged PTPRZ-B ect-
odomains, isolated from conditioned medium of transfected HEK-293FT cells, also rescued 
the PTPRZ knock-down effect on E98 cell migration (Figure 6C). Contactin-1 has been put 
forward as a membrane-anchored PTPRZ ligand, binding to the CAH domain and impact-
ing on cell migration [251]. In line with this, endogenous contactin-1 from E98 cells indeed 
bound to PTPRZ-B ecto-VSV that was preloaded onto anti-VSV antibody-coupled beads (Fig-
ure 6D), underscoring PTPRZ-B – contactin-1 interplay in E98 glioma cells.
Our results did not disclose PTPRZ phosphatase activity as a regulator of glioma cell migra-
tion and proliferation. It is reasonable to assume, however, that the phosphotyrosine-con-
trolled activity of cellular kinases is affected following PTPRZ1 knockdown in E98 cells. A 
comparison of E98-SCR and E98-shPTPRZ1 cell extracts in a tyrosine kinase microarray 
activity assay [260] revealed that PTPRZ1 knock-down cells displayed reduced activity, most 
notably towards PDGFRB- and MET-derived peptides (Supplementary Figure S2). We previ-
ously reported on the importance of MET for E98 cell migration [140]. Immunoblot analyses 
confirmed that in shPTPRZ1-expressing E98 cell lysates MET tyrosine phosphorylation was 
reduced four-fold (Figure 6E). Additionally, PTPRZ1 knock-down also resulted in lower MET 
protein levels, suggesting that PTPRZ-B regulates MET transcription, synthesis or degra-
dation. Interestingly, PTPRZ1 knock-down effects on MET are partly alleviated by PTPRZ-B 
ecto-VSV expression (Figure 6F). Taken together, results demonstrate a dual oncogenic role 
for PTPRZ1 in glioma cells. The PTPRZ-B intracellular PDZ domain binding site is required to 
orchestrate a submembranous complex that boosts cell proliferation, while the extracellular 
portion binds receptors and adhesion molecules on nearby cells and stimulates migration.
shSCR control lysates, are depicted in between the blot images. D) E98 shPTPRZ1 cells were seeded on 
collagen-coated glass coverslips and hours later, transduced with the indicated expression constructs. 
Three days after transduction cells were labeled with BrdU, fixed and stained. Fluorescent images were 
taken and the percentage of BrdU-positive nuclei among DAPI-stained cells was determined (n>3). Error 
bars indicate SD. Confidence levels, as determined by ANOVA, are represented by asterisks (* p<0.05; 
n.s., not significant). The dashed line indicates the percentage in E98 shSCR cells as obtained in com-
parable experiments. E) Percentage of BrdU-positive nuclei in DAPI-stained E98 or E98 shPTPRZ1 cells 
following transduction with the indicated constructs (n=3). Error bars indicate SD. Confidence levels, as 
determined by ANOVA, are represented by an asterisk (* p<0.05; n.s., not significant).
Figure 5 continued:
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Figure 6. The PTPRZ-B ectodomain stimulates glioma migration. A) E98 or E98 shPTPRZ1 cells 
were lentivirally transduced with indicated constructs. Three days later spheroids were generated and 
the next day seeded on a thin Matrigel layer. After being cultured for another 24 hrs cells were fixed and 
stained with DAPI. Pictures were collected and two representative images are shown. B) Using these im-
ages the migration, in arbitrary units, was calculated per spheroid (light grey data points) as the average 
distance cells traveled from the spheroid border using FIJI-based software. Box-plot whiskers represent 
minimum and maximum values. Significance levels are indicated by asterisks (* p<0.05; ** p<0.01; *** 
p<0.001; Kruskal-Wallis p<0.0001). C) Using the above set-up, spheroid migration was also determined 
following addition of immunopurified PTPRZ-B ecto-VSV to E98 shPTPRZ1 cells (shPTPRZ1 +PTPRZ-B 
ecto-VSV protein) during the 24 hrs of culturing on Matrigel. Kruskal-Wallis p<0.003. D) PTPRZ-B ec-
to-VSV was immunopurified, using mouse anti-VSV monoclonal antibody-coupled beads, from condi-
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tioned medium (CM) of HEK-293FT cells transfected with PTPRZ-B ecto-VSV (ecto-VSV) or empty vector 
(EV) expression plasmids (left panel). Subsequently, beads were incubated with E98 whole cell lysates 
and co-purifying proteins were analyzed on western blots using Contactin-1 antiserum (right panel). E) 
Lysates of E98 cells, that were transduced with indicated shRNA constructs and blasticidin-selected, 
were prepared and analyzed on immunoblots. Size markers (kDa) are indicated on the left. Upper pan-
els: PTPRZ-B immunostaining, using GAPDH as loading control. Middle and lower panels: blots were 
probed with antisera against MET (middle) and Y1234-1235-phosphorylated MET (lower) while tubulin 
staining served as control. Representative images are shown. On the right, the quantification (n>3) of 
normalized signal intensities (arbitrary units) is given. Error bars indicate SD and asterisks reflect signif-
icance based on one-sample Student t-test (** p<0.01). F) E98 shPTPRZ1 cells were transduced with 
indicated constructs and 72 hrs later whole cell lysates were prepared and analyzed as described under 
(E). E98 shSCR cell lysate was included for comparison. Representative images are shown on the left 
and quantification (n>3) of normalized signal intensities (arbitrary units) is given on the right. Dashed 
lines indicate removal of in-between lanes from the depicted blots. Error bars indicate SD and asterisks 
reflect significance (* p<0.05, Student t-test). 
Figure 6 continued.
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Discussion
 Effective treatment of glioma patients requires that also tumor cells that diffusely 
spread out into the brain parenchyma are therapeutically addressed. In the current study we 
assessed the contributions of different PTPRZ-B domains to glioma cell migration and pro-
liferation using models that faithfully recapitulate infiltrative tumor growth. We show that PT-
PRZ1 knock-down in E98 glioblastoma and E434 oligodendroglioma cells results in impaired 
growth and motility in vitro and reduced tumor growth in vivo, also in diffuse infiltrative tumor 
areas. Furthermore, our rescue experiments disclose a dyad functionality for this RPTP. The 
intracellular PTPRZ-B C-terminal PDZ domain binding site, and not its enzymatic PTP activity, 
turned out essential for effects on cell proliferation. Conversely, the PTPRZ-B extracellular 
moiety, which in part resembles the naturally occurring phosphacan isoform, impacted on 
cell migration. 
 PTPRZ1 is upregulated in gliomas, which likely contributes to enhanced tumor cell 
migration [253-255]. A role for PTPRZ in proliferation was less clear. Reduction of tumor 
growth as well as absence of growth effects have been reported for PTPRZ1 knock-down 
experiments [254, 256]. Administration of soluble PTPRZ ectodomain is known to inhibit pro-
liferation of oligodendroglial precursor cells [261]. In our study, the PTPRZ-B ectodomain 
did not affect the reduction of E98 cells in S-phase that resulted from PTPRZ1 knock-down. 
Addition of wild-type or enzymatically inactive PTPRZ-B did suffice to rescue proliferation 
impairment, but a C-terminally tagged version did not. If PTPRZ phosphatase activity would 
have been crucial for glioma cell proliferation, expression of an inactive ‘substrate protection’ 
mutant in PTPRZ1 knock-down cells might act dominant-negative and worsen the effect. On 
the contrary, proliferation rescue by the catalytically dead PTPRZ-B mutant and not by the 
C-terminally tagged version rather implicates PTPRZ-B’s C-terminal protein interaction po-
tential as important for signaling complexes that steer glioma proliferation. As yet we cannot 
rule out that also protein interactions mediated by PTPRZ-B domains other than its C-terminal 
PDZ domain binding motif contribute to its proliferation signaling mode.
 Multiple PDZ-containing proteins have been reported to bind to the PTPRZ C-ter-
minus; PSD95 [262], MAGI-3 [263], MAGI-1, GOPC, Mupp1, Synj2bp, Snta1, Sntb1 and 
Veli-3 [264]. This opens up several mechanisms by which PTPRZ may influence proliferation. 
For instance, tyrosine kinase ErbB4 auto-activation is suppressed by PSD95 through PDZ 
domain-mediated interactions with both the enzyme PTPRZ and the substrate ErbB4 [265]. 
Likewise, PTPRZ and its substrate β-catenin form a complex through MAGI-1 [264, 266]. 
However, current findings argue against an enzymatic role for PTPRZ in such PDZ-based 
complexes and rather point to a scaffolding role. By clustering proteins submembranously 
in glioma cells, PTPRZ might contribute to efficient funneling of growth stimulatory signals 
towards the cell’s interior. 
 In both our glioblastoma and anaplastic oligodendroglioma model, the PTPRZ ect-
odomain did not impinge on proliferation but rather was instrumental for migration. Also in 
U87-MG glioblastoma cells, PTPRZ positively influenced adherence and migration [253] and 
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an antibody targeting the PTPRZ extracellular region delayed U87-MG compact tumor for-
mation in vivo [267]. PTPRZ ectodomain binding partners include extracellular matrix com-
ponents like pleiotropin, tenascin-C and tenascin-R, and cell surface molecules [261] like 
contactin-1 [249, 250]. Extracellular binding of PTPRZ and contactin-1 is hypothesized to 
recruit additional proteins, such as tenascins, to the complex [251]. In oligodendroglial pre-
cursors this inhibits proliferation and triggers differentiation towards myelinating cells. In our 
glioma models, PTPRZ-contactin-1 interactions apparently lead to migratory responses. This 
difference may result from separate PTPRZ-mediated interactions in either system or, alter-
natively, by absence or presence of facilitator proteins involved. Contactin-1, tenascin-C and 
tenascin-R have adhesion and migration effects in glioma cells [250, 253, 254, 267, 268]. 
 Recently we showed that MET inhibition by cabozantinib effectively stops E98 cell 
migration [140]. Here, migration impairment in E98-shPTPRZ1 cells co-incided with reduced 
MET activity. For a candidate substrate, rather increased phosphorylation levels are expect-
ed upon knock-down of PTPRZ, and thus far MET does not meet PTPRZ substrate criteria 
[269]. Together with ErbB and PDGFR family members, MET represents one of the oncogen-
ic drivers in glioma tumor biology [66]. Whereas E98 cells displayed a scattered, single-cell 
migration pattern in spheroid outgrowth experiments, E434 cells showed a more collective 
migratory behavior. This may reflect MET signaling differences in the two models, bearing in 
mind ‘scatter factor receptor’ as alternative name for MET. In our in vivo experiments we were 
unable to assess PTPRZ-B’s migratory role on tumor formation because this was blurred by 
effects on cell proliferation. Current findings now provide a basis to experimentally separate 
both type of effects through independent targeting of PTPRZ-B intracellular and extracellular 
binding potential. Further knowledge on PTPRZ intracellular and extracellular signaling in-
volvement will strengthen its candidacy as a therapeutic target in gliomas.
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Supplementary Figure S1. Plasmid maps of constructs used to create lentiviral vectors for glioma 
cell transduction. A) Schematic overview of the expression construct that is generated in an LR Gate-
way cloning reaction, using pLenti6/PGK-DEST-tagRFP and the appropriate cDNA-containing pENTR 
plasmid (in this case full-length PTPRZ-B). B) Schematic overview of the scrambled control knock-down 
construct that resulted from an LR Gateway reaction involving the pLenti6/Blocki-iT-DEST variant (with 
added fluorescent protein expression cassette) and the pENTR/U6 plasmid with inserted oligonucle-
otide heteroduplex for shSCR production. Long terminal repeat (LTR) regions, attR1 and attR2 Gateway 
recombination sites, and the CMV promoter-driven TagRFP and EGFP expression cassettes as well as 
the SV40 early promoter-driven Blasticidin selection cassette are indicated.
A B
4.0.0
12.0
2
lo
g 
sig
na
l in
te
ns
ity
shSCR shPTPRZ1
50% signal decrease 
vs. control
25% signal decrease 
vs. control
Mean LFC
shPTPRZ1/shSCR
Supplementary Figure S2. Kinase activity profiling of E98 cells stably expressing shSCR/GFP and 
shPTPRZ1/TagRFP constructs. A) Heatmap representation of the mean signals (n=4) for 144 different 
peptides on the Tyrosine Kinase PamChip® Array upon incubation with lysates from shSCR or shPT-
PRZ1-expressing E98 cells. The order of peptide signal depiction (top, highest signal in red; bottom, 
lowest signal in blue) was determined by that in the shSCR sample. B) List of 37 peptides that were 
significantly differentially phosphorylated by shSCR- and shPTPRZ1-expressing E98 lysates. The ID 
column contains the protein name and first and last amino acid position of the peptide. Corresponding 
UniProt accession numbers are shown in the second column, and column ‘Tyr’ lists the positions of the 
phosphorylatable tyrosines in the peptide. The final column is a color-coded representation of the lower 
signals obtained with shPTPRZ1 E98 extracts as compared to the scrambled control. 
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Supplementary Methods
Cell lines and antibodies
 Generation and maintenance of orthotopic glioma xenograft models E98 (glioblas-
toma) and E434 (anaplastic Oligodendroglioma) have been described previously [92].  E98 
and E434 orthotopic xenograft-derived cells were cultured as spheroids in neurobasal medi-
um supplemented with B27 Supplement, 2 mM L-glutamin, 2 μg/mL Heparin, 1% penicillin/
streptomycin (all Gibco), 20 ng/mL EGF and basic-FGF (both PromoCell) [98]. Regular pas-
saging of spheroids was done by gentle mechanical dissociation. In addition, E98 cells were 
grown as adherent cultures in DMEM supplemented with 10% FCS, and passaged using 
trypsinisation [176]. E434 cells cannot be propagated under these conditions.
 Antibodies used were as follows: for Western Blotting: mouse anti-PTPRZ (1:1000; 
BD Biosciences, #610179), mouse anti-VSV (IP: 5μl; P5D4 [341]), mouse anti-tubulin (1:5000; 
DSHB, University of Iowa, E7), rabbit anti-MET (1:2000; Cell Signaling Technology, #8198), 
rabbit anti-pMET (1:2000; Cell Signaling Technology, #3027), rabbit anti-GAPDH (1:5000; 
Cell Signaling Technology #2118), rabbit anti-Contactin-1 (1:2000) [251], for immunohisto-
chemistry mouse anti-BrdU (1:50; Sigma-ALDRICH, #2531), rabbit- ki67 (1:200 Clone SP6; 
Thermo Scientific #Rm-9106) rabbit-cleaved caspase 3 (1:200; Cell Signaling Technology, 
#9661) rabbit anti-GFP (1:1000) [342], and rabbit anti-TagRFP (1:500; Evrogen, AB233). As 
secondary antibodies, IRDye 680- or 800-conjugated goat anti-mouse and goat anti-rabbit 
antibodies (1:20.000; LI-COR Bioscience), Alexa Fluor 488 goat-anti-mouse and Alexa Fluor 
647 goat-anti-rabbit antibodies (1:300; Alexa) or biotinylated goat-anti-rabbit IgGs (1:200; 
Dako) were used.
Plasmid constructs
 The plasmid pLenti6/BLOCK-iT-DEST (Invitrogen) was adapted to also contain CMV 
promoter-driven TagRFP or EGFP expression cassettes. Briefly, the CMV-TagRFP cassette 
was PCR-amplified from pTagRFP-C (Evrogen) using oligonucleotide set 1 (all oligonucle-
otide sequences are listed in Supplementary Table S1), digested with XbaI and XhoI, and 
ligated into XbaI/XhoI-digested pLenti6/BLOCK-iT-DEST. Likewise, the CMV-driven EGFP 
expression cassette was amplified from pEGFP-N2 (Clontech) using oligonucleotide set 2, 
digested with XbaI and ligated in the XbaI-linearized pLenti6/BLOCK-iT-DEST. For over-ex-
pression purposes, the mouse phosphoglycerate kinase (PGK) promoter was inserted up-
stream of the attR1 recombination site in these pLenti6/Block-it-DEST-TagRFP and -EGFP 
variants. Briefly, oligonucleotide set 3 was used to amplify the pLenti6.2/V5-DEST (Invitro-
gen) PGK fragment and the ClaI digested amplicon was ligated to produce plasmids pLen-
ti6/PGK-DEST-TagRFP and pLenti6/PGK-DEST-EGFP. To create knock-down constructs, 
shPTPRZ1 (set 4) and shSCR (set 5) oligonucleotide heteroduplexes were ligated in pENTR/
U6 vector and subsequently Gateway-cloned into pLenti6/Block-iT-DEST-TagRFP (for shPT-
PRZ1) and pLenti6/Block-iT-DEST-EGFP (for shSCR) according to the manufacturer’s proto-
cols (Invitrogen). 
 A pENTR/U6 derivative was customized by inserting oligonucleotide heteroduplex 
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set 6 between the unique SalI-XbaI sites, rendering pENTR/NotI-XhoII. To clone PTPRZ-B 
cDNA (Refseq NM_001206838.1), we first tailored pENTR/NotI-XhoI by inserting an SstII 
site-containing linker (set 7) in the unique HindIII site. The PTPRZ-B open reading frame was 
produced by reverse-transcriptase PCR using oligonucleotide set 8 and E98 total RNA as 
template. The SstII and NotI digested cDNA was subsequently inserted into the SstII site-con-
taining pENTR/NotI-XhoI variant, resulting in plasmid pENTR-wtPTPRZ-B. A shPTPRZ1-resis-
tant PTPRZ-B version (further indicated as pENTR-PTPRZ-B) was created via introduction of 
a silent C-T mutation at nucleotide position 1861 (numbering according to NM_001206838) 
in the shPTPRZ1 recognition site, using oligonucleotide set 9 and the Quickchange site-di-
rected mutagenesis kit (Stratagene) according to manufacturer’s instructions. 
 PTPRZ-B cDNA was subsequently adjusted via site-directed mutagenesis to en-
code an enzymatically inactive PTPRZ-B C/S mutant (GC to CG, at positions 3613-3614) 
using oligonucleotide set 10 and the afore-mentioned protocol. Furthermore, a C-terminal-
ly VSV-tagged full-length PTPRZ-B variant was generated by first generating a KpnI site 
(AGTTTAA to GGTA, pos. 4757-4763) using oligonucleotide set 11, and subsequently intro-
ducing oligonucleotide heteroduplex set 12, encoding an in-frame C-terminal VSV-G epitope 
tag (flanked by KpnI sites). To enable expression of the PTPRZ-B ecto-domain only, first a 
KpnI site was created at the codon preceding the PTPRZ-B transmembrane-encoding re-
gion (AGTTATA to GGTA, pos. 2726-2732) using oligonucleotide set 13 in the mutagenesis 
protocol. Subsequent ClaI digestion and re-ligation resulted in removal of residues 776-1448 
comprising the PTPRZ-B intracellular domains. Finally, the new KpnI site was used to insert 
the VSV-G epitope tag-encoding heteroduplex 12. All resulting pENTR-PTPRZ-B plasmid 
variants were sequence-verified before being used in Gateway LR cloning reactions with 
pLenti6/PGK-DEST-TagRFP as destination vector. Also using Gateway cloning, the empty 
pENTR/NotI-XhoI vector served to generate pLenti6/PGK-EV-TagRFP as empty vector con-
trol.
Lentiviral transduction of glioblastoma cells and spheroids
 Lentiviruses were produced using HEK-293FT cells according to the manufactur-
er’s instructions (Invitrogen). Briefly, 95% confluent 10cm culture dishes with HEK-293FT 
cells were transfected overnight, using JetPRIME reagent (Westburg) and the appropriate 
plasmid cocktail. The next day, medium was refreshed and 48-72 hrs later virus-containing 
medium was harvested, passed through a 0.45 µm pore size filter and stored at -80 °C. E98 
Glioma cells or E434 spheroids were transduced by adding virus-containing medium to the 
cultures, at a 1:2 to 1:5 virus to medium ratio. After an overnight incubation, cells were su-
perinfected with virus to increase the percentage of transduced cells. Routinely, this led to 
80-100% transduction efficiency for E98 cells and 40-80% for the spheroid E434 cultures. 
Stably transduced E98 cells were selected by adding Blasticidin (2 µg/mL; Invitrogen). For 
rescue experiments, cells were first transduced twice with shPTPRZ1-expressing lentivirus-
es. Several days later, two or three rounds of transduction with PGK promoter-driven rescue 
constructs were performed and cells were subjected to the proliferation and migration as-
says 72 hrs later. 
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Real-time quantitative RT-PCR
 Total RNA was isolated using RNA-Bee (Tel-Test Inc. cs104B) using standard 
trizol-chloroform extraction methods, and concentrations were measured spectrophotomet-
rically. Reverse transcriptase reactions were performed using Iscripttm cDNA synthesis kit 
(Bio-Rad) according to the supplier’s specifications. Specificity and efficacy of real-time 
quantitative PCR primer pairs for PTPRZ1 and β-actin (Qiagen) have been verified previously 
by Schmidt et al. [345]. Reactions, containing 3 μL of cDNA, 1 µL of the pre-mixed primer 
pair, 5 μL of SYBR Green PCR master mix (Bio-Rad) and 1 µL MQ, were run on a CFX96tm 
Real Time system using the C1000tm Thermal Cycler (Bio-rad). Reactions were initialized at 
95 °C for 15 minutes and then cycled 40 times at 95 °C for 15 s and 60 °C for 40 s. After the 
last cycle, a dissociation curve was recorded between 60 °C and 95 °C with and increment 
of 0.5 °C. The amount of PTPRZ1 RNA was determined relative to ACTB levels using the delta 
Ct method [343].
Immunoblotting and immunoprecipitation 
 Cells were washed with cold PBS and scraped in ice-cold lysis buffer (50 mM Tris-
HCl, pH 7.5; 150 mM NaCl; 1% Triton X-100 (Serva); 1 mM PMSF; 100 mM NaF; 2 mM Na-
3VO4; 20 mM Na4P2O7; complete protease inhibitor cocktail, Roche, #13006200 (1 tablet in 
1.5 mL MQ, 20 μl solution per mL lysis buffer)). Samples were either further processed for 
immunoprecipitation (see below) or added to 2x SDS sample buffer (60 mM Tris-HCl, pH 
6.8; 2% SDS; 100 mM dithiothreitol; 0.001% bromophenol blue; 10% glycerol) and heated 
at 95 °C for 5 min. Protein samples were size-separated using SDS-PAGE on 8% gels and 
electro-blotted onto PVDF membrane (Immobilon-FL, #IPFL00010) according to standard 
protocols. Membranes were blocked using 1% BSA in TBST (10 mM Tris-HCl, pH 8.0; 150 
mM NaCl; 0.1% Tween-20 (Sigma-Aldrich)) for 1 hr at RT, and subsequently incubated with 
primary antibodies in 1% BSA in TBST, overnight at 4 °C. Membranes were then washed 
three times for 10 min in TBST and subsequently incubated with the appropriate secondary 
antibodies for 1 hr at RT in the dark. Blots were analyzed using the Odyssey imaging system 
(LI-COR Biosciences). Immunoblot images were analyzed quantitatively using standard FIJI 
software.
 To visualize PTPRZ-B ecto-VSV in E98 conditioned medium, immunoprecipitation 
was performed. 30 μl ProtG sepharose beads (GE Healthcare, #17-0618-01) were incubated 
with mouse-VSV antibody overnight at 4 °C. Beads were washed 5 times with TBS and incu-
bated with E98 conditioned medium overnight at 4 °C. Beads were washed 5 times with TBS 
and suspended in SDS sample buffer. After centrifugation, the supernatant was used for gel 
loading and blotted as described above. For purification purposes PTPRZ-B ecto-VSV was 
produced in HEK-293FT cells transfected with pLenti6/PGK-PTPRZ-B ecto-VSV-TagRFP, us-
ing JetPRIME according to the manufacturer instructions. The secreted PTPRZ-B ectodomain 
was purified from conditioned medium via immunoprecipitation using mouse anti-VSV bound 
to ProtG sepharose beads, as described above. VSV-tagged proteins were eluted from the 
beads using excess VSV peptide [344]. 
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 For co-immunoprecipitation, mouse anti-VSV was coupled to ProtG sepharose 
beads by overnight rotation at 4 °C in TBS. After 5 subsequent washes with TBS, conditioned 
medium from HEK293FT cells transfected with either pLenti6/PGK-EV-TagRFP or pLenti6/
PGK-PTPRZ-B ecto-VSV-TagRFP was added to the beads allowing coupling to VSV over-
night at 4 °C. After 5 washes, E98 cell lysates (prepared as described above) were added 
to the beads and were incubated overnight at 4 °C. The next day, beads were washed 5 
times with TBS before being taken up in 2x SDS sample buffer. Samples were processed for 
immunoblotting as described above.
Immunohistochemistry
 FFPE sections of 4 μm were subjected to immunohistochemical stainings according 
to standard procedures [140]. In brief, sections were de-paraffinized in xylene and rehydrat-
ed in PBS. Endogenous peroxidases were blocked in 3% H2O2 in PBS, followed by epitope 
retrieval (10 min boiling in 10 mM sodium citrate, pH 6.0). Slides were then washed twice in 
PBS, blocked in 20% normal serum (from the species in which the secondary antibody was 
raised) in PBA (1% BSA in PBS) for 20 min, and incubated overnight at 4 °C with primary 
antibodies in PBA. After 3 PBS washes, sections were incubated with biotinylated secondary 
antibodies in PBA for 1hr at room temperature. Slides were washed 3x with PBS and signals 
were then enhanced by incubation with Avidin/Biotin complexes (Vector Laboratories, #PK-
6100), both 1:100 in PBA for 45 min, followed by 3 PBS washes and visualization of specific 
signals using 3,3′-diaminobenzidine (Bright-DAB, ImmunoLogic, #B04). All sections were 
counterstained with haematoxylin and mounted in Quick-D Mounting medium (Klinipath BV, 
#7280). 
 Quantification of immunodetected EGFP and TagRFP signals was done using 
KS400 software (Carl Zeiss AG) and a custom-written macro. Sections of FFPE brains with 
orthotopic glioma xenografts were included in the analysis (n=3 and 2 for E98 and E434, 
respectively) and at least five non-overlapping microscopic fields (magnification x200) were 
measured per immunostaining for each animal. The TagRFP- or GFP-positive area per tumor 
field was divided by the total tumor area as determined via nuclear DAPI staining, and av-
erage values per animal were determined and used to calculate TagRFP/GFP ratios. Ratios 
were compared to those prior to injection using the one-sample Student’s t-test.
Peptide microarray analysis
 E98 cells stably expressing shSCR/GFP and shPTPRZ1/TagRFP constructs were 
grown to 80% confluency in 6-well plates (4 wells per sample). Cells were washed twice with 
ice-cold PBS prior to lysis with M-PER Mammalian Extraction Reagent supplemented with 
protease and phosphatase inhibitor cocktails (Thermo Scientific) for 30 min at 4 °C. Lysates 
were centrifuged (15 min, 14,000 rpm, 4 °C), and supernatants were snap frozen in liquid 
nitrogen and stored at -80 °C. Protein concentrations were determined using the BCA protein 
assay (Thermo Scientific). Kinase activity measurements were performed in quadruplicate 
on Tyrosine kinase PamChip arrays on a PamStation 12 instrument (PamGene International 
BV) essentially as described [260]. Sample input was 5 µg per array. A Student’s t-Test was 
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used to identify the peptides that are significantly (p<0.05) different between the treatments.
Statistical analysis
 Statistical analysis was performed using GraphPad Prism 5 or PamGene’s propri-
etary BioNavigator software. For two conditions the Student t-test was applied. For other 
conditions ANOVA, repeated measure ANOVA or non-parametric Kruskal-Wallis with post-
hoc tests were performed. When all experimental conditions were included, Tukey’s multiple 
comparison test was used. In contrast, when comparisons were made to a single “control” 
experimental condition the Dunn’s post-hoc test was applied.
Supplementary Table S1. Oligonucleotide sequences used in generating plasmid constructs.
 
Oligonucleotide (set) Sequence
1:  CMV-TagRFP Forward
Reverse
5’- GGCTCGAGTAGTTATTAATAGTAATC -3’
5’- CCTCTAGATCAATTAAGTTTGTGCCCC -3’
2:  CMV-EFGP Forward
Reverse
5’- GGCGCTCTAGATAGTTATTAATAGTAATCAATTACG -3’
5’- GGCGCTCTAGATTACTTGTACAGCTCGTCCATG -3’
3: PGK promoter Forward
Reverse
5’- GGCATCGATCTCGAGCTACCGGGTAGGGGAGGCGC -3’
5’- GCCGCATCGATGTCGAAAGGCCCGGAGATG -3’
4: shPTPRZ1 Forward
Reverse
5’- CACCGGAAGTGAATTCTCTGGAAAGCGAACTTTCCAGAGAAT-
TCACTTCC -3’
5’- AAAAGGAAGTGAATTCTCTGGAAAGTTCGCTTTCCAGAGAAT-
TCACTTCC -3’
5: shSCR Forward
Reverse
5’- CACCGTCAAACTGCTTACTCTAGACGAATCTAGATGTAAGCAGTTTGAC 
-3’
5’- AAAAGTCAAACTGCTTACATCTAGATTCGTCTAGATGTAAGCAGTTGAC 
-3’
6: NotI-XhoI adapter Forward
Reverse
5’- TCGACGCGGCCGCGAATTCCCGGGATCCACCGGTCTCGAGAAGCT-
TATCG ATACCGT -3’
5’- CTAGACGGTATCGATAAGCTTCTCGAGACCGGTGGATCCCGGGAAT-
TCGC GGCCGCG -3’
7: SstI linker 5’- AGCTGACCGCGGTC -3’
8: PTPRZ-B cDNA Forward
Reverse
5’- GCGCGCGGCCGCCCACTCTGAGAAGCAGAGGAG -3’
5’- GCGCCCGCGGGTGTTAAACTAAAGACTCTAAG -3’
9: mutagenesis PTPRZ-B rescue Forward
Reverse
5’- CAAGAGGAAGTGAATTTTCTGGAAAGGGTGATG -3’
5’- CATCACCCTTTCCAGAAAATTCACTTCCTCTTG -3’
10: mutagenesis PTPRZ-B C/S Forward
Reverse
5’- CCTGTTGTCGTCCACTCGAGTGCTGGAGTTGG -3’
5’- CCAACTCCAGCACTCGAGTGGACGACAACAGG -3’
11: mutagenesis KpnI full-length 
PTPRZ-B
Forward
Reverse
5’- GCTGAGAGCTTAGAGTCTTTGGTACCCGCGGTCAGCTTATCGAT -3’
5’- ATCGATAAGCTGACCGCGGGTACCAAAGACTCTAAGCTCTCAGC -3’
12: KpnI VSV-stop Forward
Reverse
5’- CTTATACAGACATAGAGATGAACCGACTTGGAAAGTAGGTAC -3’
5’- CTACTTTCCAAGTCGGTTCATCTCTATGTCTGTATAAGGTAC -3’
13: mutagenesis KpnI PTPRZ-B 
ectodomain
Forward
Reverse
5’- GTTGGAATCCGAGAAGAAGGCGGTACCCCTTGTGATCGTGTCAGC -3’
5’- GCTGACACGATCACAAGGGGTACCGCCTTCTTCTCGGATTCCAAC -3’
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Abstract
 Point mutations in genes encoding NADP+-dependent isocitrate dehydrogenases 
(especially IDH1) are common in lower grade diffuse gliomas and secondary glioblastomas 
and occur early during tumor development. The contribution of these mutations to gliom-
agenesis is not completely understood and research is hampered by the lack of relevant 
tumor models. We previously described the development of the patient-derived high-grade 
oligodendroglioma xenograft model E478 that carries the commonly occurring IDH1-R132H 
mutation. We here report on the analyses of E478 xenografts at the genetic, histologic and 
metabolic level. 
 LC-MS and in situ mass spectrometric imaging by LESA-nano ESI-FTICR revealed 
high levels of the proposed oncometabolite D-2-hydroxyglutarate (D-2HG), the product of 
enzymatic conversion of α-ketoglutarate (α-KG) by IDH1-R132H, in the tumor but not in sur-
rounding brain parenchyma. α-KG levels and total NADP+-dependent IDH activity were sim-
ilar in IDH1-mutant and -wildtype xenografts, demonstrating that IDH1-mutated cancer cells 
maintain α-KG levels. Interestingly, IDH1-mutant tumor cells in vivo present with large densi-
ties of mitochondria and increased levels of mitochondrial activity as compared to IDH1-wild-
type xenografts. It is not yet clear whether this altered mitochondrial activity is a driver or a 
consequence of tumorigenesis. 
 The oligodendroglioma model presented here is a valuable model for further func-
tional elucidation of the effects of IDH1 mutations on tumor metabolism and may aid in the 
rational development of novel therapeutic strategies for the large subgroup of gliomas carry-
ing IDH1 mutations.
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Introduction
 Diffuse gliomas are notoriously difficult to treat, and remain incurable to this date. 
Based on WHO guidelines, these tumors are categorized in grade II-IV, grade IV (glioblasto-
ma) being the most aggressive subtype [1]. Grade IV gliomas may develop de novo (primary 
glioblastoma) or evolve from lower grade tumors (secondary glioblastoma) [3, 5, 7, 270]. 
The role of specific tumor suppressor genes and oncogenes in gliomagenesis has rapidly 
been elucidated in the last decades [68, 271-276]. A recent breakthrough was the discov-
ery of the involvement of mutations in the genes for isocitrate dehydrogenase 1 (IDH1) and, 
less frequently, IDH2 [85, 86, 277] in grade II/III gliomas and secondary glioblastomas. IDH 
mutations are uncommon in other tumor types, with the exception of acute myeloid leukemia 
(AML), angioimmunoblastic T-cell lymphomas, intrahepatic cholangiocarcinomas and chon-
drosarcomas [277-281]. Mutations in glioma almost always involve an arginine-to-histidine 
conversion at position 132 in the catalytic site of IDH1 [86, 87, 282].
 The high frequency of mutations in IDH1 suggests an important role for the mutant 
protein in early glioma development, but the exact underlying oncogenic mechanism is not 
completely understood. IDH1 is a cytoplasmic enzyme that converts isocitrate to α-ketoglu-
tarate (α-KG), with simultaneous reduction of NADP+ to NADPH [283]. The other family mem-
bers IDH2 and -3 reside in mitochondria and are either NADP+- (IDH2) or NAD+-dependent 
(IDH3). For as yet unknown reasons, the occurrence of IDH mutations in glioma is restricted 
to the NADP+ dependent variants [88].  
 The R132H mutation equips the enzyme with a neomorphic activity resulting in a 
reduction of α-KG to D-2-hydroxyglutarate (D-2HG) [90], an NADPH consuming process. 
D-2HG may be an ‘oncometabolite’, but whether and how it contributes to gliomagenesis 
is a matter of debate. Patients with D-2-hydroxyglutaric aciduria, a rare metabolic condition 
in which high levels of D-2HG occur due to mutations in the D-2HG dehydrogenase gene 
D2HGDH or in IDH2, do not show increased levels of tumor development [284]. Paradoxical-
ly, the metabolic condition L-2-hydroxyglutaric aciduria has been suggested to predispose 
for brain tumorigenesis [285, 286]. Depletion of α-KG, an essential citric acid cycle inter-
mediate, in IDH1 mutant tumor cells may play a role during tumor development [287] but 
competitive inhibition by D-2HG of the 60 known α-KG-dependent enzymes appears to be 
a more important factor [288]. For example, inhibition of α-KG-dependent TET2 and histone 
demethylase KDM4C (also known as JMJD2C) results in DNA hypermethylation and histone 
demethylation respectively and, as a result, blocks cell differentiation [289-291]. Further-
more, increased degradation of hypoxia-inducible factor 1α (HIF1α) via inhibition of α-KG 
dependent EGLN prolyl 4-hydroxylases may play a role [292]. Recently, it was described 
that this mechanism contributes to leukemogenesis in a reversible manner [293]. 
 IDH1 mutations nearly always occur in a heterozygous fashion and the presence of 
a wild type (wt) allele is required for the maximal neomorphic activity of the mutant protein 
[294]. The enzyme consists of two independently acting subunits. Wild type enzyme sub-
units, either as homodimer or in mutant/wt heterodimers, convert isocitrate to α-KG which is 
subsequently processed by the mutant enzyme (subunits) to D-2HG [295]. Whereas wtIDH1 
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can convert α-KG back to isocitrate in a CO2- and NADPH-dependent manner, this activity is 
lost by the R132 mutation [283]. The stoichiometry of IDH1 wt and mutant proteins is likely an 
important parameter which determines α-KG and D-2HG levels and may therefore influence 
cell metabolism [294]. Therefore, it is not clear to what extent exogenous introduction of 
recombinant mutant IDH1 in cell lines provides relevant information as overexpression may 
result in a non-physiological amount of IDH1-mutant homodimers which may differ in activity 
from heterodimers [296]. Moreover, metabolism of cells under standard culture conditions 
may significantly differ from in vivo conditions where local areas of hypoxia and hypoglyce-
mia routinely occur. Therefore, it is important to study relevant orthotopic glioma xenograft 
models that recapitulate the biology of tumors carrying the endogenous mutation. It has been 
shown by several groups that gliomas with IDH1 mutations are difficult, if not impossible, to 
culture and propagate in vitro under standard serum-free or serum-containing culture con-
ditions [101, 297, 298]. Similarly, in vivo models are difficult to propagate and as a result, 
preclinical glioma models carrying the IDH1 or IDH2 mutation are scarce.
 Here, we report on the genetic, histologic and metabolic characterization of the 
E478 human oligodendroglioma xenograft line which carries the endogenous heterozygous 
IDH1-R132H mutation and provide novel insight into the metabolism of these tumors.
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Materials & Methods
Intracranial xenografting
 Athymic female BALB/c nu/nu mice (18-25 gram, age 6-8 weeks) were kept under 
specified pathogen-free conditions and received food and water ad libitum. The local Ani-
mal Experimental Committee of the Radboud University Nijmegen Medical Centre approved 
all experiments. Glioma cell suspensions, directly obtained from surgically resected tumor 
tissue of a patient with an anaplastic oligodendroglioma, which was later shown to carry 
the IDH1-R132H mutation, were injected intracranially as described previously [92]. Ani-
mals were closely monitored and sacrificed when evident signs of tumor burden (especially 
weight loss >15% in two days, severe neurological abnormalities) were observed. The xeno-
graft line has been maintained by direct intracerebral passaging of tumor cell suspensions, 
generated from E478-bearing mouse brains as described [92].
Cryopreservation of xenograft brains
 To test whether E478 cancer cells retain their tumorigenic potential upon cryopres-
ervation, cell suspensions of tumor-bearing brains were generated in PBS and washed twice 
followed by suspension in DMEM (containing 0.45% w/v glucose; PAA Laboratories, Pas-
ching, Austria) with 5% DMSO (Merck, Nottingham, UK). Cell suspensions were frozen at 
-1˚C/min in Nalgene Mr. Frosty containers (ThermoScientific, Landsmeer, The Netherlands) 
at -80˚C and subsequently stored in liquid nitrogen for at least a month. For re-injection, cells 
were rapidly thawed at 37˚C, washed twice and suspended in PBS, followed by intracranial 
injection in mice (n=5) as described above. When animals developed tumor-related symp-
toms, a tumor of one of the mice was transplanted into new animals (n=5). 
Array comparative genomic hybridization (aCGH)
 aCGH was carried out with DNA of the originating patient tumor and several pas-
sages of the derived xenografts. DNA was digested using the restriction enzymes RsaI and 
AluI, followed by labeling using the Bio Prime CGH Genomic Labeling Kit (Invitrogen, Carls-
bad, CA) and Cy3 and Cy5 dyes (GE Healthcare, Buckinghamshire, UK), according to stan-
dard protocols for Agilent CGH. Commercially available female DNA pooled from multiple 
donors (Promega Cat:G1521) was used as reference. Labeled DNA was competitively hy-
bridized to SurePrint G3 Human 2x400k CGH microarrays (G4448A, Agilent Technologies, 
Amstelveen, The Netherlands) following standard protocols. The slides were scanned at 
3 μm resolution using the Agilent High-Resolution Microarray scanner and the image data 
were extracted with Feature Extraction software (Agilent Technologies). Feature extraction 
files were imported into Genomic Workbench 7.0 for visualization and analysis. Briefly, after 
diploid centralization and GC correction, aberrations were called using the ADM2 algorithm 
with a threshold setting of 20, centralization on with a threshold of 25 and an aberration filter 
min Probes=5 and minAvgAbsLogRatio=0.25 for amplifications and deletions.  
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Immunohistochemistry (IHC)
 Animals with tumor-related symptoms were sacrificed by cervical dislocation and 
brains were removed for fixation in buffered formalin and subsequent paraffin embedding. 
Parts were also snap frozen in liquid nitrogen and stored for protein analysis and DNA/RNA 
isolation, D-2HG measurements and metabolic mapping.
 H&E and immunohistochemical stainings were performed as described previous-
ly [127] including the use of antibodies directed against IDH1-R132H (clone H09, Diano-
va, Hamburg, Germany), Ki67 (for proliferation index assessment, clone Sp6, Neomarkers, 
Fremont, CA), cleaved caspase 3A (for detection of apoptotic cells, clone C92-605, BD 
Pharmingen, Franklin Lakes, NJ), CD34 (for endothelial cell staining, clone MEC14.7, Hycult 
Biotech, Uden, The Netherlands), GLUT-1 (Neomarkers), mouse IgG (Vector, Burlingame, 
CA), MCT-1 and MCT-4 (clones C-20 and H-90 respectively, Santa Cruz, CA). Primary an-
tibody incubations were performed using 4 µm-thick sections of formalin-fixed paraffin-em-
bedded tumor samples. Appropriate biotinylated secondary antibodies were used for de-
tection using the ABC-method (Vector Laboratories). Specific signals were visualized by 
staining with 3-amino-9-ethyl-carbazole (Scytek Laboratories, West-Logan, Ut). All sections 
were counterstained with haematoxylin and mounted in Imsol Mount medium (Klinipath B.V., 
Duiven, The Netherlands). For all stainings, control incubations were carried out by omitting 
the primary antibody.
 Metabolic mapping
 Activities of NADPH- and NADH-producing dehydrogenases were visualized using 
metabolic mapping [299, 300] using 10 µm thick unfixed cryostat sections of mouse brains 
infiltrated with E478, E434 or E98 glioblastoma xenografts [92]. The wt IDH1 status of E434 
and E98 xenograft lines (oligodendroglioma and glioblastoma, respectively) was previously 
confirmed. Control incubations to establish the specificity of the enzyme reactions, were 
performed in the absence of relevant substrates [299, 300].
Electron microscopy
 Tissue samples of approximately 1-2 mm3 were fixed in 2% glutaraldehyde in cac-
odylate buffer (100 mM) for 4 hours, rinsed in cacodylate buffer and post-fixed for 1 hour 
in a solution of 1% osmium tetroxide containing 1% potassium hexacyanoferrat. Semithin 
(1 mm) sections and ultrathin (70 nm) sections were cut on an ultramicrotome (Leica EM 
UC6). Semithin sections were stained with toluidin blue for light microscopical previewing 
and ultrathin sections were collected on 200 mesh copper grids and contrasted with uranyl 
acetate and lead citrate. All sections were examined and images generated on a JEM1200 
transmission electron microscope (Jeol, The Netherlands).
D-2HG measurements by isotope dilution LC-MS-MS
 D-2HG levels in serum and tissue extracts were measured using stable isotope 
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dilution liquid chromatography tandem mass spectrometry (LC-MS). D-2HG for the prepa-
ration of calibration standards was purchased from Sigma Aldrich. Samples of 100 µl were 
mixed with 50 µl of 13C5-2-HG stable isotope solution (Chiralex, Nijmegen, The Netherlands; 
10 µM in deionized water) before passing it through a Microcon YM-30 filter (Millipore) by 
centrifugation (14,000xg; 30 min). After acidification of the filtrate with 10 µl 4% formic acid in 
deionized water, 5 µl was injected into a Luna PFP column (2.1 mm*100 mm*3 µm, Phenome-
nex). The mobile phase consisted of methanol and water containing 0.3% formic acid. 2-HG 
was separated from its isomers 3-hydroxyglutarate and 2-hydroxy-2-methylsuccinate using 
a water-to-methanol gradient at 250 µl/min. The column was connected to an electrospray 
tandem mass spectrometer (Quattro LC, Micromass) operated in negative mode (capillary 
voltage 3 kV, cone voltage 20V) with an argon filled collision cell (0.18 Pa, 9eV). The tandem 
mass spectrometer was set to monitor the water loss of both D-2HG and 13C5-2-HG recording 
the mass transitions of m/z 147 to 129 and m/z 152 to 134, respectively. The temperature 
settings for the source and ion block were 400°C and 100°C respectively. Nitrogen was used 
as drying and nebulizer gas set at flow rates of respectively 650 L/h and 100 L/h.
In situ metabolite quantification by LESA-nano ESI-FTICR
 In a separate set of experiments, we quantified D-2HG and α-KG levels via LESA 
(Liquid Extraction Surface Analysis, Nanomate, Advion) coupled to ESI-FTICR (Fourier trans-
form ion cyclotron resonance, Solarix 7T, Bruker Daltonics, Bremen) and Quantinetix Soft-
ware (ImaBiotech, France) allowing very sensitive detection and quantification of metabolites 
in small tissue plugs taken from 10 µm thick cryostat brain sections (Cryostat  HM560, Mi-
crome). The Nanomate system was used in LESA mode with a 400 µm diameter surface ex-
traction. Sample plates were cooled down to 12°C during analyses. Spray parameters were 
set as follows: Voltage to apply 1.30 kV and gas pressure 0.40 psi. Extraction solvent con-
sisted of 65:15:20 MeOH:IPA:Water + 5mM ammonium acetate using LCMS quality solvents. 
0.6 µL extraction solvent was used to extract analytes from the surface and was injected then 
into the nano-electrospray source. Tissue suppression was calculated using Quantinetix to 
address matrix effect and to normalize signals of 2-HG and α-KG. A dilution range of pure 
metabolites mixed with brain tissue was applied next to the samples for absolute quantifica-
tion and data for each LESA spot were analyzed using QuantinetixTM (ImaBiotech, France) 
taking 10 mDa mass tolerance around theoretical m/z of 2-HG and α-KG. Data were normal-
ized against a standard included in the extraction solvent (m/z 141.019). Mass spectrometry 
was performed using the negative mode with the nano-electrospray source and CASI mode 
(isolation of m/z 150 +/- 50 Da in the quadrupole) in the mass range 71-160 Da. Each acqui-
sition was a result of 80 accumulated spectra.
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Results
Development of IDH1-R132H xenografts
 In our institute, we have a long history of developing patient-derived orthotopic gli-
oma xenograft models by direct intracerebral implantation of cancer cell suspensions from 
surgically-obtained glioma specimens [92]. As long-term in vitro cell cultures are known to 
be genetically unstable [93], the development of such direct orthotopic xenografts is im-
portant in the context of clinical relevance and reproducibility. Remarkably, from 5 biopsies 
derived from IDH1-R132H-mutated high-grade oligodendroglioma specimens only one so 
far gave rise to the stable xenograft line described here (E478). This is in line with a previous 
report which demonstrated that xenografting of cultured IDH1 mutant glioma cells hardly re-
sults in in vivo tumor growth [297] and is in sharp contrast with our experience with orthotopic 
xenografting of IDH1wt gliomas in which success rates approach 100%. Attempts to culture 
E478 cells in vitro using both neurosphere and standard culture conditions were so far un-
successful (data not shown). Occasionally, we managed to maintain short-term organotypic 
spheroid cultures [301] and these were used for genetic analyses (supplementary Figure 
S1).
 To increase the versatility of the E478 model, we generated cell suspensions direct-
ly from xenografts and cryopreserved these before re-injecting them intracerebrally in mice. 
This procedure resulted in successful orthotopic engraftment in 100% of the animals, also 
after re-transplantation. 
 The E478 xenograft model has now been maintained in the brains of Balb/c nu/
nu mice by serial transplantation for over 32 passages (P) in a period of over 8 years. PCR 
sequencing of IDH1 confirmed the maintenance of the heterozygous c.395G>A mutation 
[NM_005896.2] resulting in the R132H conversion in IDH1 (Figure 1A), similarly to the paren-
tal tumor (data not shown). Cytoplasmic expression of the mutant IDH1 protein was readily 
detected in E478 xenografts using IHC and a monoclonal antibody that specifically recogniz-
es the R132H mutated IDH1 protein [302] (Figure 1B). Tumor take of E478 xenografts after 
intracerebral passaging is over 95% and the median time until mice are sacrificed because 
of tumor-related symptoms is 78 days (n=200, P 0, 10 and 20 shown in Figure 1C).
 Genetic analysis of E478 xenografts
 To compare the chromosomal aberrations in the E478 xenografts and the paren-
tal tumor, we performed array comparative genomic hybridization (aCGH) analyses (Figure 
1D). The original tumor showed complete hemizygous loss of chromosomal arms 1p and 
19q, a characteristic feature of oligodendroglial tumors. Additionally, hemizygous losses of 
chromosomes 4, 9 as well as 13q21.33-31.2 were detected. A region in chromosome 4 
(59.5-62.2Mb), which is devoid of any known genes or miRNAs, was homozygously de-
leted. Furthermore, the tumor was triploid for 7p15.2-qter, 8q12.3-qter and 11 (Figure 1D, 
upper panel). All aberrations were maintained in late passages (Figure 1D, lower panel). 
Some additional aberrations were also detected in the xenograft, including loss of 2q22-qter, 
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3pter-p21.2, chromosomes 10, 12 and 18 as well as gains of chromosome 21 (Supplemen-
tary Figure S1). Glial tumors show a high level of intratumoral genomic heterogeneity [228], 
which might explain the differences observed between the original tumor biopsy and its 
derived xenograft.
 We determined the DNA quantity per cell of the xenograft tumor by flow cytometry 
of DAPI-labeled nuclei (Supplementary Figure S2A). A minor fraction of the cells appeared 
to be diploid and was considered to consist of stromal or host-derived cells. The majority of 
cells were aneuploïd with a DNA index of 1.925, which corresponds to 3.85 N. The xenograft 
tumor thus has a near tetraploïd genome with some xenograft-specific losses. The inferred 
copy number at the IDH1 locus on 2q34 is 3. 
 In order to determine the genotype at the IDH1 locus, we set up an allele-specific 
TaqMan SNP genotyping assay that can discriminate between the wildtype and R132H al-
leles of IDH1. This assay revealed that the R132H allele was twice more abundant than the wt 
allele in the xenograft (Supplementary Figure S2B), resulting in an IDH1R132H/R132H/WT genotype 
for IDH1 in the xenograft.
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Figure 1. E478 xenografts contain the IDH1-R132H mutation. A) E478 xenografts contain the G=>A 
mutation as shown by direct sequencing. B) Micrograph of a E478 xenograft in mouse brain, stained 
with the IDH1-R132H-specific antibody, bar =100 µm. C) Curves of time to sacrifice of mice in various 
passages of the E478 line, P0 being the first transplantation of surgically-obtained tumor material, direct-
ly from the patient in nude mice. D) Comparison of array CGH profiles of the tumor of the patient (blue) 
and a derived xenograft (P32, brown). The losses of chromosome arms 1p and 19q, typical for oligoden-
droglioma, are indicated by arrows in the profile of the patient tumor. All genetic aberrations that were 
present in the original tumor, are present in the profile of the xenografts as  well, with a few additional 
aberrations in the xenograft. Further details are presented in Supplementary Figure S1.
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Phenotype of the E478 xenografts
 E478 xenografts characteristically grow to diffuse infiltrative tumors in the mouse 
brain (Figure 2A,B) with proliferation indices of 34 +/- 2% as determined by Ki67 IHC staining 
(Figure 2C and not shown). Apoptotic cells, as determined by IHC for activated caspase 
3A, were hardly detected (<0.1%; data not shown). Blood vessels were often abnormal with 
signs of endothelial hyperplasia and microvascular proliferation with prominent CD34 stain-
ing (Figure 2D), reminiscent of typical high-grade glioma pathology. The presence of extra-
vascularly deposited mouse IgG indicated focal disruption of the blood brain barrier (BBB; 
Figure 2E). The tumor vasculature was positive for the BBB-marker GLUT-1 throughout the 
tumor (Figure 2F). However, tumor cell-associated GLUT-1 or monocarboxylate transporters 
MCT1 and MCT4 were not present (Figure 2F and data not shown). The absence of these 
HIF1α-regulated hypoxia markers is in accordance with recent studies that show an inhibition 
of HIF1α expression induced by D-2HG and EGLN in IDH1-mutant tumor cells [292, 293].
D-2HG production in E478 xenografts
 D-2HG levels were determined in extracts of E478 xenografts using liquid chroma-
tography coupled to mass spectrometry (LC-MS) [90]. E478 tumor extracts contained highly 
elevated levels of D-2HG (34.5 nmol/mg protein vs < 0.2 nmol/mg protein in IDH1-wt E434 
xenografts; n=3, p<0.0001; Figure 3A). D-2HG levels in plasma of tumor-bearing mice were 
A B C 
D E F 
Figure 2. Phenotypic characteristics of the IDH1 mutant xenograft model. Low (A) and high (B) 
magnifications of H&E-stained sections of E478 xenografts in mouse brain, showing diffuse infiltration 
throughout both hemispheres (note that infiltrative strands of cancer cells are interspersed in white mat-
ter [B]). C) Ki-67 staining resulted in a proliferation index of approximately 34%. D) Immunohistochemi-
cal anti-CD34 staining shows abundant presence of florid microvascular proliferations. E) Immunostain-
ing of mouse IgG shows limited and focal leakage of IgG from the tumor vasculature. The arrowhead in 
the low-magnification inset indicates the area depicted. F) Blood vessels in the tumor express GLUT-1 
that is characteristic for endothelial cells forming the blood-brain barrier. Cancer cells do not express 
GLUT-1, indicating that the tumor is not hypoxic. Size bars in A: 1 mm, B-F 100 µm.
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not altered (data not shown) which is in agreement with the recent finding that plasma levels 
of D-2HG do not correlate with IDH1-mutation status in glioma patients [303].
 D-2HG levels in the brain extracts used in our LC-MS measurements varied highly 
(Figure 3A), a likely consequence of variations in tumor/stroma ratios in the extracts. To 
more reliably determine spatial D-2HG production in E478 xenografts, we used Quantinetix 
technology which allows sensitive and quantitative measurements of metabolites in situ in 
tissue sections using Liquid Extraction Surface Analysis (LESA) coupled to High Resolution 
Electrospray Mass Spectrometry (HR-ESI-MS) (Fig. 3B). Our measurements were performed 
in spots with a size of 0.12 mm2. Concentrations were expressed as heat maps, superim-
posed on histologically stained sections (Figure 3B). D-2HG levels were increased in tumor 
tissue only (60-820 µg D-2HG/g tissue; Table I), while much lower concentrations of the 
metabolite were detected in non-tumor brain areas and in healthy mouse brain. In line with 
the LC-MS measurements, the difference in D-2HG levels between IDH1-mutant tumors and 
normal brain was over 100-fold (3.1 vs 0.02 nmol/mg; Supplementary Table I). We also found 
significantly elevated levels of D-2HG in IDH1-wt glioblastoma xenografts as compared to 
normal brain, although the levels were lower than in IDH1-mutant tumors (approximately 10-
fold difference: 3.1 vs 0.33 nmol/mg). Indeed, it has been shown that wtIDH1 can convert 
α-KG to D-2HG. However, this reaction is hampered by competitive displacement of α-KG by 
isocitrate in the catalytic site under normal conditions [295]. A low isocitrate/α-KG ratio may 
thus result in D-2HG production as well. 
 In line with previous observations [90] we detected similar levels of α-KG in all tumor 
samples, both IDH1-mutant and -wt. There was a tendency towards higher levels in tumors 
compared to normal brain, although the levels were not significantly different. These findings 
suggest that the α-KG pool is maintained at physiological levels despite its depletion by 
conversion into D-2HG in the IDH1-mutant tumor. 
 In summary we show that in IDH1-mutant xenografts D-2HG levels are approxi-
mately 100-fold higher as compared to normal brain tissue and that these high levels are 
restricted to the tumor area. Moreover, α-KG levels are maintained at physiological levels in 
these tumors. 
 
NAD+- and NADP+-dependent dehydrogenase activity in E478 tumors
 IDH1-R132H expression is expected to result in diminished levels of α-KG in the cy-
Previous page:
Figure 3. D-2HG and α-KG levels in xenografts. A) D-2HG levels in extracts of xenograft-containing 
mouse brains from E478 IDH1-mutant and E434 IDH-wild type (wt) tumors as detected by LC-MS. B) In 
situ detection of D-2HG and α-KG levels in tumor sections using LESA-nano ESI-FTICR. Upper panel 
shows H&E stained sections of mouse brain (pink) with tumors (blue) from which tissue plugs were 
analysed. Lower panels show Quantinetix views of tissue plugs for 2-HG (m/z 147.032) and α-KG (m/z 
145.017) respectively. C) Quantification of D-2HG and α-KG levels in individual tissue plugs taken from 
control brain, IDH1-mutant xenografts and IDH-wt xenografts. Sample numbers encircled in grey rep-
resent plugs derived from the tumor core as shown in (B). D) Mean D-2HG and α-KG levels in control 
brain (ctr B), IDH1-mutant xenografts (m IDH) and IDH-wildtype xenografts (wtIDH). Note the difference 
in scale of the Y-axes in these graphs.  Levels of α-KG were very low as compared to D-2HG levels, but 
clearly detectable in all plugs.
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tosol. Since we did not observe detectable decreases in total cellular a-KG levels, we argued 
that E478 cells may depend on mitochondrial IDHs to generate α-KG for cytosolic use. To 
test this, 10 µm-thick cryostat sections of E478 and E434 oligodendroglioma xenografts were 
subjected to metabolic mapping to stain activity of NAD+- and NADP+-dependent IDHs and 
succinate dehydrogenase (SDH), as a read-out for mitochondrial activity. While E434 xeno-
grafts showed low activity of SDH and NAD+-dependent IDH (Figure 4A,C), the activities of 
these enzymes  were much more  prominent in E478 xenografts (Figure 4B,D). Although NA-
DP+-dependent IDH activity was higher than NAD+-mediated IDH activity in both xenografts 
(compare E,F to C,D), this increase was far more distinct in E478 xenografts (Figure 4F). The 
high NADP+-dependent IDH activity in E478 suggests that the cancer cells compensate the 
IDH1 defect by upregulating the activity of the mitochondrial IDH2. 
E434 (IDH1-wt)
IDH-NAD+
dependent
E478 (IDH1-R132H)
SDH
A
C
IDH-NADP
dependent
E
B
D
F
Figure 4. Metabolic mapping. Localization of activity of SDH (A,B), NAD+-dependent IDH (C,D) and 
NADP+-dependent IDH (E,F). The blue color represents the activity of the respective dehydrogenases 
after 15 minutes of incubation at 37°C. Note the high activities of mitochondrial dehydrogenases in E478 
xenograft as compared with the E434 xenograft. Bar = 100 µm. 
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 To further investigate the high mitochondrial activity in E478, we performed trans-
mission electron microscopy on a panel of glioma xenografts. Measurement of mitochondrial 
densities revealed a 2-fold increase in the number of mitochondria in the IDH1-mutant E478 
tumor cells as compared to those in E434 anaplastic oligodendroglioma and the E98 glio-
blastoma xenograft lines (Figure 5A-C).
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Figure 5. Transmission electron microscopy. Transmission electron microscopical micrographs of the 
increased mitochondrial density in E478 (A) as compared to E434 xenografts (B).  C) Quantification of 
mitochondrial densities in IDHwt E98 and E434 xenografts and IDH1-R132H E478 xenografts).
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Discussion
 
We here present a detailed histologic and metabolic characterization of the E478 IDH1-
R132H mutant oligodendroglioma xenograft line, the development of which has been de-
scribed before [92]. This line was established already in 2005, before the recognition of the 
involvement of IDH1/2-mutations in gliomagenesis. The E478 xenograft line has been grown 
successfully for over 35 passages now, is genetically stable and produces elevated levels of 
the oncometabolite D-2HG.
 It is still not completely understood how IDH1 mutations in gliomas contribute to tu-
morigenesis and at the same time are correlated to good prognosis as compared to gliomas 
with wtIDH [87, 304]. Likely, the effects are multifactorial. Elevated D-2HG levels have been 
proposed to result in a block of differentiation via epigenetic alterations [289], including the 
induction of a hypermethylated DNA phenotype [294]. Hypermethylation of genes encoding 
DNA repair enzymes such as MGMT is a predictor for the response to alkylating chemo-
therapy [305]. However prognosis of patients with IDH1 mutated glioma is not confined to 
those receiving chemotherapy, suggesting that other factors may also be important. Models 
such as the E478 xenograft may contribute to elucidate the underlying mechanisms of IDH 
mutations with respect to gliomagenesis and prognostic relevance. Our data indicate that 
some answers may be found in the field of tumor metabolism as we observed mitochondrial 
hyperactivity in E478 xenografts. It remains unfortunate that only a limited number of endog-
enous IDH1-R132H mutant glioma models is currently available [297, 298] making it difficult 
to confirm our findings in other models.
 We found that NADP+-dependent isocitrate conversion was not decreased in E478 
xenografts as compared to IDHwt glioma, indicating that cells compensate for loss of IDH1 
activity by increasing mitochondrial IDH2 activity by inducing mitochondrial biosynthesis. 
This is in agreement with our finding that α-KG levels are not diminished in E478 xeno-
grafts as compared to IDHwt tumors. These data suggest that D-2HG, rather than a short-
age of α-KG, is involved in the specific features of IDH1-mutated glioma and is in line with 
D-2HG-mediated competition of α-KG dependent enzymes. Yet, our measurements do not 
allow discrimination between mitochondrial and cytosolic α-KG levels, and a role for a specif-
ic depletion of the cytosolic pool of α-KG in tumor biology cannot be excluded. For instance, 
fatty acid synthesis is an essential condition for tumor growth, and requires cytosolic α-KG 
and acetyl-CoA as precursors [306]. Depletion of cytosolic α-KG may compromise lipid 
biosynthesis and might require import of mitochondrial α-KG into the cytosol. An attractive 
hypothesis is that such processes require a lot of energy for cell survival at the expense of 
extensive tumor cell proliferation. This may be a possible explanation for the better prognosis 
of patients with IDH-mutated gliomas. 
 An alternative manner to deal with decreased cytosolic α-KG, apart from increasing 
IDH2 activity, may be increased import of glutamine via specific importers in glioma cells. 
Glutaminase converts glutamine to glutamate which is subsequently converted to α-KG by 
glutamate dehydrogenase [307]. This metabolic adaptation may be in line with the increased 
dependency of IDH1-mutant gliomas on exogenous glutamine, the low levels of glutamate in 
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IDH1-mutant gliomas [91] and the sensitivity of these tumors to glutaminase inhibitors [308]. 
The relative contribution of these systems in α-KG homeostasis remains to be determined.
 It is still enigmatic why mutations in IDH genes are only found in the NADP+-depen-
dent enzymes. It is tempting to speculate that this is related to a specific aspect of NADP+ 
metabolism. During conversion of α-KG to D-2HG by IDH1-R132H, NADPH is oxidized to 
NADP+ and is not available for generation of reduced glutathione and other detoxifying sys-
tems [299]. As reduced glutathione is essential for scavenging reactive oxygen species 
(ROS), this may result in increased oxidative stress in IDH1-mutant glioma cells, a phenom-
enon that will be further augmented by increased mitochondrial density. Indeed, glutathione 
levels appear to be lower in IDH1-mutated tumors [91]. How IDH1-mutant tumors cope with 
this stress is currently under investigation in our laboratory.
 Based on our findings we propose that tumor cells that carry the IDH1 mutation 
undergo a metabolic switch involving increased mitochondrial activity leading to impaired 
proliferation and a relatively good prognosis. Cells acquiring IDH1 mutations will become tu-
morigenic based on the oncogenic activity of D-2HG, possibly in combination with acquired 
mutations in TP53 [293, 309]. Acquiring IDH1 mutations comes at a price however, as it will 
pose the cell with an excessive need for exogenous sources of α-KG for sustained mem-
brane synthesis. The increased requirement for α-KG results in an increased dependency on 
exogenous glutamine. Interestingly, glutamine is produced at high levels by glial cells and is 
under normal conditions used by neurons as a precursor for the neurotransmitter glutamate. 
It would be interesting to investigate whether the dependency on glutamine or glutamate as 
external carbon source has a causal relation to the diffuse infiltrative growth in neuroglial tis-
sue that is characteristic of diffuse gliomas. Indeed, such a dependency suggests that tumor 
cells would benefit from the nearby presence of non-neoplastic glial cells or neurons. 
 This model thus provides novel handles for metabolic targeting of low-grade glio-
mas. Especially inhibition of glutaminolysis may be an effective way to interfere with glioma 
metabolism, although the effects of such an intervention on neuronal glutamate function will 
require careful evaluation. Combination approaches to further increase redox stress and/or 
glycolysis may further arrest tumor cells. 
Conclusions
 The E478 xenograft line represents a stable tumor model with the endogenous 
IDH1-R132H mutation. We show that this model has high mitochondrial activity, produces 
high levels of D-2HG and maintains near-physiological levels of α-KG. We propose that this 
model will be of high value for investigating novel therapies for the large group of gliomas 
that carry IDH1-R132H mutations.
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Supplementary Figures and Table
Patient 
Aberration (hatched)
Xenograft 
Spheroids
Supplementary Figure S1. Detailed comparative array CGH analysis of the original anaplastic oli-
godendroglioma of the patient, E478 xenografts (P24) and a short-term spheroid culture derived 
from E478 (P25). Some losses were present in the xenograft which were not recognized in the original 
tumor of the patient (arrows). The magnitude of these losses was at a Log2 ratio of -0.35 (dotted line) as 
compared to an average Log2 ratio of -0.8 for the losses inherited from the originating tumor (dashed 
line). This corresponds to a relative copy number of 0.75 and 0.5, respectively. The 0.75 ratio originates 
from the tetraploid tumor background.
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Supplementary Figure S2. A) Ploidy analysis of E478 xenografts. Two cell cycles are detected, the dip-
loid peak (red) corresponds to the host-derived mouse cell fraction, the aneuploid (3.86N) peak (yellow) 
corresponds to the human cancer cell fraction. B) Allele-specific quantitative PCR discriminating wild 
type and IDH1-R132H mutant alleles. The quantity of IDH1-R132H is double that of the IDH1-wild type 
allele. 
Supplementary Table I. D-2HG and αKG levels in individ-
ual spots in sections of orthotopic xenografts carrying 
the IDH1-R132H mutation (grey) or wild-type IDH.
patient
Cycle Diploid Aneuploid 
% of total 15.25% 84.75% 
DI 1 1.93 
Ploidy 2 3.86 
Fraction Host Tumor 
2N
A
IDH1R132H
IDH1wt
B
amplification plot
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Supplementary Methods
Ploidy analysis
 Xenograft tissue was minced in NST buffer [146 mM NaCl, 10 mM Tris-HCl (pH 7.5), 
0.2% Nonidet P40] containing DAPI. Nuclei were disaggregated by repetitively passing the 
minced biopsies sequentially through a 20G and a 25G needle, followed by sequentially 
passing through 50-μm and 30-μm mesh filters. Flow cytometry was carried out using a BD 
Biosystems Aria II flow cytometer with UV excitation and DAPI emission collected at >450 
nm. DNA content and cell cycle were analyzed using ModFitLtsoftware (VSH).
Allele-specific PCR
 Allele-specific PCR was carried out using a custom TaqMan SNP Genotyping as-
say (Life Technologies) following the manufacturers’ instructions. Quantitative PCR reactions 
were carried out in triplicate in a reaction volume of 25 µl in a Viia7 Instrument (Life Tech-
nologies) with the following thermal cycler conditions: 10’ at 95°C each of 40 cycles of 15’’ 
at 92°C and 1’ at 60°C. DNA quantity was 20 ng per reaction. Primers used for amplification 
were: Forward 5’-CTTGTGAGTGGATGGGTAAAACCTA-3’, Reverse 5’-CCAACATGACT-
TACTTGATCCCCATA-3’. Taqman probes were: IDH1WT CATCATAGGTCGTCATGC (VIC) 
and IDH1R132H ATCATAGGTCATCATGC (FAM). All primers were human specific and do 
not amplify mouse sequences.
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General discussion
 Diffuse gliomas are malignant primary brain tumors that remain incurable to this 
date. Especially patients with a glioblastoma (GBM, WHO grade IV) suffer from a devastating 
prognosis with a median overall survival (OS) of only little over a year [9], but also for lower 
grade tumors no cure is currently available. A hallmark of diffuse gliomas is the wide spread 
invasion of tumor cells in the surrounding brain parenchyma. Higher-grade tumors also de-
velop regions with a more compact, angiogenic growth pattern. GBMs are currently surgi-
cally resected to the maximum feasible extend, followed by chemotherapy and irradiation. 
Standard therapy has been relatively ineffective for many reasons, not the least being the 
invasive growth of GBM cells into the normal brain. A better understanding of glioma biology 
and the evaluation of novel therapies in relevant preclinical models is urgently needed. 
Targeting angiogenesis
 Inhibiting angiogenesis has long been considered for GBM treatment, the rationale 
being that these tumors are highly angiogenic [310]. Early studies with agents like bevaci-
zumab in subcutaneous angiogenesis-dependent glioma xenograft models yielded prom-
ising results [311-313]. However, there has also been controversy towards the efficacy of 
anti-angiogenic therapy in neuro-oncology. In a preclinical model for metastatic angiogenic 
melanoma, anti-angiogenic therapy led to the development of invasive lesions in which tumor 
cells grew along pre-existent vasculature in brain, in contrast to the circumscribed and hy-
pervascular tumors in untreated controls [35]. Our results with both bevacizumab (VEGF-an-
tibody) and small molecule tyrosine kinase inhibitors (TKIs) of VEGFR2 in diffuse infiltra-
tive orthotopic human glioma xenografts confirm the lack of substantial anti-tumor activity 
of these therapies. Additional PDGFR inhibition to target more mature vessels in glioma did 
not improve survival in our models (Chapter 2) [127]. Moreover, we showed that targeting of 
the VEGF/VEGFR2 axis normalizes the tumor vasculature resulting in a lack of contrast-en-
hancement in MRI scans. The radiological response in the absence of tumor response is now 
an acknowledged epiphenomenon of anti-angiogenic treatment of brain cancers [130, 314]. 
Confirmation of our preclinical results has further been found in histopathological examina-
tion of GBM material from patients treated with bevacizumab, showing that highly invasive 
tumors remained present after therapy as well [52]. 
 Very recently, the results of two large phase III clinical trials applying anti-angio-
genic treatment for GBM (AVAGlio and RTOG 0825) were published [237, 238]. Both studies 
show that neo-adjuvant bevacizumab (combined with Temozolomide (TMZ)) treatment does 
not improve overall survival for patients in newly diagnosed GBM. This illustrates that the hy-
pothesis underlying these trials (‘GBMs are angiogenic tumors’) was too simple. Meanwhile, 
starting already two decades ago, a number of studies showed that GBMs contain large 
areas of angiogenesis-independent diffuse infiltrative growth in the richly vascularized brain 
parenchyma [45, 119, 315, 316]. One can thus expect that these parts are insensitive to 
anti-angiogenic therapy. Importantly, the vascular normalization induced by anti-angiogenic 
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treatment may even antagonize effects of simultaneously delivered systemic therapies [51]. 
An advantage of normalization on the other hand involves the reduced intracranial pressure 
that patients experience as a result of anti-angiogenic therapy. This result can also be ob-
tained with inexpensive corticosteroids that however do have quite severe side effects [317].
 In a search for alternative methods to visualize gliomas after anti-angiogenic ther-
apy, we compared contrast-enhanced (CE)-MRI with MR spectroscopic imaging (MRSI). 
MRSI measures metabolites instead of vessel leakiness and is not dependent on vascular 
status, enabling the detection of tumor based on metabolic characteristics. While tumors 
treated with angiogenesis inhibitors became invisible with CE-MRI, they could still be identi-
fied based on their metabolic profile (Chapter 3) [318]. 
 An interesting observation from our MRSI experiments was that our glioma xeno-
grafts do not seem to behave exclusively according to the Warburg effect. In normal cells 
under normoxic conditions glucose is used in mitochondrial oxidative phosphorylation to 
produce ATP. Under anaerobic conditions, full oxidation is not possible and cells will convert 
glucose, via pyruvate, to lactate, a process called glycolysis. Cells that are actively cycling 
have a high demand for energy but also for carbon sources to enable synthesis of lipids, 
amino acids and nucleotide precursors. Therefore, in these cells a substantial amount of 
glucose is directed towards the pentose phosphate pathway and towards glycolysis. The 
Warburg hypothesis states that tumors have characteristically reprogrammed their metabo-
lism towards glycolysis, also under aerobic conditions [319, 320]. It is a debate whether the 
Warburg hypothesis is valid for all tumor types. Glycolysis results in the production of lactate, 
which is a necessary carbon source for tumors, but yields 18 times less ATP than when 
glucose enters mitochondrial oxidative phosphorylation. Our MRSI experiments showed that 
lactate levels were very low in our diffuse glioma xenografts, except in areas where we could 
identify hypoxia. We therefore propose that the Warburg effect is not prominent in diffuse 
gliomas. Of note, glycolysis inhibitors like dichloroacetic acid (DCA) have been suggested 
to be of benefit for GBM patients [162]. Our data, however, suggest that only hypoxic tumor 
regions may be sensitive to glycolysis inhibition.
Targeting invasion
 As invasive growth is a major problem in gliomas, strategies are needed to tackle 
this problem. Effects of inhibitors of potential key players in invasive growth can be analyzed 
in preclinical models that imitate this phenotype. MET/HGF signaling is known to be involved 
in invasion in many cancers, and is implicated in glioma invasion as well [75]. MET or HGF 
inhibition decreases the growth of glioma xenografts [321], but studies with invasive glioma 
models have been lacking. We analyzed the potency of cabozantinib (XL-184, CoMETRIQ), 
an inhibitor of both MET and VEGFR2 tyrosine kinase activity that therefore may inhibit both 
invasion and angiogenesis (Chapter 4) [140]. In vitro, E98 cells are ‘addicted’ to MET, since 
inhibition leads to a highly efficient blockade in both proliferation and migration. Although 
not curative, treatment of mice carrying orthotopic E98 GBM xenografts did result in a sig-
nificant prolongation in median OS in these animals, a response that was not observed with 
any other VEGFR2 targeting TKI in our hands (Chapter 2) [127]. The tumors that eventually 
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developed still contained significant levels of activated MET. We postulate a model in which 
cabozantinib normalizes tumor vasculature, leading to impaired distribution of the agent to 
the tumor cells and reduced MET inhibition activity. It will be interesting to perform experi-
ments in which monospecific MET TKIs and angiogenesis inhibitors are given sequentially to 
(1) saturate the tumor cell compartment with MET inhibitors and (2),  ‘close’ the BBB to lock 
the inhibitor behind the barrier. Orthotopic glioma xenograft models can be used to deter-
mine the efficacy of such ‘metronomic’ treatments.
 
 A concern with targeted therapies in glioma involves resistance, as is seen in other 
tumor types. In metastatic melanoma for example, resistance to the BRAF-V600E inhibitor 
vemurafenib occurs within months [322, 323]. Also in glioma, targeted therapy will most likely 
involve inhibiting multiple targets to prevent such ‘phenotype switching’ [67, 228]. Interest-
ingly, MET activation is frequently implicated in resistance mechanisms that arise in tumor 
cells harboring BRAF activating mutations or constitutively active receptor tyrosine kinases 
(EGFR, HER2, FGFR, PDGFR, ALK; reviewed in [73]). Combined treatment with MET inhibi-
tors potentially could restore sensitivity in such cases. 
 Several inhibitors of HGF/MET signaling are currently tested in clinical trials, includ-
ing HGF- and MET-targeting antibodies, and MET TKIs. Interestingly, we observed that our 
E98 model, which responds well to the MET inhibitor cabozantinib contains an amplified, 
mutated MET, lacking exons 7 and 8 (Chapter 5). Importantly, this mutation affects the sub-
cellular localization of the MET protein, with METΔ7-8 being present intracellularly. Other MET 
mutations involving the tyrosine kinase domain also lead to (partial) intracellular localization 
[194]. The intracellular location of MET has implications for the choice of therapy. In contrast 
to TKIs, antibodies against MET will not have access to MET in case of intracellular location 
(Chapter 4) [140]. Antibody-based tumor targeting approaches in glioma are in general less 
promising, due to an at least partially intact BBB, which makes penetrance of large antibod-
ies in all tumor regions difficult. Even for many TKIs it is still uncertain to what extent they are 
able to pass the BBB. 
 Besides MET signaling, several other potential invasion-inhibiting agents are en-
tering GBM trials. For example, recentlytropomyosin-related kinase A (TrkA) has been impli-
cated as an important mediator of GBM migration [324]. TrkA expression is limited to highly 
invasive glioma xenograft regions and is activated by surrounding reactive astrocytes that 
secrete the ligand connective tissue growth factor (CTGF). TrkA activation by CTGF induces 
transcriptional changes, including a downregulation of E-cadherin. TrkA knockdown leads 
to compact tumors in vivo and it will be of interest to examine the effects of available TrkA 
inhibitors (e.g. Danusertib).
 The development of GBM may be driven by a number of oncogenic pathways [66]. 
Tyrosine phosphorylation by (receptor tyrosine) kinases like MET, EGFR, PDGFR and TrkA is 
essential in regulating these routes. We previously hypothesized that protein tyrosine phos-
phatases (PTPs) as the counteracting partners of PTKs must therefore have a similar impor-
tance [79]. Several PTPs are implicated in gliomagenesis, including PTPRZ-B. This receptor 
is involved in regulating glioma proliferation and migration in vitro, but also in xenograft mod-
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els (Chapter 6). Surprisingly, functional analysis of the different protein domains of PTPRZ-B 
revealed that not the protein tyrosine phosphatase catalytic domains but two distinct, spa-
tially separated protein interaction domains were essential for stimulating proliferation and 
migration, respectively. PTPRZ-B’s extracellular domain is indispensable for migration, while 
the intracellular C-terminal tail, representing a binding target for PDZ domains, is required 
for proliferation. This binding motif of PTPRZ-B is known to act as a docking site for multiple 
proteins, including PSD95 [262], MAGI-3 [263], MAGI-1, GOPC, Mupp1, Synj2bp, Snta1, 
Sntb1 and Veli-3 [264]. Exploration of the PDZ-domain-containing proteins that interact with 
PTPRZ-B’s C-terminus in GBM cells, for example via affinity purification and mass spectrom-
etry analysis, will provide insight in the interactions essential for the stimulatory role of PT-
PRZ-B on proliferation in glioma. Binding partners of PTPRZ-B’s extracellular domain include 
contactin-1 [251] and tenascin-C and R [261]. PTPRZ-B’s phosphatase activity is involved 
in regulating for example TrkA and β-catenin [264, 325]. All these interacting partners and 
substrates have also been linked to glioma adhesion and invasion [250, 253, 254, 267, 268, 
324]. Interestingly, we identified a novel link between PTPRZ-B expression and invasion, 
as knock-down of this PTP resulted in reduced phosphorylation levels of the MET kinase 
domain. Rather, increased phosphorylation levels would be expected for a candidate sub-
strate upon knock-down of PTPRZ. Interacting partners for PTPRZ-B like described above 
might form the missing link involved in regulating MET activation. Unraveling the mechanism 
underlying MET regulation by PTPRZ will be of interest to expand our understanding of both 
MET and PTPRZ-B in glioma invasion. The interacting partners 
 Very recently, translocation-induced fusion genes of PTPRZ and MET were de-
scribed in secondary GBMs (15%) and GBM cell lines (16%) [207]. In all cases, the most 
N-terminal part of PTPRZ1 is linked to almost the entire MET coding sequence (starts in 
intron 1). Overexpression of the PTPRZ-B/MET fusion in U87-MG cells promotes migration 
and invasion [207]. It would be interesting to further study the fusion product in relevant cell 
models, to see if the fusion affects cellular localization similar to MET∆7-8, and to determine the 
role of PTPRZ in the fusion protein.  
Targeting metabolism
 The relatively recent finding that the vast majority of diffuse low-grade and anaplas-
tic gliomas and secondary GBMs contain a specific mutation in IDH1 or IDH2, has brought a 
revolutionary change in the field of glioma research [85]. The specific mutations in these en-
zymes involved in cellular metabolism lead to the generation of the oncometabolite D-2-hy-
droxyglutarate (D-2HG), which influences the activity of enzymes critical for regulating the 
metabolic and epigenetic state of cells [91, 288-290, 293, 326]. D-2HG can be measured 
noninvasively in patients using 1H MRSI and may be a promising biomarker [327], although 
acquiring and analyzing the MRSI data for D-2HG is challenging and requires customization 
to avoid false-positive results [328]. 
 The effects of D-2HG as an oncometabolite on epigenetics have been a major focus 
of research, both in gliomas and acute myeloid leukemia (AML). Besided being involved 
in oncogenesis, it is predicted that IDH mutations have important implications on cellular 
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metabolism. D-2HG is generated from α-ketoglutarate (α-KG), which will therefore likely be 
depleted, affecting important cellular processes in which α-KG is involved, such as lipid syn-
thesis [306, 307, 329]. Possibly this explains why IDH mutant glioma cells are almost impos-
sible to culture. In vivo, cells must have adopted alternative mechanisms to replenish α-KG 
levels to concentrations that are compatible with tumor progression [90, 283] (Chapter 1, Fig-
ure 7). We have shown that in a unique endogenous IDH1-R132H mutant orthotopic glioma 
xenograft model, a significant increase in the density of mitochondria is present, compared 
to IDH wildtype tumors (Chapter 6) [330]. Mitochondrial biosynthesis and concomitantly 
increased IDH2 activity might be an adaptation that IDH-mutated cells use to cope with the 
lack of α-KG. Evidence that this is a common mechanism in IDH mutant gliomas is lacking, 
and (additional) anaplerotic pathways may be active as well. Investigations in this direction 
may open up ways towards novel treatment options. 
 The production of D-2HG consumes NADPH. Cytosolic NADPH, ~65% of which is 
produced by IDH1 [304], is extremely important for survival as it is involved in the production 
of reduced glutathione, protecting the cell to reactive oxygen radicals (ROS) which are pro-
duced especially during radiotherapy [331]. The reduced potential to detoxify ROS would 
predict that IDH-mutated gliomas are more susceptible to radiotherapy than IDH-wt tumors, 
although this remains to be determined. 
 Recently, specific inhibitors of IDH1-R132H have been developed which inhibit 
growth of subcutaneously implanted IDH1-R132H-mutated glioma xenografts [332]. Wheth-
er these inhibitors are effective in orthotopic models of IDH-mutated glioma is not known 
yet. In fact, considering that IDH mutations impose metabolic stress on glioma cells once 
neoplastic transformation has occurred, a relief of this metabolic stress by direct inhibition of 
IDH1-R132H may increase, rather than inhibit tumor progression.
 Interestingly, compared to IDH-wt cells IDH-mutant cells are more sensitive to inhib-
itors of glutaminase, the enzyme converting glutamine to glutamate [308]. As glutamate can 
be directly converted to α-KG via glutamate dehydrogenase (GDH), glutamate oxaloacetate 
transaminase (GOT) and glutamate pyruvate transaminase (GPT), a model for glutamine 
addiction has been proposed, in which glutamine, via glutamate, is used as fuel to maintain 
sufficient levels of α-KG needed for cell proliferation [307]. Glutamate is an important neu-
rotransmitter and is present in synaptic clefts but also in the white matter [333], a location 
where diffuse infiltrative glioma growth is often found. There is circumstantial evidence that 
IDH-mutated tumor cells import glutamate from their microenvironment. Low-grade gliomas, 
of which the majority carries an IDH mutation, express the excitatory amino acid transporter 2 
(EAAT2) [334]. This transporter is normally expressed by astrocytes to remove excess gluta-
mate from the interstitium to prevent excitotoxicity [335]. Expression of EAAT2 by low-grade 
glioma cells is at least suggestive for the capacity of these cells to import glutamate from the 
surroundings. Therefore, we propose that glutamate acts as a chemotactic compound for 
glioma cells and contributes to diffuse infiltrative growth [89, 336].
 The glutamate to α-KG conversion can effectively be blocked by relatively inexpen-
sive and safe inhibitors of GDH, such as epigallocatechine gallate (EGCG, an extract from 
green tea) [337, 338] and chloroquine (an anti-malaria drug) [339, 340]. As both compounds 
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have additional anti-tumor properties because they increase oxidative stress and inhibit au-
tophagy, studies of their putative anti-glioma properties might be in place. As MRSI is able 
to measure glutamine and glutamate, there might be an important role for this diagnostic 
modality in monitoring efficacy of metabolic therapy. 
 
Future perspectives
 Designing effective strategies for diffuse glioma therapy is a major challenge and 
requires a multimodality approach with ‘smart’ timing and dosing. With relatively little invest-
ment, clues for more effective treatments can be obtained using relevant orthotopic glioma 
models. Anti-angiogenic therapies have long been considered very promising for GBM treat-
ment. Unfortunately, after a lack of survival benefit was found using anti-angiogenic treat-
ment in preclinical orthotopic animal modelsm for diffuse glioma, recently two large phase 
III clinical trials have come to the same conclusion in patients with GBM. To improve patient 
outcome, therapeutic compounds should be able to cross the BBB and tackle the diffuse 
infiltrative glioma cells. In primary GBM, this might be done by inhibiting kinase pathways 
involved in invasion, like MET or TrkA signaling. We have shown that therapies targeting such 
receptors should be chosen with caution, since certain mutations affect subcellular local-
ization. The early onset and relatively high frequency of IDH mutations in diffuse low-grade 
and anaplastic gliomas and in secondary GBMs provides a therapeutic opportunity for this 
subset of gliomas. As these tumors have an altered metabolic demand, therapies influenc-
ing metabolic pathways are an attractive focus for future studies. We have characterized a 
novel IDH1-R132H mutant model that will be instrumental in testing the concept of metabolic 
targeting.  
 Now that the field is recognizing the importance of cell and animal models that faith-
fully mimic glioma pathology, and novel diagnostic techniques rapidly add to the database 
of genetic aberrations in glioma specimens, there is a solid starting ground to start designing 
and testing innovative, personalized therapeutic regimes to combat this tumor.

 &SummaryNederlandse samenvatting
Reference list
Dankwoord
List of publications
About the author

 Summary
158
&
Summary
	 Gliomas	are	primary	brain	tumors	that	are	notoriously	difficult	to	treat.	This	is	for	a	
major	part	caused	by	their	unique	growth	pattern.	Both	low-	and	high-grade	gliomas	are	gen-
erally	characterized	by	diffuse	 infiltration	of	 tumor	cells	 throughout	 the	brain	parenchyma,	
with	high-grade	gliomas	also	 focally	presenting	with	hypoxia,	angiogenesis	and	necrosis.	
Especially	patients	with	the	most	malignant	subtype,	the	glioblastoma	(GBM),	have	a	devas-
tating	prognosis	of	only	little	over	one	year	after	diagnosis.	This	urges	for	improvements	in	
glioma	treatment.
	 The	major	aim	of	this	study	was	to	evaluate	promising	therapeutic	agents	to	target	
diffuse	infiltrative	gliomas	in	representative	preclinical	models	and	to	develop	leads	for	future	
therapeutic	strategies.	We	used	different	approaches	to	interfere	with	growth	of	glial	tumors,	
using	compounds	 that	 inhibit	 angiogenesis	 (Chapter 2, 3)	 and	 tyrosine	 kinase	 receptors	
(Chapter 4, 5),	and	using	RNAi-based	knock-down	of	a	protein	tyrosine	phosphatase	(Chap-
ter 6).	Also	we	suggest	ways	to	target	glioma	metabolism	(Chapter 7).	
 In Chapter 2 we analyzed the effects of multiple small molecule inhibitors of VEGF 
and	PDGF	receptors	and	of	the	VEGF-antibody	bevacizumab	in	different	animal	models	of	
glioma.	GBMs	present	with	 highly	 vascularized	 tumor	 areas	 as	 a	 result	 of	 angiogenesis,	
which	led	to	the	hypothesis	that	these	tumors	are	promising	candidates	for	anti-angiogenic	
therapy.	We	used	the	orthotopic	human	glioma	xenograft	models	E98	and	E473	that	both	
develop	as	invasive	lesions	with	some	compact,	angiogenic	regions.	Treatment	with	VEG-
F(R)	 inhibitors	resulted	in	a	reduced	contrast	enhancement	 in	MRI	for	all	agents,	together	
with	an	increase	in	hypoxia	in	compact	tumor	regions.	However,	there	was	no	effect	on	ani-
mal	survival.	Additional	inhibition	of	PDGFR,	which	is	important	in	vessel	maturation,	did	not	
improve	 the	effects	of	 targeting	VEGF/VEGFR2	alone.	Anti-angiogenic	agents	all	 reduced	
permeability	of	the	blood	brain	barrier	(BBB)	in	compact	tumor	regions,	thereby	leading	to	a	
loss	of	contrast	enhancement	(CE)	in	magnetic	resonance	imaging	(MRI).	The	effects	of	an-
giogenesis	inhibition	on	glioma	growth	remained,	however,	minor	and	VEGF	inhibitors	might	
even	stimulate	a	more	invasive	phenotype.
	 The	observed	pseudoresponse	induced	by	anti-angiogenic	therapy	in	CE-MRI	was	
further	examined	in	the	study	reported	in	Chapter 3.	We	tested	the	hypothesis	that	multivoxel	
1H	MR	spectroscopic	imaging	(MRSI),	a	non-invasive	technique	that	enables	the	specific	de-
tection	of	(tumor-specific)	metabolites,	is	able	to	identify	tumors,	even	after	anti-angiogenic	
treatment.	Mice	with	orthotopic	GBM	xenografts	were	treated	with	either	the	small	molecule	
inhibitor	cabozantinib	(a	combined	VEGFR2/MET	 inhibitor)	or	bevacizumab.	Treated	mice	
were	subjected	to	CE-MRI	and	1H	MRSI,	and	metabolic	maps	were	correlated	to	histology.	
Whereas	CE-MRI	did	not	visualize	tumors	after	 treatment,	 these	were	readily	visualized	 in	
metabolic	maps	showing	Cho/NAA	ratios.	Furthermore,	multivoxel	MRSI	revealed	increased	
lactate	 levels	as	a	 result	 of	bevacizumab-treatment,	but	predominantly	 in	compact	 tumor	
regions.	This	was	confirmed	in	the	brains	of	these	animals	by	immunohistochemistry	for	a	
number	of	hypoxia	markers.	Our	data	suggest	that	gliomas	are	at	least	partly	independent	
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of	glycolysis	for	their	energy	metabolism,	in	contrast	to	many	other	tumor	types	that	do	show	
this	Warburg	phenomenon. 
 Since	the	tyrosine	kinase	receptor	MET	is	strongly	implicated	in	invasive	behavior	in	
many	tumor	types,	in	Chapter 4	we	analyzed	the	potential	of	MET-targeting	as	a	therapeutic	
approach	for	glioma.	Inhibitors	such	as	cabozantinib,	which	target	both	MET	and	VEGFR2,	
allow	the	simultaneous	targeting	of	tumor	cells	and	stroma.	E98	glioma	cells	express	high	
levels	of	activated	MET	and	are	very	sensitive	to	MET	inhibition	in vitro,	as	evidenced	by	ef-
fects	on	both	proliferation	and	migration.	In vivo,	cabozantinib	therapy	induced	a	significant	
increase	 in	 overall	 survival,	 in	 contrast	 to	VEGF/VEGFR2	 inhibition	 alone	as	described	 in	
Chapter	2.	Eventually,	however,	tumors	recurred	and	activated	MET	could	still	be	detected.	
We	hypothesized	that	targeting	VEGFR2,	which	induces	changes	in	BBB	passage,	prohibits	
proper	distribution	of	cabozantinib	to	the	tumor,	making	MET	inhibition	incomplete.	
	 We	further	evaluated	the	in vitro sensitivity	of	E98	cells	to	MET	inhibition. Interest-
ingly,	MET	activation	in	E98	is	independent	of	ligand	binding.	In	Chapter 5 we	identified	a	
novel MET mutation	in	E98.	The	resulting	MET	protein	lacks	a	small	extracellular	segment,	
involving	two	IPT	domains.	This	protein,	termed	METΔ7-8,	is	inefficiently	processed	and	mainly	
localizes	intracellularly.	The	absence	of	MET	on	the	cell	surface	has	important	implications	
for	therapeutic	strategies,	because	this	mutant	will	not	be	accessible	to	therapeutic	antibod-
ies.	METΔ7-8	RNA	has	been	found	in	6%	of	the	gliomas	analyzed	so	far,	as	well	as	in	14%	of	
non-small	cell	lung	carcinomas.	Larger	studies	are	required	to	further	exploit	the	prevalence	
of	this	MET	mutant	and	the	consequences	for	targeted	treatment.
	 Tyrosine	 kinase	 receptors	 like	MET	 and	EGFR	are	 evidently	 important	 in	 glioma	
signaling.	Kinase	activity	of	these	receptors	is	controlled	by	protein	tyrosine	phosphatases	
(PTPs).	In	Chapter 6	we	evaluated	the	importance	of	PTPRZ-B	in	glioma	biology.	PTPRZ-B	is	
a	transmembrane	PTP	that	is	frequently	overexpressed	in	gliomas.	We	showed	that	lentiviral	
downregulation	of	PTPRZ	inhibited	proliferation	and	migration	in	E98	GBM	and	E434	ana-
plastic	oligodendroglioma	cell	lines,	both	in vitro and in vivo.	Interestingly,	proliferation	and	
migration	were	 regulated	by	different	protein	domains,	while	phosphatase	activity	did	not	
seem	to	be	involved.	Furthermore,	our	data	points	towards	a	role	for	PTPRZ-B	in	regulating	
MET	expression	and/or	degradation.				
 In Chapter 7	we	 focused	on	 tumor	metabolism.	Since	 IDH1 and IDH2 mutations 
have	been	 identified	 in	 the	majority	of	diffuse	 low-grade	and	anaplastic	gliomas	and	sec-
ondary	GBMs,	 targeting	 tumor	metabolism	has	gained	 interest.	Although	 these	mutations	
are	relatively	common,	representative	xenograft	models	are	scarce.	In	this	study	we	have	
characterized	one	of	 our	 xenograft	models,	developed	 from	a	 recurrent	 anaplastic	oligo-
dendroglioma,	which	contains	the	classical	IDH1-R132H	mutation.	The	model	is	genetically	
stable	and	has	remained	tumorigenic	for	over	30	passages.	The	xenografted	tumor	is	inva-
sive	in	the	mouse	brain	parenchyma	and	produces	the	oncometabolite	D-2-hydroxyglutarate	
(D-2HG).	Mutant	IDH1/2	represents	a	novel	attractive	target	for	therapeutic	strategies,	and	
our	model	is	a	powerful	asset	to	evaluate	such	approaches.		
 In this thesis diffuse gliomas were targeted using various approaches and concepts 
for	future	strategies	were	developed.	In	the	concluding	Chapter 8,	the	potency	of	targeting	
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angiogenesis,	tyrosine	kinase	receptors	and	protein	tyrosine	phosphatases	is	evaluated.	In-
hibiting	angiogenesis	has	now	been	examined	extensively	in	both	animal	models	and	clinical	
trials.	Studies	performed	by	us	and	others,	using	models	that	represent	the	invasive	glioma	
phenotype,	have	been	predictive	 for	 the	negative	 results	of	 recent	phase	 III	clinical	 trials	
with	bevacizumab	as	a	first	 line	treatment	for	primary	GBM.	These	trials	showed	a	lack	of	
improved	overall	survival	in	primary	GBM	patients.	The	lack	of	efficacy	on	patient	survival	is	
discouraging,	but	re-emphasizes	the	need	for	novel	therapeutic	strategies.	At	least	for	a	sub-
set of glial tumors IDH mutations might provide clues for novel therapeutic approaches since 
these	mutations	have	great	impact	on	the	metabolic	state	of	the	cell.	We	present	the	novel	
hypothesis that IDH-mutated	gliomas	depend	on	glutamate	 from	 the	 tumor	microenviron-
ment	to	ensure	the	continuous	generation	of	α-KG	and	NADPH.	This	warrants	investigations	
towards	therapeutic	strategies	with	inhibitors	of	GDH,	such	as	EGCG	(a	green	tea	extract)	
and	chloroquine	(an	anti-malaria	drug).	
	 In	conclusion,	diffuse	gliomas	 represent	an	extreme	challenge	 for	curative	 treat-
ment.	Therapeutic	agents	should	not	(only)	inhibit	angiogenesis,	but	also	be	able	to	cross	
the	BBB	and	tackle	the	diffuse	infiltrative	growth	of	these	tumors	in	the	brain	parenchyma.	In	
primary	GBM	this	might	be	done	by	influencing	pathways	involved	in	invasion,	like	MET	sig-
naling,	with	specific	small	molecule	inhibitors.	However,	the	high	frequency	of	IDH mutations 
in	gliomas	implicates	that	there	might	be	a	different	‘Achilles	heel’	in	these	tumors.	IDH mu-
tant	gliomas	may	be	sensitive	to	therapies	influencing	tumor	metabolism	in	combination	with	
radiotherapy,	and	studies	analyzing	this	in	relevant	models	are	urgently	needed.	Eventually,	
a smart combination of different therapies will likely be required to improve the prognosis of 
patients	suffering	from	these	gliomas.	
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  Gliomen zijn primaire hersentumoren die notoir moeilijk te behandelen 
zijn.	Dit	wordt	voor	een	groot	deel	veroorzaakt	door	de	bijzondere	groeiwijze	van	deze	tu-
moren.	Zowel	laag-	als	hoog-gradige	gliomen	worden	meestal	gekarakteriseerd	door	diffuus	
infiltratieve	 groei	 van	 tumor	 cellen	 in	 het	 hersenparenchym.	 Hooggradige	 gliomen	 tonen	
daarnaast	 locaal	 ook	 hypoxie,	 angiogenese	en	necrose.	 Vooral	 het	meest	 kwaadaardige	
subtype,	het	glioblastoom	(GBM),	heeft	een	zeer	slechte	prognose	met	een	mediane	over-
leving	van	net	iets	meer	dan	een	jaar.	Het	doel	van	de	studies	beschreven	in	dit	proefschrift	
was	om	(mogelijk)	beloftevolle	therapieën	te	evalueren	in	representatieve	modelsystemen	en	
aanwijzingen te vinden voor nieuwe aangrijpingspunten om de groei van diffuse gliomen te 
remmen.	We	hebben	gliomen	proberen	aan	te	pakken	op	een	aantal	verschillende	manieren,	
welke	beschreven	zijn	in	de	hoofdstukken	2-7.	
 In Hoofdstuk 2	analyseerden	we	de	effecten	van	meerdere	zgn.	 ‘small	molecule	
inhibitors’	van	VEGF	receptoren	en	van	het	anti-VEGF	antilichaam	bevacizumab	in	verschil-
lende	diermodellen	van	glioma.	We	gebruikten	hiervoor	de	orthotope	humane	glioma	xe-
nograft	modellen	E98	en	E473	welke	beiden	invasief	groeien	met	ook	plaatselijk	een	meer	
compacte,	angiogenese-afhankelijke	component.	Dit	groeipatroon	is	goed	vergelijkbaar	met	
dat	van	de	tumor	bij	glioma	patiënten.	VEGF(R)	remming	resulteerde	bij	alle	geteste	mid-
delen	in	een	radiologische	respons	en	een	lokale	toename	van	hypoxie.	Er	was	echter	geen	
effect	op	overleving	van	de	dieren.	Additionele	remming	van	PDGFR,	welke	van	belang	is	
voor	de	rijping	van	vaatstructuren,	verbeterde	de	effecten	van	VEGF(R)	inhibitie	niet.	Alle	an-
ti-angiogene	middelen	zorgden	voor	een	(gedeeltelijk)	herstel	van	de	bloed-hersen	barriere,	
met name in compacte tumor gebieden waar deze barrierefunctie sterk verslechterd is door 
de	activiteit	van	VEGF.	Dit	resulteerde	in	afwezigheid	van	lekkage	van	MR	contrast	middel	in	
de	tumor,	en	dientengevolge	een	slechte	zichtbaarheid	op	MRI	scans,	ook	na	contrast-toe-
diening.	De	effecten	van	remming	van	angiogenese	remming	op	groei	van	gliomen	bleven	
echter	minimaal.	We	observeerden	zelfs	dat	de	angiogenese-remmers	mogelijk	 invasieve	
groei	stimuleerden.	
	 De	pseudoresponse	in	MRI	met	contrast	middelen	welke	wordt	geïnduceerd	door	
anti-angiogene	therapieen	werd	verder	onderzocht	in	de	studie	beschreven	in	Hoofdstuk 
3.	We	testten	de	hypothese	dat	multivoxel	1H-MR	spectroscopische	imaging	(MRSI),	een	ni-
et-invasieve	techniek	welke	in	staat	is	om	(tumor-specifieke)	metabolieten	te	detecteren,	gli-
omen	kan	visualiseren,	onafhankelijk	van	de	bloed	hersen	barriere	en	dus	ook	na	anti-angio-
gene	therapie.	Muizen	met	orthotope	(dat	wil	zeggen:	in	de	hersenen	gelocaliseerde)	glioma	
xenografts	werden	behandeld	met	de	small	molecule	inhibitor	cabozantinib	(een	gecombi-
neerde	MET/VEGFR2	inhibitor)	of	bevacizumab.	Behandelde	muizen	werden	geanalyseerd	
met	zowel	CE-MRI	als	1H-MRSI	en	metaboliet-beelden	werden	gecorreleerd	met	histologie.	
Terwijl	CE-MRI	(vrijwel)	geen	aankleuring	liet	zien	van	de	tumoren	na	behandeling,	waren	
deze	wel	te	detecteren	met	behulp	van	metabole	maps	van	choline/NAA	ratio’s.	Verder	liet	
multivoxel	MRSI	verhoogde	lactaat	levels	zien	als	een	resultaat	van	bevacizumab-behandel-
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ing,	maar	voornamelijk	in	compacte	tumor	gebieden.	Dit	werd	bevestigd	met	immuunhisto-
chemie	voor	verscheidene	hypoxie	markers.	Onze	resultaten	suggereren	dat	gliomen	gro-
tendeels	onafhankelijk	zijn	van	glycolyse	voor	hun	energie	metabolisme,	dit	in	tegenstelling	
tot	veel	andere	tumortypes	waarbij	dit	zgn.	Warburg-effect	wel	bestaat.
 In Hoofdstuk 4	analyseerden	we	hoe	beloftevol	MET-inhibitie	is	als	therapie	voor	
glioma.	Deze	tyrosine	kinase	receptor	laat	een	sterke	link	met	invasie	zien	in	verschillende	
tumoren.	Remmers	 zoals	 cabozantinib,	welke	 zowel	 tegen	MET	 als	 VEGFR2	 zijn	 gericht,	
zouden in principe in staat moeten zijn om zowel –groei en migratie van tumorcellen als 
angiogenese	te	remmen.	E98	gliomacellen	hebben	hoge	expressieniveaus	van	geactiveerd	
MET	en	zijn	erg	gevoelig	voor	MET	 inhibitie	 in vitro,	met	effecten	op	zowel	proliferatie	als	
migratie.	In	orthotope	glioma	xenografts resulteerde	therapie	in	een	significante	verlenging	
van	overleving.	Dit	in	tegenstelling	tot	VEGF/VEGFR2	inhibitie	alleen	(zie	Hoofdstuk	2).	
 In Hoofdstuk 5	beschreven	we	dat	MET	activatie	in	E98	onafhankelijk	is	van	ligand	
binding.	We	identificeerden	een	nieuwe	mutatie	in	het	MET	gen,	welke	leidt	tot	de	expressie	
van	een	getrunceerde	MET	variant	met	een	kleine	deletie	van	IPT	domeinen	in	E98.	Deze	
zgn.	METΔ7-8	wordt	 inefficiënt	 ‘geprocessed’	en	komt	niet	op	het	celmembraan	tot	expres-
sie.	De	intracellulaire	localisatie	heeft	belangrijke	consequenties	voor	therapeutische	strat-
egieën.	Zo	zal	METΔ7-8	niet	toegankelijk	zijn	voor	therapeutische	antilichamen.	Het	mutante	
transcript	is	tot	nu	toe	gevonden	in	6%	van	de	gliomen	(n=102)	en	daarnaast	ook	in	14%	van	
de	niet-kleincellige	longcarcinomen	die	door	ons	zijn	onderzocht	(n=21).	Meer	onderzoek	is	
nodig om de prevalentie van deze mutatie en de consequentie voor behandeling met ‘target-
ed’	medicijnen	beter	in	kaart	te	brengen.
	 Tyrosine-kinase-receptoren	 zoals	MET	en	EGFR	 zijn	 belangrijk	 in	 oncogene	 sig-
nalering.	Kinase-activiteit	 van	deze	 receptoren	wordt	gecontroleerd	door	 ‘protein	 tyrosine	
phosphatases’	(PTPs).	In	Hoofdstuk 6	evalueerden	we	het	belang	van	PTPRZ-B	in	glioma	
biologie.	PTPRZ-B	is	een	transmembraan	PTP	welke	frequent	tot	overexpressie	komt	in	glio-
men.	We	lieten	zien	dat	zowel	in vitro als in vivo	lentivirale	downregulatie	van	PTPRZ	prolifer-
atie	én	migratie	remt	in	het	E98	GBM	en	het	E434	oligodendroglioma	model. Deze processen 
worden	gereguleerd	door	verschillende	domeinen	van	het	eiwit:	het	extracellulaire	deel	 is	
betrokken	bij	migratie,	terwijl	het	intracellulair	deel	proliferatie	stimuleert.	Verder	suggereren	
onze	data	dat	PTPRZ-B	betrokken	is	bij	het	reguleren	van	MET	expressie	en/of	degradatie.	
 IDH1 en IDH2 mutaties komen voor in het overgrote deel van de laaggradige en 
anaplastische	diffuse	gliomen	en	van	secundaire	GBMs,	maar	er	zijn	vrijwel	geen	glioma	
xenograft-modellen	met	endogene	 IDH	mutaties	beschikbaar.	 In	de	studie	beschreven	 in	
Hoofdstuk 7 hebben we één	van	onze	xenograft	modellen	 (E478)	uitgebreid	gekarakteri-
seerd.	Dit	model	werd	ontwikkeld	door	intracerebrale	implantatie	in	een	immuundeficiente	
muis	van	een	celsuspensie,	afkomstig	van	een	chirurgisch	verkregen	recidief	anaplastisch	
oligodendroglioma met een klassieke IDH1-R132H	mutatie.	Dit	model	groeit	deels	invasief	
in	het	hersenparenchym	en	produceert	het	oncometaboliet	D-2-hydroxyglutaraat	(D-2HG).	
Alhoewel	graad	II	en	III	gliomen	en	vooral	secundaire	GBMs	een	spectrum	van	genetische	
veranderingen	laten	zien	en	onderling	heterogeen	zijn,	zijn	IDH mutaties veelvoorkomend en 
waarschijnlijk	causaal	in	deze	tumoren.	Dit	maakt	IDH	mutaties	erg	interessant	voor	nieuwe	
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therapeutische	strategieën.	Ons	model	kan	een	belangrijke	rol	spelen	bij	de	evaluatie	van	
zulke	benaderingen.
 Samengevat hebben we in dit onderzoek verscheidene methoden geanalyseerd 
om	invasieve	gliomen	te	behandelen.	In	Hoofdstuk 8 houden we de potentie van deze ver-
schillende	therapieën	nog	eens	tegen	het	licht.	Angiogenese-inhibitie	is	uitgebreid	geanal-
yseerd	in	zowel	diermodellen	als	ook	in	klinische	trials.	Onderzoeken	van	ons	en	anderen,	
welke gebruik maakten van modellen welke het invasieve glioma groeigedrag goed repre-
senteerden,	 zijn	predictief	 gebleken	 voor	de	 resultaten	 van	grote	 recente	 klinische	 trials.	
Twee	fase	III	trials	met	bevacizumab	hebben	nu	bevestigd	dat	anti-angiogene	therapie	geen	
effect	heeft	op	overleving	van	patiënten	met	een	GBM.	Het	gebrek	aan	effect	op	overleving	
is	ontmoedigend,	en	maakt	duidelijk	dat	nieuwe	strategieën	onderzocht	moeten	worden	om	
deze	tumoren	meer	effectief	te	behandelen.	Voor	een	deel	van	de	diffuse	gliomen	zouden	
IDH1/2 mutaties mogelijk een aangrijpingspunt kunnen bieden voor toekomstige behandelin-
gen,	omdat	deze	mutaties	een	grote	impact	hebben	op	de	metabole	staat	van	de	cel.	We	
formuleren de nieuwe hypothese dat IDH-gemuteerde	gliomen	afhankelijk	zijn	van	glutamaat	
vanuit	het	omliggende	brein	om	te	voorkomen	dat	er	tekorten	aan	α-KG	en	NADPH	ontstaan	
door	de	productie	van	D-2HG.	De	aanvoer	van	glutamaat	kan	(deels)	geblokkeerd	worden	
via	de	remming	van	GDH	via	EGCG	(de	actieve	component	van	groene	thee)	en	chloroquine	
(een	anti-malaria	drug)	in	IDH mutante	tumoren.
 De meeste patienten met een diffuus glioom hebben momenteel nog steeds een 
zeer	slechte	prognose.	Om	dit	 te	verbeteren	moeten	therapieën	niet	alleen	aangrijpen	op	
angiogenese,	maar	ook	in	staat	zijn	om	de	BBB	te	passeren	en	de	diffuus	infiltratieve	groei	
van	deze	tumoren	te	remmen.	In	primaire	GBM’s	zou	dit	gedaan	kunnen	worden	door	paden	
te	beïnvloeden	welke	betrokken	zijn	bij	invasie,	zoals	MET	signalering,	met	specifieke	rem-
mers.	Echter,	de	hoge	frequentie	van	IDH1/2 mutaties in subsets van gliomen impliceert een 
andere	Achilles	hiel	in	deze	tumoren.	IDH mutante gliomen zouden gevoelig kunnen zijn voor 
therapieën	welke	het	metabolisme	beïnvloeden	in	combinatie	met	radiotherapie.	Studies	in	
relevante	modellen	zijn	van	groot	belang	om	dit	verder	uit	 te	zoeken.	Uiteindelijk	zal	een	
slimme	combinatie	en	timing	van	verschillende	therapieën	noodzakelijk	zijn	om	de	prognose	
van	glioma	patiënten	te	kunnen	verbeteren.	
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Dankwoord
 Yes,	het	is	ein-de-lijk	af!	Ondanks	al	mijn	goede	voornemens	heeft	dit	proefschrift	
toch	een	hele	tijd	op	zich	laten	wachten.	Alles	wat	je	had	kunnen	lezen	in	de	voorgaande	
hoofdstukken voordat je snel doorbladerde naar dit dankwoord had ik niet kunnen doen 
zonder	de	hulp	van	vele	anderen.	Hoog	tijd	dus	om	een	aantal	mensen	te	bedanken!
 Allereerst Pieter,	 jij	gaf	me	de	kans	om	 te	beginnen	als	promovenda	binnen	de	
neuro-oncologie.	Het	was	fijn	om	dit	onderzoek	onder	 jouw	deskundige	supervisie	 te	mo-
gen	uitvoeren	en	ik	ben	je	gaan	waarderen	als	wetenschapper	maar	zeker	ook	als	mens.	
Ondanks	jouw	immer-drukker	wordende	agenda	vond	jij	steeds	de	tijd	om	op	korte	termijn	
te	overleggen,	samen	coupes	te	bekijken	of	snel	manuscripten	te	herzien,	maar	je	was	ook	
altijd	geïnteresseerd	in	hoe	het	verder	ging.	Ik	ben	benieuwd	naar	de	aanstaande	vernieu-
wing	van	de	glioma	classificatie	waarin	jij	zeker	een	belangrijke	rol	zult	spelen.	
 William,	jouw	bijdrage	aan	het	gereed	komen	van	dit	boekje	was	zonder	twijfel	zeer	
groot.	We	hebben	heel	wat	overleggen,	brainstorms,	en	microscopie	sessies	achter	de	rug,	
onder	het	genot	(?)	van	liters	koffie.	Jouw	kritische	blik	en	gave	om	out-of-the-box	te	kunnen	
denken	zijn	duidelijk	terug	te	vinden	in	dit	proefschrift.	Na	het	harde	werken	was	je	ook	altijd	
in	voor	een	drankje	bij	de	Aesculaef	of	een	last-minute	borrel	in	huize	Leenders.	Dank	voor	
alle	mogelijkheden	die	 je	me	hebt	gegeven,	ook	om	aan	het	glioma	onderzoek	te	kunnen	
blijven	werken.	
	 Beste	Wiljan,	dit	hele	promotietraject	was	waarschijnlijk	niet	door	mij	uitgevoerd	als	
ik	geen	scriptie	over	gliomen	en	PTPs	bij	 jou	had	mogen	schrijven.	Dit	was	het	begin	van	
een	mooie	samenwerking,	een	gezamenlijk	PTP	review	en	een	blijvende	voorliefde	voor	de	
receptor	 tyrosine	kinase	en	fosfatase	signalering.	Onze	overleggen	werden	door	 jou	altijd	
voorzien	van	verhelderende	uitleg.	Alle	handremmen	en	gaspedaaltjes	die	de	tumorcel	geb-
ruikt	om	ons	te	slim	af	te	zijn	werden	erbij	gehaald.	Dank	voor	de	goede	samenwerking.
 Lieve paranimfen Kiek en Sanne,	met	jullie	deel	ik	ondertussen	al	geruime	tijd	veel	
lab	 lief-en-leed.	Super	dat	 jullie	mijn	paranimfen	willen	 zijn!	Kiek,	 opperhoofd	 kleuringen,	
koffiemaatje	en	mede-liefhebster	van	de	blaasmuziek.	Je	hebt	heel	wat	van	mijn	muizenbre-
intjes	voorzien	van	mooie	(dubbel)kleuringen.	Bij	jou	kan	ik	gelukkig	altijd	aankloppen	voor	
nuttig	advies	over	daadwerkelijk	alles.	Sanne,	onze	creatieveling.	Dankzij	jou	worden	al	onze	
ijsboxen	tegenwoordig	opgefleurd	door	mooie	labkonijnen	en	dergelijke.	Je	bent	een	echte	
metabolisme	slimmerik,	of	verklap	ik	nu	een	goed	bewaard	geheim?	Succes	met	de	laatste	
loodjes	en	je	plan	om	binnen	4	jaar	te	promoveren!
	 Tijdens	mijn	promotietijd	(en	het	verlengde	daarvan)	is	de	samenstelling	van	onze	
onderzoeksgroep	 flink	 aan	 verandering	 onderhevig	 geweest.	 Verschillende	 mensen	 zijn	
vertrokken,	maar	gelukkig	kwamen	er	ook	anderen	bij.	Allereerst	Sander,	onze	conjugati-
eman.	Dankzij	jou	zijn	onze	protocollen	voor	VHH	productie	en	conjugatie	tot	in	de	puntjes	
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uitgezocht.	 Bedankt	 voor	 alle	 hulp	 bij	 het	 sortaggen	 en	 klikken.	 En	Krissie,	 ben	 je	 echt	
nog	maar	net	begonnen?	Stapels	celkweekflessen	in	de	stoof,	allerlei	nieuwe	Western	blot	
tools,	en	uiteraard	ook	nog	het	organiseren	van	de	VriMiBo(rrel),	dat	belooft	nog	wat	voor	de	
komende	jaren!	Ook	Carlijn heel	veel	succes	met	het	palbociclib	project.	De	Fucci-filmpjes	
zijn	in	ieder	geval	al	prachtig!	
 An,	in	mijn	begintijd	als	junior	onderzoeker	heb	jij	me	alle	kneepjes	van	het	proef-
dierwerk bijgebracht. Jij	had	al	een	mooie	basis	gelegd	voor	het	dierexperimenteel	werk	en	
kon	me	gelukkig	in	jouw	laatste	maandjes	op	het	lab	nog	goed	op	gang	helpen.	Veel	dank	
daarvoor.	Judith,	 jij	 hebt	me	wegwijs	 gemaakt	 in	 de	 genetica	 van	 de	 gliomen.	Ons	 ge-
zamenlijke	bezoek	aan	de	SNO	in	Montreal	was	super,	inclusief	onze	top	floor	room.	Jammer	
dat	je	de	neuro-oncologie	hebt	verlaten,	maar	heel	begrijpelijk	voor	zo’n	mooie	nieuwe	baan.	
Bastiaan,	jij	hebt	onze	glioma	genetica	helemaal	hip	gemaakt	met	de	nieuwste	sequencing	
technieken.	Ik	hoop	dat	ons	NGS	&	neurosphere	project	een	goede	basis	gaat	zijn	voor	in-
teressante	ontdekkingen	in	de	toekomst.	
 Analisten van de histologie,	cytologie,	immuno,	electronen microscopy en mo-
leculair	biologische	technieken,	 ik	heb	dankbaar	gebruikt	gemaakt	van	al	 jullie	expertise.	
Dank	voor	jullie	hulp	bij	het	 inblokken	van	muizenbreintjes,	de	agarcyto’s,	de	prachtige	in	
situ’s	(Patricia,	FISH-kanjer,	veel	dank!),	het	EMen,	de	fingerprints	en	al	het	troubleshooten	
eromheen.	Ook	de	research	analisten	Jos,	Jeroen,	Melissa,	Elisa,	en	Shannon bedankt 
voor	het	up	&	running	houden	van	het	lab.	Jos,	het	inzetten	van	MLPAs	met	olie(crisis)-drup-
pels	onder	jouw	supervisie	was	een	feest.	Jeroen,	dank	voor	de	leuke	gesprekken	onder	het	
pipetteren:	van	de	laatste	promotie-dip	tot	het	nieuwe	album	van	The	Boss,	er	was	altijd	wel	
iets	te	bespreken.	Irene,	gelukkig	ben	jij	heel	geduldig	en	altijd	bereid	om	de	verschillende	
microscopen	binnen	de	PA	op	een	begrijpelijke	manier	uit	te	leggen.	Jeroen van der Laak, 
alle	kwantificaties	van	kleuringen	zijn	met	behulp	van	jouw	programmeertalent	gedaan.	Bin-
nenkort	weer	eens	vrijdagmiddag-borrelen?	
	 Tijdens	mijn	promotietijd	en	het	verlengde	daarvan	heb	ik	gelukkig	ook	heel	veel	
hulp	gehad	 van	een	 flink	 aantal	 stagiaires.	Bas, Maaike (de Nijs), Alireza, Lise, Bahar, 
Maaike (de Pooter), Lynn, Corina, Willem, Max, Arvid en Roos,	allemaal	bedankt!
	 Oud	kamergenootjes	Carlijn en Karlijn,	het	 lijkt	alweer	een	eeuwigheid	geleden	
dat	we	met	zijn	drieën	bij	de	PA	zaten.	Heel	wat	promotiestress	hebben	we	gedeeld,	maar	
ook	veel	lol	gehad.	Carlijn,	ons	zangtalent	binnen	de	kamer,	en	soms	ook	daarbuiten	(denk	
aan	‘busje	komt	zo’	bij	de	PA	karaoke	kerstborrel),	jij	krijgt	echt	alles	voor	elkaar.	Ondanks	
de	kleine	patiëntengroep	waar	 je	mee	moest	werken,	wist	 je	 tot	de	mooiste	publicaties	te	
komen.	En	kleine	Karlijn,	als	vriendinnetjes	van	de	uni	en	daarbuiten	kwamen	we	op	hetzelf-
de	lab	terecht.	Jammer	dat	het	niet	is	geworden	wat	je	ervan	had	gehoopt.	Toch	ben	je	altijd	
een	ras-optimist	gebleven	en	ben	 ik	blij	dat	we	elkaar	nog	steeds	geregeld	zien.	Emmy,	
METgezel	als	het	gaat	om	de	tyrosine	kinase	receptoren	en	targeted	therapieën	in	muizen.	
Altijd	goed	om	tips-and-tricks	uit	te	wisselen! Manja,	oud-collega,	maar	vooral	ook	toegewijd	
PowerYoga-docente,	jouw	maandagavondlessen	waren	altijd	goed	voor	de	nodige	afleiding.	
Astrid,	dank	voor	je	InDesign	hulp.
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 Alle muizenproeven in dit boekje waren onmogelijk geweest zonder de ondersteun-
ing	van	een	goed	team	biotechnici	van	het	CDL.	Aan	het	begin	van	mijn	project	werden	de	
xenograft	lijnen	nog	met	grote	zorgvuldigheid	onderhouden	door	Geert en Aglaya.	Onder	
de	geduldige	supervisie	van	Geert	leerde	ik	de	praktische	beginselen	van	het	proefdierwerk.	
Jeroen (Dr.	Brain),	jij	nam	het	stokje	met	veel	toewijding	over.	Je	was	altijd	geïnteresseerd	in	
ons	onderzoek	en	immer	bereid	om	te	helpen.	Dank	voor	al	je	hulp.	Ook	andere	biotechnici	
en	verzorgers	van	de	EBD,	veel	dank	voor	alle	goede	zorgen	voor	onze	muisjes.	
	 Vrijwel	alle	therapie	experimenten	eindigden	in	de	kelder	van	het	CDL.	Eerst	war-
en	er	enkel	de	MRI	scanners.	Later	werd	het	steeds	makkelijker	om	proeven	te	doen	toen	
het	PRIME	werd	ingericht.	Bianca,	Henk,	Kitty en Iris,	jullie	zijn	een	superteam	om	mee	te	
werken.	Gelukkig	ook	erg	flexibel	en	altijd	bereid	om	nog	een	muisje	 te	 injecteren	of	een	
canule	te	zetten,	soms	op	de	meest	onmogelijke	tijden	omdat	er	weer	in	het	weekend	of	de	
avonduren	gemeten	moest	worden.	Bedankt	voor	alle	hulp!
 Voor mijn onderzoek heb ik ook met heel wat mensen van andere afdelingen mogen 
samenwerken.	Vooral	bij	de	afdeling	Celbiologie	heb	ik	de	deur	zo	nu	en	dan	platgelopen.	
Jan,	wat	een	enorme	berg	werk	heb	jij	verzet.	Jij	was	altijd	bereid	om	mee	te	werken	aan	de	
knockdown	van	onmogelijke	genen	zoals	MET	en	PTPRZ,	en	mopperde	enkel	op	de	glioma	
cellijnen	die	zo	traag	groeiden.	Dank	voor	je	hulp	bij	alles!	Annika en Marieke,	hoe	vaak	heb	
ik	niet	bij	jullie	aangeklopt	voor	de	nodige	spullies,	advies	of	het	uitvoeren	van	experimenten	
op	jullie	mooie	apparatuur.	Annika,	veel	succes	met	het	vervolgen	van	het	PTP-werk.	Pavel,	
our	collaboration	has	been	very	inspiring.	You	are	a	real	glioma	know-it-all.	Your	p120-paper	
will	be	beautiful!
 Voor alle muizen imaging ben ik bijzonder veel dank verschuldigd aan de onder-
zoekers	van	de	afdeling	Radiologie.	Bob,	heel	wat	dagen	hebben	we	in	de	kelder	muizen	
zitten	meten	voor	ons	MRS	verhaal,	wat	niet	altijd	even	makkelijk	 te	combineren	was	met	
jouw	jong	gezinnetje.	Dankzij	jouw	Matlab	skills	is	het	uiteindelijk	een	heel	mooi	verhaal	ge-
worden.	Arend,	veel	dank	voor	de	mogelijkheden	die	we	kregen	om	gebruik	te	maken	van	
de	mooie	imaging	apparatuur	en	de	goede	samenwerking.	Andor,	jij	was	er	voor	al	het	MR	
troubleshooten	en	bleef	steeds	geduldig	uitleg	te	geven	aan	een	MRI-leek	als	ik. Houshang 
and Morteza,	it	has	been	great	collaborating	with	you.	Tom,	veel	succes	bij	je	onderzoek! 
Arno en Ron Wevers,	veel	dank	voor	alle	2HG	metingen.	Paul,	FACS-expert	en	ras-optimist,	
dank	voor	al	je	hulp	bij	de	flow	experimenten.
	 Ook	buiten	het	Radboud	zijn	er	verschillende	onderzoekers	belangrijk	geweest	in	
de	afgelopen	jaren.	Tom Wurdinger, jouw enthousiasme voor onderzoek doen werkt zeer-
aanstekelijk.	Goed	om	samen	te	werken	aan	het	METd78	project.	Viola Caretti,	the	E98NT	
and	FM	cell	 lines	have	been	essential	 for	our	 research,	 thanks	 for	sharing	 those. Remco 
Molenaar, wat interessant om samen te werken met iemand bij wie de puzzelstukjes van het 
IDH	metabolisme	zo	snel	in	elkaar	passen. Stefan Pusch,	thanks	for	your	help	in	learning	me	
the	neurosphere	procedure,	you	are	a	good	teacher.	Theresa,	your	visit	to	our	lab	has	been	
a	great	pleasure.	I	really	enjoyed	the	return	visit	to	Valencia	as	well,	with	all	the	nice	people	I	
met	and	off	course	the	amazing	wines	and	food	(best	paella	ever!).	
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	 Naast	werken	was	er	natuurlijk	ook	genoeg	steun	en	afleiding	van	vrienden	en	fam-
ilie.	Nardie,	je	bent	een	supervriendin	waar	ik	altijd	aan	kan	kloppen.	Sorry	dat	ik	de	laatste	
tijd	soms	te	druk	was	om	af	te	spreken,	ik	ga	het	aankomende	zomer	goedmaken.	Sziget	
wordt	vast	helemaal	geweldig!	Karen,	Jij	was	altijd	geïnteresseerd	in	alle	promotie-zaken.	
Ik	ben	blij	dat	we	elkaar	weer	vaker	spreken	en	zien.	
 Nijmeegse vierdaagsegenootjes Carla en Karlijn,	wat	hebben	we	samen	lekker	
afgezien!	De	urenlange	wandelingen	waren	altijd	een	mooie	gelegenheid	om	onze	labw-
erkzaamheden	en	alles	eromheen	uitvoerig	te	bediscussiëren.	Dat	we	de	vierdaagse	achter	
ons	hebben	gelaten	vind	ik	niet	zo	erg,	al	mis	ik	wel	onze	gesprekken!	José,	Tanzania	was	
top!	De	Kili-klim	was	zwaar,	de	safari	en	Zanzibar	geweldig.	Ook	al	 is	de	zoektocht	niet	
altijd	makkelijk,	je	gaat	vast	en	zeker	een	hele	mooie	opleidingsplek	vinden.	Walter,	jij	bent	
altijd	een	goede	gesprekspartner:	het	onderzoek,	maar	ook	de	laatste	hardloopresultaten	
passeren	altijd	even	de	revue. Super	dat	het	zo	goed	gaat	met	 je	carrière. Veel	succes,	
ook Sanne, in	Mainz. Ronald en Maurijn,	 veel	 succes	met	de	 laatste	 loodjes	 van	 jullie	
proefschrift..! Rebecca,	wat	fijn	dat	je	helemaal	op	je	plek	terecht	bent	gekomen	bij	GE!
 Lieve mensen van harmonie KNA,	wat	een	geluk	dat	ik	eigenlijk	per	toeval	bij	ju-
llie terecht	kwam	in	2009.	De	donderdagavonden	waren	altijd	een	heerlijke	afleiding:	eerst	
muziek	maken	en	dan	gezellig	naborrelen!	Jacqueline en Thea,	mijn	vaste	borrelgenootjes,	
mede-bestuur,	en	vele	anderen,	wat	zijn	jullie	een	leuke	en	sociale	vereniging.	Bernau	war	
ganz	toll! Ook	medehoornisten	van	het	Gelders Hoornensemble en sportievelingen van 
Loopgroep Ooijpolder	bedankt	voor	de	afgelopen	jaren.
 Oma en de rest van de familie Manuel,	jullie	zijn	echt	een	leuke	en	behulpzame	
schoonfamilie.	De	familie-	en	verjaardagen	zijn	altijd	zeer	geslaagd.	Johan en Karin,	het	
is	bij	jullie	altijd	als	thuiskomen	en	heerlijk	om	ons	dagenlang	te	vermaken	met	Kolonisten,	
“Takkes”,	of	zelfs	het	Zombie-spel	 in	 teams,	uiteraard	samen	met	Emiel en Lotte.	 Jullie	
zijn	ook	vaak	een	grote	hulp	geweest	als	wij	weer	eens	gingen	verhuizen.	Ook	familie	Van 
Bentum	bedankt	voor	alle	steun	en	interesse	die	jullie	altijd	hebben	getoond.	Tante	Jeanet,	
bezoekjes	aan	Kampen	waren	zowel	vroeger	als	nu	altijd	zeer	geslaagd.	
 Evelien,	lief	klein	zusje.	Wat	ben	jij	goed	terechtgekomen!	Jammer	dat	je	zo	ver	
weg	woont.	Het	is	altijd	gezellig	bijkletsen,	en	zeker	nu	je	kleine	wondertje	geboren	is	zou	
ik	willen	dat	we	elkaar	vaker	kunnen	zien.	Heel	veel	geluk	samen	met	Peter en Faye in jullie 
nieuwe	huisje.	Mamma,	jij	hebt	je	zo	nu-en-dan	afgevraagd	of	“het	nog	wel	door	zou	gaan”.	
Nou,	gelukkig	gaat	het	dan	toch	nog	gebeuren!	Het	zijn	spannende	tijden	nu	ook	jij	gaat	
verhuizen.	Dank	dat	je	altijd	voor	me	klaarstaat.	En	Pappa,	wat	had	ik	graag	gewild	dat	jij	
hier	bij	zou	zijn!	Jij	hebt	me	altijd	op	het	hart	gedrukt	hoe	belangrijk	het	is	om	te	studeren	en	
zou	zo	trots	geweest	zijn.	Dit	boekje	is	voor	jou.		
 Lieve Remy,	wat	een	geluk	dat	ik	jou	ben	tegengekomen	tijdens	de	Biologie	intro.
Mijn	persoonlijke	statisticus	maar	natuurlijk	zoveel	meer.	Ik	wil	nooit	wennen	aan	jou!	
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